dla pacjentów i lekarzy
Onkologia - aktualności medyczne dla lekarzy
The role of durvalumab in combination with gemcitabine and cisplatin has been established in the first-line setting for advanced BTC; however, the role of this combination in subsequent line, adjuvant, neoadjuvant, and in combination with liver-directed approaches requires further exploration.
FDA Grants Accelerated Approval to Mosunetuzumab-axgb for Relapsed or Refractory Follicular Lymphoma
FDA granted accelerated approval to mosunetuzumab-axgb, a bispecific CD20-directed CD3 T-cell engager for adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic treatment. Mosunetuzumab-axgb was evaluated in GO29781 (NCT02500407), an open-label, multicentre, multi-cohort study.
Patients With Small Cell Lung Cancer That Metastasizes to the Brain May Benefit From Stereotactic Radiosurgery. Here's What We Know
Small cell lung cancer has a higher tendency than other solid tumors to metastasize to the brain, which can cause significant morbidity and mortality. For solid tumors that metastasize to the brain, the primary treatment approaches include surgery, stereotactic radiosurgery, and whole-brain radiation therapy.
Intrahepatic cholangiocarcinoma is an aggressive cancer, with poor outcomes resulting from late-stage diagnosis and limited treatment options for patients with advanced disease.
Researchers were surprised to find pre-surgery immunotherapy for a common type of colorectal cancer was even more effective at early- and mid-stages than the already-proven high rate of success in metastatic disease.
Adagrasib Shows Promising Activity as Monotherapy, Even Greater in Combination with Cetuximab, and Reversible Side Effects in Patients with Previously Treated KRAS G12C–Mutated mCRC
Adagrasib demonstrated antitumour activity in the KRYSTAL-1 phase I/II study conducted among heavily pretreated patients with KRAS G12C–mutated metastatic colorectal cancer (mCRC), both as oral monotherapy and in combination with cetuximab.
Triplet Therapy Has a Place in Metastatic Hormone-Sensitive Prostate Cancer Treatment, But For Whom?
Several clinical trials have reported success in treating metastatic hormone-sensitive prostate cancer with strategies including chemotherapy, androgen receptor–targeted agents, and radiation. Triplet therapy trials are gathering data suggesting that up-front treatment with docetaxel may be enhanced with the addition of an ARTA.
Triplet Therapy Has a Place in Metastatic Hormone-Sensitive Prostate Cancer Treatment, But For Whom?
Several clinical trials have reported success in treating metastatic hormone-sensitive prostate cancer with strategies including chemotherapy, androgen receptor–targeted agents, and radiation. Triplet therapy trials are gathering data suggesting that up-front treatment with docetaxel may be enhanced with the addition of an ARTA.
Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor–Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update
ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an evidence review and follow the guideline development processes outlined in the ASCO Guideline Methodology Manual.
Sotorasib Shows Promising Activity and Acceptable Safety in Patients with Previously Treated KRAS p.G12C–Mutated Advanced Pancreatic Cancer
In a phase I/II CodeBreaK 100 study, sotorasib monotherapy showed promising anticancer activity in patients with heavily pretreated KRAS p.G12C–mutated advanced pancreatic cancer.
New indication concerns the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.
Stereotactic radiosurgery versus whole brain radiotherapy in patients with intracranial metastatic disease and small-cell lung cancer
Patients with small-cell lung cancer are at high risk for intracranial metastatic disease (IMD). Although stereotactic radiosurgery (SRS) has supplanted whole brain radiotherapy (WBRT) as first-line treatment for IMD in most solid cancers, WBRT remains first-line treatment for IMD in patients with SCLC. We aimed to evaluate the efficacy of SRS in comparison with WBRT and assess treatment outcomes following SRS.
The European Cancer Organisation is proud to announce the release today of its ‘Essential Requirements for Quality Cancer Care: Glioma’. The new document, crafted by European experts representing different disciplines, provides oncology teams, patients, policymakers, and managers with an overview of the critical elements needed in any healthcare system to establish high-quality glioma care.
Low-Pass Genomic Instability Characterisation Assay Identifies Germline Mismatch Repair Deficiency and Risk of Cancer Onset
In a study conducted by the International Replication Repair Deficiency Consortium, the researchers used a well-annotated data set of childhood cancers and patients with cancer predisposition syndromes to provide evidence that low-pass genome analysis can be used to diagnose replication repair deficiency in cancerous and normal tissues.
Results from KEYNOTE-177, BEACON, TRIPLETE, and more recent trials spurred new recommendations in the management of metastatic colorectal cancer.The new ASCO guideline includes recommendations on various therapy indications, the role of immunotherapy and targeted therapies.
Debates in Treatment Sequencing in ALK-Rearranged NSCLC: Weighing Therapeutic Benefit Versus Troubling Toxicities
Several next-generation ALK tyrosine kinase inhibitors (TKIs) are approved by the U.S. Food and Drug Administration for advanced, ALK-rearranged non–small cell lung cancer in the first-line setting.
Incidence and severity of neurological side effects from chimeric antigen receptor (CAR) T-cell therapy were higher in patients who had hypophosphatemia (low blood phosphate levels), according to results published in Cancer Immunology Research, a journal of the American Association for Cancer Research.
Pembrolizumab is recommended, within its marketing authorisation, as an option for the adjuvant treatment of renal cell carcinoma at increased risk of recurrence after nephrectomy, with or without metastatic lesion resection, in adults.
EMA adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product lutetium (177Lu) vipivotide tetraxetan intended for the treatment of prostate cancer.
Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
This ESMO Clinical Practice Guideline provides key recommendations for managing immunotherapy-related toxicity. The guideline covers assessment, diagnosis and treatment of the most common and severe immunotherapy-related toxicities. Recommended assessment and treatment algorithms according to the grade of toxicity are provided.
Najnowsze wyniki badań leczenia rybocyklibem, w postaci nowej zbiorczej analizy eksploracyjnej przeprowadzonej dla wszystkich badań MONALEESA, wykazały dodatkowy rok korzyści w zakresie całkowitego czasu przeżycia dla najszerszej grupy pacjentek, w tym z agresywnym zaawansowanym rakiem piersi HR+/HER2- ujemnym.
The Update Panel revisited recommendations from the 2015 guideline and expanded the scope of the guideline to address topics that have emerged since the publication of the 2015 guideline. The recommendations of the Update Panel are specifically focused upon biomarkers that aid clinicians in making therapeutic decisions.
PTChO zaprasza do udziału w VI Konferencji Naukowej Rak Piersi Onkologia i Plastyka która odbędzie się w dniach 14/15 października br. Jak zawsze spotkanie z dużą ilością ważnych i zarazem praktycznych informacji dotyczących diagnostyki i leczenia raka piersi.
Phase II LCMC3 Study of Neoadjuvant Atezolizumab Met Primary Endpoint with a Major Pathological Response Rate of 20% in Resectable Stage IB–IIIB NSCLC
Results of the largest study of preoperative immune checkpoint inhibitor monotherapy in patients with early-stage non-small cell lung cancer to date. The findings are published on 12 September 2022 in the Nature Medicine.
Initial COSMIC-313 Data Show First-Line Triplet Therapy Prolongs PFS in Advanced RCC With Greater Toxicity
COSMIC-313 represents the first phase 3 trial to compare triplet versus doublet therapy in advanced renal cell carcinoma. Adding cabozantinib to dual immunotherapy in the first-line setting led to a significant improvement in PFS, decreasing the risk of disease progression or death by 27%.
FDA Approves Ibrutinib for Paediatric Patients with Chronic Graft Versus Host Disease, Including a New Oral Suspension
FDA approved ibrutinib for paediatric patients ≥ 1 year of age with chronic graft versus host disease (cGVHD) after failure of 1 or more lines of systemic treatment. Formulations include capsules, tablets, and oral suspension. Efficacy was evaluated in iMAGINE (NCT03790332) study.
FDA approved durvalumab in combination with gemcitabine and cisplatin for adult patients with locally advanced or metastatic biliary tract cancer (BTC). Efficacy was evaluated in TOPAZ-1 (NCT03875235), a randomised, double-blind, placebo-controlled, multiregional study.
Metastatic triple-negative breast cancer (TNBC) carries the worst prognosis of the 3 major breast cancer categories. Multiple mechanisms of resistance have been described to all therapeutic agents in metastatic TNBC, which has driven development of new approaches for pretreated patients.
ESMO: Resekcja raka jelita grubego w stopniu pT4 w połączeniu z HIPEC daje mniejszy odsetek wznów miejscowych niż sam zabieg operacyjny
W dniach 9-13 września w Paryżu odbywa się konferencja Europejskiego Towarzystwa Onkologii Medycznej (ESMO). Wśród wielu nowości omawiano także postępy w leczeniu raka jelita grubego. Wśród nich przedstawiono wyniki badania porównującego standardowe leczenie chirurgiczne raka jelita grubego, do leczenia w którym włączono procedurę HIPEC.
In patients with resectable NSCLC, neoadjuvant nivolumab plus chemotherapy resulted in significantly longer event-free survival and a higher percentage of patients with a pathological complete response than chemotherapy alone. The addition of nivolumab to neoadjuvant chemotherapy did not increase the incidence of adverse events or impede the feasibility of surgery.
ASCO Guideline Rapid Recommendation Update: Chemotherapy and Targeted Therapy for Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That Is Either Endocrine-Pretreated or Hormone Receptor–Negative
ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The goal of these articles is to disseminate updated recommendations, in a timely manner, to better inform health practitioners and the public on the best available cancer care options.
ESMO Expert Consensus Statements on Cancer Survivorship: Promoting High-Quality Survivorship Care and Research in Europe
We identified five main components of survivorship care: physical effects of cancer and chronic medical conditions; psychological effects of cancer; social, work and financial effects of cancer, surveillance for recurrences and second cancers; and cancer prevention and overall health and well-being promotion.
Zapraszamy wszystkich zainteresowanych lekarzy, lekarzy stażystów i studentów wydziału lekarskiego do wzięcia udziału w webinarium „Chirurgia Onkologiczna – czy ta specjalizacja jest dla mnie?”, które odbędzie się w dniu 15.09.2022 o godz 16:00. Webinar zorganizowany jest przez Sekcję Młodych Chirurgów Onkologów Polskiego Towarzystwa Chirurgii Onkologicznej i Fundację PTChO. W trakcie spotkania opowiemy m.in. o tym czym zajmuje się chirurg onkolog, o naszym towarzystwie, jak przebiega specjalizacja z chirurgii onkologicznej.
FDA Approves Pemigatinib for Relapsed or Refractory Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement
FDA approved pemigatinib for adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor receptor 1 (FGFR1) rearrangement. Efficacy was evaluated in FIGHT-203 (NCT03011372).
New Study in JNCCN Suggests Way to Predict Outcomes with High Accuracy Prior to Surgery for Pancreatic Cancer Patients
According to Mayo Clinic Comprehensive Cancer Center researchers, metabolic imaging (FDG-PET) in combination with traditional treatment response assessment methods can provide clinicians with critical information they need to guide therapy for pancreatic cancer patients.
Exploring the Paradigm Shift in the Management of Unresectable or Metastatic Hepatocellular Carcinoma
Globally, malignancies involving the liver and intrahepatic bile duct are the sixth most common cause of cancer and the third leading cause of cancer-related deaths. Hepatocellular carcinoma (HCC) remains the most common type of primary liver cancer, with the majority of patients presenting with unresectable disease at the time of diagnosis.
Research on the molecular background of lung cancer has yielded insights into various signaling pathways that are driving lung tumorigenesis, particularly key driver mutations. Throughout the 2000s, HER2 mutations have been identified as actionable oncogenic drivers in non–small cell lung cancer, leading to increased research efforts in this field.
Analysis of ctDNA used with paired exome sequencing from archival tissues of patients with RAS wild-type metastatic colorectal cancer (mCRC) found that acquired resistance to anti-EGFR antibodies occurs via a multiplicity of concurrent subclonal alterations.
W dniach 1-3 września 2022 w Gdańsku odbył się 28 Zjazd Polskiego Towarzystwa Chirurgii Onkologicznej. Tematem tegorocznej konferencji było skojarzone leczenie nowotworów z centralną rolą chirurgii. Trzy dni wykładów i dyskusji, liczne warsztaty poszerzające wiedzę i umiejętności praktyczne, sesja młodych lekarzy i wiele innych form naukowo-dydaktycznych złożyło się na całokształt tegorocznego zjazdu.
Zapraszamy w imieniu organizatorów na Konferencję naukowo-szkoleniową „Jak zabezpieczyć płodność u chorych onkologicznych – wyzwania A.D. 2022” Na spotkanie zapraszamy lekarzy ginekologów, onkologów, pediatrów, chirurgów onkologicznych, a także pozostałych specjalistów zainteresowanych tematyką wydarzenia.
TIL Densities Association with Disease-Free Survival Differs by Primary Tumour Sidedness in Stage III Colon Cancer
The NCCTG N0147 Alliance researchers found significantly higher tumour infiltrating lymphocyte (TIL) densities in right- versus left-sided colon cancers. Moreover, a low versus high TIL density was significantly and independently associated with poorer disease-free survival (DFS) in patients with stage III colon cancer.
Mismatch repair-deficient, locally advanced rectal cancer was highly sensitive to single-agent PD-1 blockade. Longer follow-up is needed to assess the duration of response.
Teclistamab Results in a High Rate of Deep and Durable Response in Patients with Triple-Class–Exposed Relapsed or Refractory Multiple Myeloma
In a phase I/II study that involved patients with relapsed or refractory multiple myeloma, a once-weekly subcutaneous dose of a bispecific antibody, teclistamab that mediates T-cell activation and subsequent lysis of myeloma cells expressing B-cell maturation antigen (BCMA) induced responses in 63% of the patients, including a complete response in 39.4%.
New research presented during the August ASCO Plenary Series showed that about 1 of every 7 patients with lung cancer harbored a pathogenic germline mutation—the vast majority of which were clinically actionable.
EMA adopted a positive opinion, recommending the granting of a conditional marketing authorisation for the medicinal product teclistamab (Tecvayli), intended for treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies.
Intratumoural Administration of the Oncolytic Herpes Virus Shows Survival Benefit and a Safe Profile in Patients with Residual or Recurrent Glioblastoma
Phase II single-arm study demonstrates the efficacy and safety of G47∆, a triple-mutated, third-generation oncolytic herpes simplex virus type 1 (HSV-1), in 19 adult patients with residual or recurrent, supratentorial glioblastoma after radiation therapy and temozolomide. The 1-year survival rate of 84.2%, the median overall survival (OS) of 20.2 months and progression-free survival (PFS) of 4.7 months after G47Δ initiation compare favourably with other treatments.
Patients with breast cancer who have an ultralow risk of recurrence are typically grouped together with low-risk patients, although the optimal treatment regimens may differ. Accurately identifying patients with ultralow-risk breast cancer may help de-escalate therapy in this patient group.
Novel Drug Delivery Systems for Patients With Advanced Prostate Cancer: A Focus on Radioligand Therapy and ADCs
The therapeutic landscape for patients with advanced prostate cancer has expanded over the past 2 decades. Although androgen deprivation therapy has historically been the backbone of treatment for patients with recurrent or metastatic disease, additional agents—including chemotherapy, hormone therapy, immunotherapy, radionuclide therapy, and targeted therapy—have improved survival for patients with advanced disease.
Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies
Sacituzumab govitecan is recommended, within its marketing authorisation, as an option for treating unresectable triple-negative locally advanced or metastatic breast cancer in adults after 2 or more systemic therapies, at least 1 of which was for advanced disease.
Nivolumab plus ipilimumab is recommended as an option for untreated unresectable malignant pleural mesothelioma in adults, only if they have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Zero Mutation ctDNA Triage for Selection of Patients with Metastatic Colorectal Cancer for Panitumumab Rechallenge
The authors explained in the background that treatment of patients with mCRC who initially respond and then progress after cetuximab or panitumumab remains an unmet clinical need. The molecular bases of relapse are patient specific and difficult to define, as tissue biopsies at the time of progression cannot be systematically performed in clinical practice and have intrinsic risks.
Toward Improved Outcomes for Patients With Lung Cancer Globally: The Essential Role of Radiology and Nuclear Medicine
Lung cancer is the number one cancer killer worldwide. The essential role that medical imaging and nuclear medicine play in early diagnosis and disease staging cannot be overstated, pivotal in selecting the many patients for whom measurably improved outcomes are attainable.
FDA approved darolutamide tablets in combination with docetaxel for adult patients with metastatic hormone-sensitive prostate cancer (mHSPC). Efficacy was based on ARASENS (NCT02799602), a randomised, multicentre, double-blind, placebo-controlled clinical study in 1306 patients with mHSPC.
It is indicated for the first-line treatment of advanced melanoma in adults and adolescents 12 years of age and older with tumour cell PD-L1 expression < 1%.
ASCO Guideline Update: Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
The purpose of this guideline update is to provide oncologists, other health care practitioners, patients, and caregivers with recommendations regarding guidance for optimal management of patients with human epidermal growth factor receptor 2 (HER2)–positive metastatic breast cancer.
ASCO Guideline Update: Management of Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases
The purpose of this guideline update is to provide updated evidence- and consensus-based guideline recommendations to practicing oncologists and others on the management of brain metastases for patients with human epidermal growth factor receptor 2 (HER2)–positive advanced breast cancer up to 2021.
Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer
Alpelisib plus fulvestrant is recommended as an option for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated, locally advanced or metastatic breast cancer in adults, only if their cancer has progressed after a CDK4/6 inhibitor plus an aromatase inhibitor.
Nivolumab is recommended as an option for the adjuvant treatment of muscle-invasive urothelial cancer that is at high risk of recurrence after radical resection in adults whose tumours express PD-L1 at a level of 1% or more. It is recommended only if adjuvant treatment with platinum‑based chemotherapy is unsuitable.
Neoadjuvant Niraparib Demonstrates Promising Antitumour Activity and Safety in Patients with Localised HER2-negative, BRCA-mutated Breast Cancer
In a pilot, single-arm, phase II study, neoadjuvant treatment with single-agent niraparib demonstrated feasibility, promising antitumour activity and high levels of tumour penetration in patients with HER2-negative, BRCA-mutated, localised breast cancer.
Trastuzumab Deruxtecan Shows High Intracranial Response Rate in Patients with Active Brain Metastases from HER2-positive Breast Cancer
In an investigator-initiated prospective, open-label, single-arm phase II TUXEDO-1 study conducted among patients with newly diagnosed or progressive brain metastases from HER2-positive breast cancer, antibody drug conjugate trastuzumab deruxtecan yielded responses by response assessment in neuro-oncology brain metastases.
Analysis of data from two ovarian cancer consortia shows that frequent aspirin use was associated with a 13% reduction in ovarian cancer risk. A similar risk reduction was observed for high-grade serous ovarian cancer, the most common and one of the most fatal histological types, which is important because most established risk factors are weakly associated with high-grade serous ovarian cancers.
The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy
The results of this randomised trial establish the benefit of adding short-term ADT to PBRT to prevent progression in prostate cancer. To our knowledge, these are the first such findings to show that extending salvage radiotherapy to treat the pelvic lymph nodes when combined with short-term ADT results in meaningful reductions in progression after prostatectomy in patients with prostate cancer.
Genetic testing, along with assessment of clinical risk factors, could be used to identify survivors at high risk for severe obesity and associated cardio-metabolic complications.
This radiopharmaceutical precursor must be used only for the radiolabelling of carrier medicines that have been specifically developed and authorised for radiolabelling with lutetium chloride.
Pralsetinib is not recommended, within its marketing authorisation, for treating RET fusion-positive advanced non-small-cell lung cancer (NSCLC) in adults who have not had a RET inhibitor before.
Phase 3 studies have demonstrated overall survival improvement with the addition of docetaxel, abiraterone, enzalutamide, or apalutamide to initial androgen deprivation therapy (ADT) for mHSPC. More recently, the PEACE-1 and ARASENS trials demonstrated overall survival benefit with the addition of abiraterone or darolutamide to ADT plus docetaxel.
Radiopharmaceutical Therapy for Metastatic Castration-Resistant Prostate Cancer After Chemotherapy: A New Player in Town
The indications for radiotherapy continue to expand in the treatment of prostate cancer. There is now evidence from randomized trials that supports the use of radiotherapy for localized, clinically node-positive, biochemical recurrence post-prostatectomy, low-volume metastatic hormone-sensitive prostate cancer (mHSPC), and for oligorecurrent mHSPC.
KRASG12D-Mutated NSCLC is Subtype with Distinct Co-mutations, a Colder Immune Microenvironment, and Worse Outcomes to PD-1 Blockade Monotherapy
Findings from a comprehensive analysis of the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small cell lung cancer.
Antitumour Activity of Combination of Lenvatinib and Pembrolizumab in Patients with Advanced Melanoma with Confirmed Progression on Previous Anti-PD-(L)1-Based Treatment
A combination of lenvatinib plus pembrolizumab demonstrated antitumour activity and tolerability in patients with melanoma resistant to prior anti-PD-(L)1-based treatment, irrespective of baseline clinical characteristics, intercurrent systemic treatment, or the number of previous therapies.
In this trial involving patients with metastatic, hormone-sensitive prostate cancer, overall survival was significantly longer with the combination of darolutamide, androgen-deprivation therapy, and docetaxel than with placebo plus androgen-deprivation therapy and docetaxel, and the addition of darolutamide led to improvement in key secondary end points.
The evidence base consisted of 52 systematic reviews, and an additional 23 randomized controlled trials. The most commonly studied types of cancer were breast, prostate, lung, and colorectal.Exercise during cancer treatment led to improvements in cardiorespiratory fitness, strength, fatigue, and other patient-reported outcomes.
This ESMO Clinical Practice Guideline provides key recommendations for managing gastric cancer. The guideline covers clinical and pathological diagnosis, staging and risk assessment, treatment and follow-up. Treatment and management algorithms for localised and advanced/metastatic disease are provided.
This ESMO Clinical Practice Guideline provides key recommendations for managing oesophageal cancer. The guideline covers clinical and pathological diagnosis, staging and risk assessment, treatment and follow-up. Algorithms for the management of locoregional and advanced/metastatic disease are provided.
Significant 20-Year Benefit of 2 Years of Adjuvant Goserelin and Tamoxifen in ER-Positive Premenopausal Patients with Breast Cancer
Stockholm part of the Zoladex in Premenopausal Patients study (STO-5) of premenopausal patients with oestrogen receptor (ER)-positive breast cancer demonstrates a significant 20-year benefit of 2 years of goserelin, tamoxifen, and the combination, compared with no adjuvant endocrine treatment.
An Intensive Follow-Up in Surgically Treated Patients for Endometrial Cancer Does Not Improve Overall Survival, Even in High-Risk Setting
The results of the TOTEM study do not show any improvement in overall survival (OS) and in early detection of relapses for patients surgically treated for endometrial cancer and followed with a 5-year intensive regimen of follow-up, independently from their risk of relapse.
EMA Recommends Granting a Marketing Authorisation for Melphalan Flufenamide for the Treatment of Multiple Myeloma
EMA adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product melphalan flufenamide, intended for the treatment of multiple myeloma.
Exploring the Role of Hyperthermic Intraperitoneal Chemotherapy in Oligometastatic Colorectal Cancer to the Peritoneum
Over the past 2 decades at many institutions, cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have been the standard of care for isolated PM from colorectal cancer (CRC).
Maximum Frontline Immune Checkpoint Inhibition Versus Response-Adapted Treatment Escalation After Anti–PD-1 Failure for Patients With Advanced Melanoma
Although unresectable and metastatic melanoma remains a life-threatening disease, a growing armamentarium of highly effective immune-modulating agents are now available. The optimal selection and sequence of frontline agents for patients with advanced melanoma has yet to be elucidated.
Adding Autologous Stem-Cell Transplantation to Triplet Treatment, Followed by Lenalidomide Maintenance Prolongs PFS in Newly Diagnosed Multiple Myeloma
A large, randomised, phase III DETRMINATION study investigated the effect of adding autologous stem-cell transplantation to triplet treatment of lenalidomide, bortezomib, and dexamethasone, followed by lenalidomide maintenance treatment until disease progression in adult patients with newly diagnosed multiple myeloma.
Konferencja adresowana jest do wszystkich zainteresowanych osób, a w szczególności do lekarzy, fizjoterapeutów, dietetyków, psychologów oraz pacjentów. Celem konferencji jest prezentacja wyników badań naukowych oraz dyskusja na temat aktualnych zaleceń dotyczących profilaktyki oraz leczenia raka piersi.
First-Line Treatment with Pembrolizumab-Chemotherapy Results in Longer OS than Chemotherapy Alone for Advanced TNBC with PD-L1 CPS of 10 or More
In a prespecified interim analysis of phase III KEYNOTE-355 study, the addition of pembrolizumab to chemotherapy resulted in longer progression-free survival than chemotherapy alone among patients with advanced triple-negative breast cancer whose tumours expressed programmed death ligand 1 (PD-L1) with a combined positive score of 10 or more.
Artificial sweeteners and cancer risk: Results from the NutriNet-Santé population-based cohort study
In this large cohort study, artificial sweeteners (especially aspartame and acesulfame-K), which are used in many food and beverage brands worldwide, were associated with increased cancer risk. These findings provide important and novel insights for the ongoing re-evaluation of food additive sweeteners by the European Food Safety Authority and other health agencies globally.
FDA approved crizotinib for adult and paediatric patients 1 year of age and older with unresectable, recurrent, or refractory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumours (IMT).
No OS Benefit for Active Maintenance Treatment with Olaparib Relative to Placebo in Patients with Metastatic Pancreatic Cancer and a Germline BRCA Mutation
POLO is the first randomised phase III study to investigate active maintenance treatment in patients with germline BRCA-mutated metastatic pancreatic cancer who had previously received first-line platinum-based chemotherapy.
Several abstracts presented at the 2022 ASCO Annual Meeting address efforts to decrease toxicities while maintaining similar outcomes through deintensification of therapies among some populations with head and neck squamous cell carcinoma.
ECHELON-1 makes a compelling case for upfront use of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (AAVD) in advanced Hodgkin lymphoma. Patients receiving AAVD regimen are 41 % less likely to die than patients receiving doxorubicin, bleomycin, vinblastine, and dacarbazine regimen.
The gut microbiome is involved in a complex network of innate and adaptive immune response, and influences the development, training, and maturation of the immune system. It has been attractive to evaluate the gut microbiome in the context of cancer care in which immune surveillance is dysregulated, and specifically in the setting of immunotherapy.
Results from a randomized phase 2 trial in patients with advanced non–small cell lung cancer who had received prior immune checkpoint inhibitor therapy and chemotherapy found that treatment with ramucirumab plus pembrolizumab led to better overall survival compared with those receiving standard of care.
New indication concerns the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2 based regimens.
ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an evidence review and follow the guideline development processes outlined in the ASCO Guideline Methodology Manual.
The results of the DESTINY-Breast04 trial are practice changing for several reasons, with the ability to use trastuzumab-deruxtecan in patients with Her-2 1+/2+, a patient population that was previously ineligible for treatment with this drug.
A study presented at the 2022 ASCO Annual Meeting investigated the efficacy of immune checkpoint inhibitors in early-stage dMMR/MSI-H rectal cancer. Several chemotherapy agents and biologics have been approved by the FDA as first-line treatments for EGFR/KRAS wild-type metastatic colorectal cancer, but the optimal number of agents and the duration of treatments remain an active area of research.
The 2022 ASCO Annual Meeting displayed a wide range of histology-specific trials, some impacting day-to-day clinical care for patients with sarcoma, and others setting the stage for future clinical research. In this editorial, we discuss the results and clinical implications of select abstracts presented at the Meeting.
Anticancer Drugs in the Adjuvant Setting Have Considerable Costs Per Event Averted, Raising Questions of Sustainability
A cross-sectional analysis of all approved anticancer drugs by the US FDA from January 2018 through March 2022 identified 11 randomised studies in solid tumours in the adjuvant setting. Adjuvant therapies are often approved based on composite, surrogate endpoints with high costs per event averted.
Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence
Abemaciclib with endocrine therapy is recommended as an option for adjuvant treatment of hormone receptor-positive, HER2-negative, node‑positive early breast cancer in adults whose disease is at high risk of recurrence, defined by the following clinical and pathological features:
The European Cancer Organisation (ECO) has published an action report today on Men and Cancer: Raising the issues. The report provides a detailed account of the presentations and contributions shared during the April 2022 ECO Community 365 Roundtable Meeting on Men and Cancer.
Patients with Advanced Hodgkin’s Lymphoma Treated with Brentuximab Vedotin Plus AVD Have a Survival Advantage Over Those Who Received ABVD Regimen
In the ECHELON-1 study that involved patients with previously untreated stage III or IV Hodgkin’s lymphoma, treatment with a CD30-directed antibody–drug conjugate, brentuximab vedotin, plus doxorubicin, vinblastine, and dacarbazine (AVD), resulted in a risk of death that was significantly lower than that observed with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) regimen.
In an analysis that evaluated the outcomes of anticancer drug studies in advanced disease setting with regards to patients’ quality of life, improved QoL outcomes were associated with improved overall survival, but not with improved progression-free survival. Almost half of the anticancer drug studies that demonstrated improved PFS showed no improvements in OS or QoL.
ASCO Updated Guideline of Biomarkers in Metastatic Breast Cancer Supports PIK3CA, BRCA1/2, PD-L1 Testing
ASCO has issued a new practice guideline update on the use of biomarkers in the management of metastatic breast cancer. The updated guideline makes a total of 11 recommendations, including in cases in which the Expert Panel found insufficient evidence to recommend routine testing for specific biomarkers.
New indication concerns its use in combination with venetoclax for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia.
Clinical development of novel therapeutics has dramatically improved the outcomes for patients with advanced cutaneous melanoma. Despite these breakthrough advances in immunotherapy and targeted therapy, there remains a substantial population of patients who either do not benefit from or only derive a transient benefit from current standard-of-care therapies.
No Benefit With Modified FOLFOXIRI Versus FOLFOX When Combined With Panitumumab for Upfront Treatment of RAS/BRAF Wild-Type mCRC
For patients with unresectable RAS/BRAF wild-type metastatic colorectal cancer (mCRC) who are receiving upfront treatment with chemotherapy plus panitumumab, a modified FOLFOXIRI backbone appears to provide no efficacy benefit over a FOLFOX backbone, while increasing gastrointestinal toxicity.
NICE recommends alpelisib and sacituzumab govitecan, maintaining 100% approvals of breast cancer drugs since 2018
NICE has recommended alpelisib used with the hormonal therapy fulvestrant, for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated locally advanced or metastatic breast cancer that has grown after treatment with combined hormonal therapy and a cancer growth inhibitor.
Trastuzumab Deruxtecan Leads to Longer PFS and OS Compared with Chemotherapy in Previously Treated HER2-Low Unresectable or Metastatic Breast Cancer
Findings from randomised, phase III DESTINY-Breast04 study show significantly longer progression-free survival and overall survival with trastuzumab deruxtecan than with the physician’s choice of chemotherapy among patients with previously treated HER2-low unresectable or metastatic breast cancer, regardless of hormone receptor status.
Changing Practice in NSCLC: Should We Optimize Immunotherapy Responses, Novel Drug Delivery Mechanisms, or Both?
Several presentations at the 2022 ASCO Annual Meeting highlighted promising early-phase clinical data on a range of platforms expanding into larger registrational trials. Discussed here are 2 very different recent strategies and their potential impact on the treatment of non–small cell lung cancer.
Molecular Profiling with Targeted Panel Tests that Includes Fusion Detection Has a Substantial Clinical Impact for Young Patients with Solid Tumours
An interim report from the GAIN/iCat2 study shows that molecular profiling of paediatric solid tumours clarifies diagnostic classifications and provides opportunities for matched targeted therapy.
XXVIII Zjazd Polskiego Towarzystwa Chirurgii Onkologicznej to najważniejsze wydarzenie dla środowiska polskich chirurgów onkologów. Cieszy się również dużym zainteresowaniem wśród lekarzy onkologów. To spotkanie od blisko 30 lat łączy środowisko lekarskie wokół szerokiego spektrum diagnostyki i terapii onkologicznej.
PTGO zaprasza na pierwsze spotkanie z cyklu DEBATY EKSPERTÓW PTGO. Najbliższą debatę chcielibyśmy poświęcić diagnostyce i leczeniu raka jajnika. Nasi Eksperci, na podstawie przesłanych przez Państwa pytań i problemów klinicznych, omówią obecne możliwości, skonfrontują je z EBM i przedyskutują kontrowersyjne kwestie.
National Comprehensive Cancer Network Shares New Recommendations for Treating Children with Brain Tumors
NCCN published new NCCN Clinical Practice Guidelines in Oncology for Pediatric Central Nervous System (CNS) Cancers. This is now the fifth current NCCN Guidelines to focus on childrens’ cancers, following recent publications of evidence-based, expert consensus guidelines for Pediatric Acute Lymphoblastic Leukemia, Pediatric Aggressive Mature B-Cell Lymphomas, Pediatric Hodgkin Lymphoma, and Wilms Tumors.
New Guideline Updates Address Stage IV Non–Small Cell Lung Cancer With and Without Driver Alterations
Two ASCO guideline updates provide new evidence-based recommendations for the systemic treatment of stage IV non–small cell lung cancer with and without driver alterations. Among several other updates, these new guidelines add the ALK and ROS1 inhibitor lorlatinib and the PD-L1 immune checkpoint inhibitor atezolizumab to the treatment landscape for these patient populations.
Efficacy was evaluated in TRANSFORM (NCT03575351), a randomised, open-label, multicentre study in adult patients with primary refractory LBCL or relapse within 12 months of achieving complete response (CR) to first-line therapy.
Leveraging Extensive Real-World Data to Systematically Identify Mutations that Predict the Outcomes of Patients with Eight Common Cancer Types on Specific Therapies
Using the patients’ tumour mutation profile, data on treatments received and survival outcomes, the researchers identified 458 genomic alteration biomarkers that significantly predict the outcome of patients on specific immunotherapies, chemotherapies or targeted therapies.
Current standard-of-care immunotherapies for metastatic melanoma include immune checkpoint inhibitors directed at PD-1 (nivolumab and pembrolizumab) and CTLA-4 (ipilimumab) given as monotherapy or in combination. Although these checkpoint inhibitors have revolutionized treatment outcomes, research is ongoing to develop new therapies to further improve outcomes while limiting toxicity.
It is a new therapeutic option for adults with Philadelphia chromosome positive chronic myeloid leukaemia in chronic phase, previously treated with two or more tyrosine kinase inhibitors.
The therapy landscape for patients with non–small cell lung cancer has, in recent years, blossomed to include many targeted therapies. The ability to offer targeted treatments depends on reliable and accessible genomic testing that reveals the molecular landscape of a patient's tumor.
Pharmacokinetically Guided Dose Optimisation of Oral Targeted Therapies Reduces the Proportion of Underexposed Patients
Findings from the Dutch Pharmacology Oncology Group - Therapeutic Drug Monitoring study show that pharmacokinetically guided dose-adjustments of oral targeted therapies are feasible in clinical practice.
The ASCO Endorsement Panel determined that the recommendations from the ASTRO guideline, published May 6, 2022, are clear, thorough, and based upon the most relevant scientific evidence. ASCO endorses “Radiation Therapy for Brain Metastases: An ASTRO Clinical Practice Guideline.”
Targeted drug therapies and immunotherapy in the management of non–small cell lung cancer (NSCLC) have recently revolutionized outcomes for patients with advanced-stage and metastatic disease.
EMA granted of a marketing authorisation for the medicinal product Vegzelma (bevacizumab), intended for the treatment of carcinoma of the colon or rectum, breast cancer, non-small cell lung cancer (NSCLC), renal cell cancer, epithelial ovarian, fallopian tube or primary peritoneal cancer, and carcinoma of the cervix.
Timing of Ga68-PSMA PETCT and patterns of recurrence after prostate radiotherapy: Implications for potential salvage
Early Ga68-PSMA PETCT for rising PSA after definitive prostate radiotherapy detected majority of recurrent lesions and identified oligorecurrences amenable to focal salvage therapy.
FDA Grants Accelerated Approval to Dabrafenib in Combination with Trametinib for Unresectable or Metastatic Solid Tumours with BRAF V600E mutation
FDA granted accelerated approval to dabrafenib in combination with trametinib for the treatment of adult and paediatric patients ≥ 6 years of age with unresectable or metastatic solid tumours with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options.
The inclusion of carboplatin with anthracycline-taxane neoadjuvant chemotherapy appears to be a reasonable treatment for medically fit, high-risk patients with stage II-III TNBC.
Selecting Patients for PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer
The treatment landscape for men with metastatic castration-resistant prostate cancer and mutations in homologous recombination repair genes has expanded in recent years with FDA approvals and breakthrough designations for certain PARP inhibitors.
Long-Term Benefit of Nivolumab Plus Low-Dose Ipilimumab in Previously Treated Patients with MSI-H/dMMR Metastatic Colorectal Cancer
Nivolumab plus low-dose ipilimumab provided durable clinical benefit over 4 years of follow-up in the CheckMate 142 study, characterised by high response rates, low rates of disease progression, and long-term survival benefit.
In this article, we seek to address relevant questions and concerns about the use of e-cigarettes and e-liquid products, highlight some of the current knowledge, and identify gaps in knowledge for further research.
Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer
Pembrolizumab plus chemotherapy (paclitaxel or nab‑paclitaxel) is recommended as an option for treating triple‑negative, locally recurrent unresectable or metastatic breast cancer in adults who have not had chemotherapy for metastatic disease. It is recommended only if the tumours express PD‑L1 with a combined positive score of 10 or more and an immune cell staining of less than 1%.
Cemiplimab is recommended as an option for treating metastatic or locally advanced cutaneous squamous cell carcinoma in adults when curative surgery or curative radiotherapy is not suitable, only if it is stopped at 24 months, or earlier if their disease progresses.
Long-Term Survival in a Significant Proportion of Patients with a 1p/19q Codeleted Anaplastic Oligodendroglioma
Final survival results in EORTC 26951 and RTOG 9402 phase III studies with addition of procarbazine, lomustine, and vincristine to radiotherapy.
Assess Once daily (OD) chemoradiation effectiveness for limited stage small cell lung cancer compared with twice daily (BID) chemoradiation.
New indication concerns the adjuvant treatment of adult patients with germline BRCA1/2 mutations who have HER2-negative, high risk early breast cancer.
Age and Frailty Should Be Considered Independently When Evaluating Potential Risk for Side Effects Among Older Adults Treated with ICIs
When evaluating both age and frailty in the same model, the identified associations remained significant. The authors concluded that age and frailty may need to be considered independently when evaluating their use as potential factors influencing risk of toxicity among older adults receiving ICIs.
Dyskusja odnośnie skuteczności HIPEC w leczeniu raka jajnika toczy się od wielu lat, ale nabrała intensywności po opublikowaniu przez zespół badaczy holenderskich wyników badania OVHIPEC w roku 2018.
Diagnoza choroby nowotworowej oraz związanego z tym leczenia może obniżać jakość relacji intymnych pacjentek. Czy jesteśmy w stanie im pomóc? Jak prawidłowo rozmawiać z pacjentką? Gościem PTGO będzie specjalista w dziedzinie seksuologii, ginekolog onkolog prof. dr hab. Krzysztof Nowosielski.
FDA granted accelerated approval to tisagenlecleucel for adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. Evidence for efficacy is based on the results from the ELARA study.
EMA Issues Direct Healthcare Professional Communications for Crizotinib-Related Vision Disorders in Paediatric Patients
EMA issued Direct Healthcare Professional Communications (DHPC) to inform healthcare professionals of the risk of ocular toxicity, severe visual loss and the need for monitoring in paediatric patients treated with crizotinib.
Zalecenia Polskiego Towarzystwa Ginekologii Onkologicznej dotyczące diagnostyki i leczenia raka endometrium
Wkrótce Polskie Towarzystwo Ginekologii Onkologicznej opublikuje nowe zalecenia dotyczące diagnostyki i leczenia raka endometrium. Powołany został zespoł do spraw opracowania zaleceń.
Cancer-directed therapies—chemotherapeutic agents, radiation, targeted therapies, and immunotherapy—can all damage the cardiovascular system, causing cancer survivors to have a higher cardiovascular mortality risk than the general population.
Encouraging data from the phase 2 CITYSCAPE trial led to the Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the combination of the anti-TIGIT drug tiragolumab with atezolizumab at the start of 2021.
Long-term follow-up of chemoradiotherapy treatment in glioma patients shows significantly increased survival
Glioma is a type of brain cancer that is rare and difficult to treat. Until quite recently, gliomas were considered to be incurable and often became rapidly fatal, but now two trials have shown that the addition of chemotherapy to radiotherapy (RT) can improve both disease control and survival in the long term for patients with a glioma.
ASCO Releases First Comprehensive Evidence-Based Guidelines for Metastatic Clear Cell Renal Cell Carcinoma
ASCO has released the first comprehensive set of guidelines for the management of metastatic clear cell renal cell carcinoma (ccRCC). The guidelines were formulated using data obtained from a systematic review of literature published between 2007 and March 2022.
Perioperative Therapy for Early-Stage Non–Small Cell Lung Cancer: What Advances Have Been Made, and What Questions Remain?
The standard of care for non–small cell lung cancer (NSCLC) is evolving, with adjuvant chemotherapy after complete resection being supplemented by treatment options such as EGFR tyrosine kinase inhibitors (TKIs) and neoadjuvant PD-L1 inhibitors.
PTChO zaprasza na kolejne warsztaty z zakresu diagnostyki inwazyjnej gruczołu sutkowego. Tym razem spotkanie odbędzie się w trybie Webinaru. Jego celem jest zapoznanie uczestników z inwazyjną diagnostyką gruczołu sutkowego, głównie z systemami biopsji piersi wspomaganymi próżniowo. Termin 29.06.2022, godzina 17:00.
Pragnę zaprosić Państwa na kolejne, XXI Spotkanie Po ASCO, które odbędzie się w Gdańsku w dniach 1-2 lipca 2022 roku. Z racji utrzymującego się zagrożenia epidemicznego, w tym roku postanowiliśmy utrzymać formułę konferencji on-line. Mamy nadzieję, że interesujący program merytoryczny pozwoli choć częściowo zrekompensować Państwu brak bezpośredniego kontaktu - Jacek Jassem.
Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation
Durvalumab is recommended as an option for treating locally advanced unresectable non-small-cell lung cancer (NSCLC) in adults whose tumours express programmed cell death ligand 1 (PD‑L1) on 1% or more of cells and whose disease has not progressed after platinum-based chemoradiation, only if they have had concurrent platinum-based chemoradiation.
Risk of Anal Cancer Significantly Lower with Treatment for Anal High-Grade Squamous Intraepithelial Lesions
In a phase III study, the ANCHOR Investigators Group found that participants who had undergone treatment for anal high-grade squamous intraepithelial lesions had a rate of progression to anal cancer that was 57% lower than those who had undergone active monitoring.
New population study on adjuvant hormone therapy for breast cancer finds correlation between hot flashes and poorer outcomes—in contrast to clinical trial results; likely due to patients with side-effects ending treatment early.
Efficacy and Safety of Trastuzumab and Pertuzumab in Combination with FLOT for Perioperative Treatment of Resectable, HER2-positive Oesophagogastric Adenocarcinoma
A randomised phase II study evaluated the clinical efficacy of the combination of trastuzumab and pertuzumab with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT regimen) as perioperative treatment for patients with resectable, locally-advanced HER2–positive oesophagogastric adenocarcinoma.
Patterns of relapse after adjuvant (chemo)radiation for cervical cancer in a phase III clinical trial
Study supports the use of newly published NRG/RTOG contouring guidelines in patients with cervical cancer who have undergone hysterectomy. Further data is needed to ascertain if anterior extension of the CTV is needed as in PARCER trial.
A Clinical Signal of Efficacy Observed with a Combination of Nivolumab and Ipilimumab Over Platinum Doublet in Fit Elderly Patients with Advanced NSCLC
The authors explained in the study background that a combination of PD1 and CTLA4 monoclonal antibodies have shown superiority over chemotherapy in patients with advanced NSCLC, but data for fit elderly or patients with PS 2 are scarce.
NICE’s final draft guidance recommends abemaciclib for people with hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence who have had surgery to remove their tumour.
Carriers of a Germline Pathogenic Variant in CDKN2A are at a High Lifetime Risk of Pancreatic Ductal Adenocarcinoma
Surveillance in this population leads to diagnosis of early-stage disease in one third of patients resulting in increased resectability and a substantial 5-year survival rate.
Detecting Molecular Residual Disease to Inform CRC Treatment: Are We Ready for Universal Postoperative ctDNA Screening?
Circulating tumor DNA (ctDNA), when used as a marker for minimal residual disease after curative-intent resection, is increasingly recognized as a powerful prognostic marker for patients with colorectal cancer (CRC).
Patients with Child-Pugh B liver cirrhosis are a heterogeneous group and should be treated based on individual scores and features of presentation.
No Survival Benefit for Adding Adjuvant Chemotherapy to Endocrine Therapy in Older Patients with ER-positive/HER2-negative Breast Cancer with High Genomic Grade Index
A large phase III Unicancer ASTER 70s study showed that adding adjuvant chemotherapy to endocrine therapy does not result in a statistically significant overall survival benefit in patients older than 70 years with oestrogen receptor (ER)-positive, HER2-negative breast cancer with a high tumour genomic grade index.
New indication concerns a combination of selinexor with bortezomib and dexamethasone for the treatment of multiple myeloma.
Longest Follow-Up of CAR T-Cell Therapy in Mantle Cell Lymphoma Points Out to Long-Term Responses with Relapsed/Refractory Disease
After nearly a 3-year follow-up for patients with relapsed/refractory mantle cell lymphoma in ZUMA-2 study, treatment with anti-CD19 chimeric antigen receptor T-cell therapy, brexucabtagene autoleucel showed durable responses and sustained survival with a manageable safety profile.
Refining the definition of biochemical failure in the era of stereotactic body radiation therapy for prostate cancer
The Phoenix definition remains an excellent definition for biochemical failure post-SBRT. Its high false positivity can be mitigated by applying additional criteria.
It is approved for use in the older or patients with comorbidities who have acute myeloid leukaemia with a susceptible IDH1 mutation detected by an FDA-approved test.
Substantial Clinical Activity of Teclistamab in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma
In a phase I/II study, teclistamab showed substantial clinical activity that compares favourably with that of existing therapies in patients with heavily pretreated relapsed or refractory multiple myeloma.
Adagrasib Shows Clinical Efficacy in Patients with Previously Treated KRASG12C-Mutated Advanced NSCLC
In a phase II cohort study conducted among the patients with previously treated advanced KRASG12C-mutated non-small cell lung cancer (NSCLC), adagrasib showed clinical efficacy without new safety signals.
Chemo Plus Endocrine Therapy Does Not Improve Survival in Older Patients With HER2-Negative Breast Cancer and High Tumor Genomic Grade Index
Results from the Unicancer ASTER 70s trial showed that adding adjuvant chemotherapy to endocrine therapy does not result in a statistically significant survival benefit in patients older than 70 with estrogen receptor–positive, HER2-negative breast cancer with a high tumor genomic grade index.
Promising Safety and Efficacy With Intermediate Dosing Regimen of MDM2–p53 Antagonist in Patients With Advanced or Metastatic Liposarcoma
Updated phase 1a/1b data on the MDM2–p53 antagonist BI 907828 found that intermittent dosing increased the safety profile while demonstrating promising efficacy in patients with advanced for metastatic liposarcoma.
Trastuzumab Deruxtecan Shows Encouraging Results in Patients With HER2-Expressing Biliary Tract Cancers
The investigator-initiated phase 2 HERB trial of patients with HER2-positive biliary tract cancers showed that trastuzumab deruxtecan treatment leads to significant improvement in objective response rate.
Overall Survival Increased Among Patients With Recurrent Platinum-Resistant Ovarian Cancer Who Received Intermittently Dosed Relacorilant
An updated analysis of an open-label, 3-arm, phase 2, randomized trial of relacorilant plus nab-paclitaxel for patients with recurrent platinum-resistant ovarian cancer found that cortisol modulation improved median overall survival.
This ESMO Clinical Practice Guideline provides key recommendations for managing endometrial cancer. The guideline covers clinical and pathological diagnosis, staging and risk assessment, treatment and follow-up. Treatment and management algorithms according to risk-groups and for advanced/metastatic or recurrent disease are provided.
FDA Approves Nivolumab in Combination with Chemotherapy and Nivolumab in Combination with Ipilimumab for First-Line Treatment of Oesophageal Squamous Cell Carcinoma
FDA approved the following for the first-line treatment of patients with advanced or metastatic oesophageal squamous cell carcinoma: nivolumab in combination with fluoropyrimidine- and platinum-based chemotherapy, nivolumab in combination with ipilimumab.
High Sensitivity of Mismatch Repair–Deficient Locally Advanced Rectal Cancer to Single-Agent PD1 Blockade
In a prospective phase II study that involved patients with mismatch repair–deficient locally advanced rectal cancer, treatment with neoadjuvant single-agent, PD1 inhibitor dostarlimab resulted in a clinical complete response.
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer
Among men with high-risk non-metastatic prostate cancer, combination therapy is associated with significantly higher rates of metastasis-free survival compared with ADT alone. Abiraterone acetate with prednisolone should be considered a new standard treatment for this population.
Presence of Intratumoural TLSs in Advanced STS as a Potential Predictive Biomarker to Improve Patients’ Selection for Pembrolizumab
Findings from the PEMBROSARC study on presence of tertiary lymphoid structures in patients with advanced soft tissue sarcomas.
Adjuvant Denosumab Improves Long-term Survival and Bone Protection in Patients With Early-Stage Breast Cancer Taking Aromatase Inhibitors
The addition of the human monoclonal antibody denosumab to endocrine therapy with aromatase inhibitors (AIs) extends disease-free survival (DFS), overall survival, and bone metastasis–free survival (BMFS) while also improving bone health over a median of 8 years.
LUMINA Trial: Omitting Radiotherapy in T1N0 Luminal A Breast Cancer Yields Low Rates of Local Recurrence
The LUMINA trial prospectively evaluated the rates of recurrence in women who have undergone breast-conserving surgery for luminal A grade 1-2 T1N0 breast cancer and were treated with adjuvant endocrine therapy alone, without adjuvant radiation.
DESTINY-Breast04 Establishes Trastuzumab Deruxtecan As a New Standard of Care for HER2-Low Metastatic Breast Cancer
DESTINY-Breast04 is the first randomized clinical trial to show that targeting HER2 provides clinically meaningful benefits for patients with HER2-low metastatic breast cancer.
Panitumumab Combined With FOLFOX Emerges As the New First-Line PARADIGM for Left-Sided RAS Wild-Type Metastatic Colorectal Cancer
PARADIGM represents the largest randomized first-line study to prospectively compare the efficacy of different targeted therapies in combination with standard doublet chemotherapy based on tumor sidedness.
Addition of Neoadjuvant Nivolumab to Chemotherapy Improves Pathologic Complete Response in Resectable Stage IIIA NSCLC
The NADIM II trial found that neoadjuvant nivolumab plus carboplatin-based chemotherapy improves pathologic complete response for patients with resectable stage IIIA NSCLC compared with chemotherapy alone, validating the results of CheckMate-816.
Polskie Towarzystwo Chirurgii Onkologicznej ogłasza konkurs na najlepszą pracę dotyczącą czerniaka opublikowaną od 2021 roku do końca czerwca 2022 roku przez zespół autorski, w którym pierwszy autor i/lub ostatni autor posiada afiliację krajowego ośrodka.
Improving Outcomes in Pancreatic Cancer: Identifying New Targets and Testing Novel Combination Therapies
During the 2022 ASCO Annual Meeting, poster presentations from 3 different studies focused on identifying new therapeutic targets and improving outcomes for patients with pancreatic cancer.
CDK4/6 Inhibition Plus Endocrine Therapy Extends Post-Progression PFS in HR-Positive/HER2-Negative Metastatic Breast Cancer
The MAINTAIN trial found a significant progression-free survival (PFS) benefit when patients with hormone receptor-positive/HER2-negative metastatic breast cancer changed endocrine therapies and received ribociclib following progression on CDK4/6 inhibitor.
Pooled Analysis Describes Incidence and Patterns of MACE and Associated irAEs With Immune Checkpoint Inhibitor–Based Therapies
This was a pooled analysis of National Cancer Institute Cancer Therapy Evaluation Program (NCI CTEP)–sponsored clinical trials immune checkpoint inhibitor (ICI) focusing on major adverse cardiac events (MACE).
Sacituzumab Govitecan Provides PFS Benefit Over Single-Agent Chemotherapy in Heavily Pretreated HR+/HER2− Metastatic Breast Cancer
Sacituzumab govitecan demonstrated a significant progression-free survival improvement over chemotherapy of physician's choice in patients with HR+/HER2− metastatic breast cancer previously treated with endocrine therapy, a CDK4/6 inhibitor, and a median of 3 lines of chemotherapy.
In a phase 1/2 study, the novel HER3-targeting antibody-drug conjugate patritumab deruxtecan demonstrated activity in patients with heavily pretreated HER3-expressing metastatic breast cancer across subtypes and regardless of the level of HER3 expression.
NRG-BR002 Trial: Adding Ablation to Systemic Therapy Fails to Boost PFS in Oligometastatic Breast Cancer
Stereotactic radiotherapy or surgery for treatment metastatic lesions failed to improve progression-free survival for patients with oligometastatic breast cancer, defined as 4 or fewer metastatic lesions.
FOENIX-CCA2 Analysis Confirms Safety and Efficacy of Futibatinib for Advanced Intrahepatic Cholangiocarcinoma With FGFR2 Fusions/Rearrangements
Data from the pivotal FOENIX-CCA2 trial presented during the 2022 ASCO Annual Meeting upholds previously reported efficacy and safety outcomes of futibatinib for patients with intrahepatic cholangiocarcinoma and FGFR2 fusions/rearrangements.
Second-line pembrolizumab plus ramucirumab demonstrated a potential survival benefit for patients with advanced non–small cell lung cancer with immune checkpoint inhibitor resistance compared with standard-of-care regimens that included docetaxel plus ramucirumab.
Effect of Adding Chemotherapy to First-Line Immunotherapy in Advanced NSCLC With PD-L1 ≥ 50% Varies by Age in Exploratory FDA Pooled Analysis
In a retrospective pooled analysis from 12 trials in patients with previously untreated advanced non–small cell lung cancer with PD-L1 ≥ 50%, OS did not appear different between chemoimmunotherapy and immunotherapy alone across most patient subgroups.
Immune Checkpoint Inhibitor Plus Chemotherapy Offers Similar Benefit in NSCLC Regardless of KRAS Status
Patients with KRAS-mutated non–small cell lung cancer benefit similarly from the combination of an immune checkpoint inhibitor (ICI) and chemotherapy as those with wild-type disease.
Adagrasib, a second-in-class agent that specifically targets KRAS G12C, exhibits promising efficacy and is well tolerated in patients with previously treated advanced non–small cell lung cancer.
Two hypomethylating agents, decitabine and 5-azacytidine are used clinically. There are many mechanisms of action of these drugs, including irreversibly binding to and inhibiting DNA methyltransferases, which result in hypomethylation and up-regulation of genes such as tumour suppressors.
More than half of patients with localized pancreatic ductal adenocarcinoma (PDAC) have unresectable disease, and the remainder have potentially resectable tumors, either upfront resectable or borderline resectable.
The latest findings affirm that routine molecular profiling should be considered for all patients with advanced CCA, and that knowledge of targeted therapeutic agents' specific toxicities is critical to the treatment of patients with CCA.
ASCO Guideline Update Aims to Improve Patient Outcomes for HER2-Positive Breast Cancer With Brain Metastases
ASCO has released a new guideline update because of new advancements in the treatment of patients with advanced HER2-positive breast cancer.
ASCO Guideline Update Supports New Second- and Third-line Systemic Treatments for HER2-Positive Breast Cancer
ASCO has issued a new practice guideline update on the use of systemic therapy for HER2-positive breast cancer that could inform new therapeutic algorithms and potentially alter the standard of care in systemic therapy for this patient population.
FDA approved azacitidine for paediatric patients with newly diagnosed juvenile myelomonocytic leukaemia. Efficacy was evaluated in AZA-JMML-001 (NCT02447666), an international, multicentre, open-label study.
W dniach od 3 do 4 czerwca 2022 roku odbywa się, po dwóch latach przerwy spowodowanej pandemią COVID-19, siedemnasta już edycja konferencji Usteckie Dni Onkologiczne. W tym roku spotkanie ma miejsce jak w poprzedniej edycji w gościnnym Gdańsku.
PTChO zaprasza 9 czerwca 2022 r. (czwartek) o godz. 17.00 do udziału w webinarium organizowanym przez Fundację Polskiego Towarzystwa Chirurgii Onkologicznej pt. „Genetyka nowotworów i rak piersi”.
Findings from the largest circulating tumour cells study in patients with metastatic renal cell carcinoma.
R2-ISS: an Improved and Simple Prognostic Staging System Allows Better Stratification of Patients with Intermediate-Risk Newly Diagnosed Multiple Myeloma
Within the HARMONY project, the European Myeloma Network collected data from 10,843 patients with newly diagnosed multiple myeloma to propose a second revision (R2-ISS) of the Revised International Staging System (R-ISS).
ASCO Guideline Update: Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer
This guideline update provides evidence-based recommendations to optimally use currently available biomarkers in the population of women presenting with early-stage breast cancer with known estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) status.
Extended indications concern the treatment of melanoma in adolescents aged 12 years and older and in adjuvant setting extend to Stage IIB and IIC.
Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer
Neoadjuvant gemcitabine-based chemoradiotherapy followed by surgery and adjuvant gemcitabine improves OS compared with upfront surgery and adjuvant gemcitabine in resectable and borderline resectable pancreatic cancer.
New indication concerns he treatment of adult patients with relapsed or refractory follicular lymphoma after three or more lines of systemic therapy.
Gene Expression Signature May Predict Response to PD-1 Inhibition in High-Risk, HER2-Negative Early Breast Cancer
A test for the expression of a set of 53 genes, called the ImPrint signature, may help predict patients with high-risk, HER2-negative early breast cancer who will respond to PD-1 inhibition, according to a subgroup analysis of the I-SPY2 phase 2 trial.
New findings from a phase 1a/1b trial (Abstract 1021) show that the novel SERD imlunestrant is safe and demonstrated preliminary efficacy in ER-positive advanced breast cancer and endometrial endometrioid cancer.
Two Clinical Trials on CDK4/6 Inhibitors for HR-Positive Breast Cancer Reveal Distinct Quality of Life Outcomes
A comparative effectiveness analysis between 2 randomized clinical trials found ribociclib plus aromatase inhibitor (AI) to be associated with better patient-reported quality of life compared with abemaciclib plus AI as a first-line treatment for hormone receptor (HR)–positive, HER2-negative advanced breast cancer.
Reduced-Dose Exemestane Noninferior to Standard Daily Dose in Postmenopausal Women With Early ER-Positive Breast Cancer
Findings from a noninferiority phase 2b biomarker study indicate that the aromatase inhibitor exemestane taken 3 times per week is noninferior to the standard daily dose among postmenopausal women with estrogen receptor-positive breast cancer.
Collective findings from the SURF study conducted in Japan indicate that surgery and radiofrequency ablation (RFA) confer similar long-term outcomes when used in patients with early-stage hepatocellular carcinoma (HCC).
The different immunohistochemistry (IHC) assays available to test for PD-L1 positivity in patients with gastric cancer yield significantly discordant results.
Taking the Unconventional Route: Locoregional Administration of Novel Pharmacotherapies Shows Promise
A key shortcoming of select systemic anticancer therapies is limited penetration into solid tumors. One potential solution is to deliver highly active drugs locoregionally at the site of the malignant lesions, thereby maximizing the cytotoxic effects while minimizing systemic toxicity.
A personalized neoantigen-specific immunotherapy vaccine is immunogenic in pancreatic ductal adenocarcinoma (PDAC) and can be manufactured in real time and delivered in a median of 9 weeks following surgery, according to findings from an investigator-initiated phase 1 trial (Abstract 2516).
A post hoc exploratory analysis of 35 participants from the PACIFIC trial with stage III EGFR-mutation positive (EGFRm) non–small cell lung cancer (NSCLC) indicated a similar survival benefit of durvalumab treatment versus placebo.
Stereotactic Radiosurgery Demonstrates Similar Survival Outcomes as Whole-Brain Radiation in SCLC and IMD
New research findings suggest stereotactic radiosurgery (SRS) may be associated with comparable survival outcomes to whole-brain radiation therapy in patients with small cell lung cancer (SCLC) and intracranial metastatic disease.
Improving Outcomes in NSCLC: Understanding the Mechanisms of Resistance to ICIs and Expanding Treatment Options With Bispecific Antibodies
Despite drastic improvement in survival brought on by the approval of immune checkpoint inhibitors for non–small cell lung cancer, less than 50% of patients with advanced NSCLC do not respond to immunotherapy and, of those who achieve an initial response, a significant fraction will progress over time.
Lurbinectedin Monotherapy Continuation After Induction of Lurbinectedin/Doxorubicin Is Associated With Prolonged OS in Advanced SCLC
New data suggest patients experience similar, and in some cases better, tumor response from switching to monotherapy with the novel drug lurbinectedin following administration of combination lurbinectedin/doxorubicin.
Stanowisko PTGO w sprawie dawki Bewacizumabu stosowanej w I linii leczenia chorych z rakiem jajnika po 1 maja 2022r
W związku ze zmianami sposobu refundacji leku bewacizumab, Polskie Towarzystwo Ginekologii Onkologicznej w oparciu o badania kliniczne, opinie AOTMiT oraz doświadczenia własne, przedstawia opinię dotyczącą dawki bewacizumabu stosowanej w I linii w leczeniu chorych z rakiem jajnika.
New injectable immunotherapy treatment for rare form of triple negative breast cancer recommended by NICE
People with triple negative breast cancer that has spread to other parts of the body may soon benefit from pembrolizumab in combination with chemotherapy (paclitaxel or nab-paclitaxel) following the final draft recommendation from NICE.
Arm Z1F of the NCI-MATCH study run by ECOG-ACRIN met a primary endpoint with copanlisib, showing promising clinical activity in select PIK3CA-mutated cancers in the late-line, refractory setting.
An academic clinical decision support system to better address the challenges of delivering biomarker-driven oncology.
The 2022 ASCO Annual Meeting will feature the Education Session “Contemporary Treatment of Older Adults with Acute Myeloid Leukemia: Merging the Science with Clinical Practice”.
Rada Przejrzystości AOTMiT uznaje za zasadną kontynuację refundacji leków zawierających substancję czynną capecitabinum w terapii nowotwóru złośliwego trzustki w ramach uzupełniającego leczenia pooperacyjnego trzustki w skojarzeniu z gemcytabiną.
New indication concerns the adjuvant treatment of patients with early-stage non-small cell lung cancer.
Is Radiation-Induced Cardiac Toxicity Reversible? Prospective Evaluation of Patients With Breast Cancer
RT was associated with short-term perfusion defects that improved within one year and was not correlated with late cardiac events. The ventricular volumes receiving 5.0 Gy and 10 Gy were correlated with late cardiac events.
The study that evaluated the associations of chronic hepatitis B and nucleos(t)ide analogue treatment with the risk of the development of extrahepatic malignancies point out to a need for more attention to the higher risk of extrahepatic malignancy in patients with chronic hepatitis B than in the general population.
This is an evidence-based guideline for prostate brachytherapy. Throughout levels of evidence quoted are those from the Oxford Centre for Evidence based Medicine.
Screen-Detected Colorectal Cancers Have a More Favourable Stage Distribution than Colorectal Cancers Detected Otherwise
The authors concluded that the proportion of colorectal cancer cases detected by screening varied widely between countries and regions. However, in all countries, screen-detected cancers had a more favourable stage distribution than cancers detected otherwise.
ASCO Guideline Rapid Recommendation Update: Use of Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer
This American Society of Clinical Oncology (ASCO) Clinical Practice Guideline Recommendation Update provides a recommendation update, with review and analysis of the relevant literature for the recommendation.
The Education Session will discuss the history and challenges of treating KRAS mutations, the CodeBreaK 100 trial, and what's next in the KRAS inhibitor pipeline.
The review follows interim results from the ongoing ARIEL4 study indicating that overall survival was shorter in patients treated with rucaparib than in those who received chemotherapy.
Niespecyficzne objawy kliniczne powodują opóźnienie diagnostyki, a w konsekwencji rozpoznanie raka jajnika w stadium rozsianej choroby. Wybór metody leczenia zależy od stopnia zaawansowania tego nowotworu. Chirurgia jest niezwykle ważnym elementem całego procesu diagnostyczno-terapeutycznego.
A new ASCO guideline offers evidence-based recommendations for exercise, diet, and weight management during cancer treatment with the hope these recommendations will mitigate treatment-related side effects of cancer therapy and reduce the risk of postoperative complications associated with certain interventions.
Incidence of Colorectal, Breast, Kidney, Pancreatic, and Uterine Cancers is Increasing in Young Adults
Group of investigators from UK and Australia found that the incidence of colorectal, breast, kidney, pancreatic, and uterine cancers is increasing in younger age groups, whilst the incidence of lung, laryngeal and bladder cancers is decreasing.
Tepotinib is recommended as an option for treating advanced non-small-cell lung cancer (NSCLC) with METex14 skipping alterations in adults.
EMA adopted a positive opinion for the medicinal product mosunetuzumab, intended for the treatment of relapsed or refractory follicular lymphoma.
Draft NICE guidance recommends innovative technology used to establish whether breast cancer has spread
A magnetic marker liquid injected into people with invasive breast cancer will help surgeons discover if the cancer has spread, after the technology was recommended in draft NICE guidance.
Palliative RT improves QoL. Both SBRT and cRT have a comparable effect on patient-reported QoL outcomes in patients with painful bone metastases. Functional interference and psychological aspects scores improved more in patients treated with cRT versus patients offered SBRT.
Long-Term Responders with No Evidence of Disease Have Better Survival to First-Line HER2 Targeted Therapy for MBC
Evaluation of clinical characteristics of patients with HER2-positive metastatic breast cancer with no evidence of disease (NED) versus those with residual disease experiencing long-term response to first-line HER2-targeted therapy showed that those with NED status have better survival.
More people could benefit from life-extending advanced lung cancer treatment after it was recommended for routine use
NICE has published a draft final appraisal document recommending Durvalumab as an option for treating non-small-cell lung cancer (NSCLC) in adults.
Adolescent and Young Adult Leukemia Survivors Face Higher Mortality Rates Than the General Population for Decades After Diagnosis
The long-term survival of adolescent and young adult acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) survivors was shorter than that of the general population, and the differences persisted for up to 30 years after diagnosis.
EMA adopted a positive opinion for the medicinal product capmatinib, intended for treatment of patients with advanced non-small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping.
We examined the literature to issue new recommendations on active surveillance (AS) for managing localised prostate cancer.
Jeszcze w tym roku uruchomiony zostanie nowy system e-KRN+ oraz pierwszy rejestr narządowy – Polski Rejestr Onko-Hematologiczny (PROH). W związku w tym, zespół Krajowego Rejestru Nowotworów zaprasza pracowników placówek medycznych na spotkanie informacyjne, podczas którego zostaną omówione szczegóły techniczne i organizacyjne planowanych zmian.
Antitumour Activity and Favourable Safety Demonstrated After Treatment with Nivolumab and Ipilimumab Combined with SBRT for Refractory Metastatic Pancreatic Cancer
First prospective evaluation demonstrates a clinical benefit and safety of stereotactic body radiotherapy (SBRT) in combination with nivolumab and ipilimumab in pretreated patients with refractory metastatic pancreatic cancer.
Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy
Avelumab is recommended as an option for maintenance treatment of locally advanced or metastatic urothelial cancer that has not progressed after platinum-based chemotherapy in adults, only if avelumab is stopped at 5 years of uninterrupted treatment or earlier if the disease progresses.
Remote Monitoring of Patients Treated with Oral Anticancer Drugs Improves Patient Care Experience and Optimises Healthcare Resources
In a single-centre, randomised phase III CAPRI study that compared an intervention combining nurse navigator-led follow-up and a smartphone application on top of usual care versus usual care in patients with advanced cancers treated with oral anticancer drugs met its primary endpoint of significant improvement in relative dose intensity.
A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides guidance on the use of radiation therapy to treat patients with brain metastases. Evidence-based recommendations guide the multidisciplinary planning and delivery of advanced radiation therapy techniques to manage intact and resected brain metastases from non-hematologic solid tumors.
The multi-centre EORTC PEACE-1 Phase 3 trial examines the effect of Abiraterone on men with metastatic hormone-naïve1 prostate cancer. Patients have been randomised into groups studying the impact of standard therapy with or without radiotherapy and standard treatment plus Abiraterone with or without radiotherapy.
Shortening Duration of Adjuvant Treatment from 6 to 3 Months Did Not Compromise Efficacy in Asian Patients with Stage III Colon Cancer
In Asian patients with stage III colon cancer, shortening duration of adjuvant treatment from 6 to 3 months did not compromise efficacy. Disease-free survival (DFS) and overall survival (OS) at 5 years were comparable in the 3-month and 6-month treatment groups.
Comparison of Efficacy and Side Effects of Bicalutamide Compared With Luteinizing Hormone-Releasing Hormone Analogs in Combination With Radiation Therapy
CHHiP is a randomised trial evaluating moderately hypofractionated radiation therapy for treatment of localised prostate cancer. This exploratory analysis compares efficacy and side effects in a nonrandomised comparison.
FDA Grants Regular Approval to fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HER2-positive Breast Cancer
FDA approved fam-trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within 6 months of completing therapy.
Polskie Towarzystwo Chirurgii Onkologicznej ogłasza konkurs na najlepszą pracę dotyczącą czerniaka opublikowaną od 2021 roku do końca czerwca 2022 roku przez zespół autorski, w którym pierwszy autor i/lub ostatni autor posiada afiliację krajowego ośrodka.
New indication concerns a neoadjuvant and adjuvant treatment of adult patients with triple negative breast cancer at high risk of recurrence.
Imiquimod is a Safe and Effective Alternative to Surgery for Vulvar High-Grade Squamous Intraepithelial Lesions
According to findings from a multicentre, randomised, phase III, non-inferiority study imiquimod is a safe, effective, and well accepted alternative to surgery for women with vulvar high-grade squamous intraepithelial lesions and can be considered as first-line treatment.
As a reflection of both how far breast cancer treatment has come and how much progress is still needed, a trio of Education Sessions at the 2022 ASCO Annual Meeting will discuss some of the latest advances in managing breast malignancies.
The upcoming 2022 ASCO Annual Meeting Education Session “Novel Therapies in Germline Syndromes” will discuss the recent advances in treatments for inherited disease.
New indication concerns the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
Education Session to Address the Increasing Complexity of Treatment Sequencing in Resectable Lung Cancer
A 2022 ASCO Annual Meeting Education Session, “Treatment Sequencing in Resectable Lung Cancer: The Good and the Bad of Adjuvant Versus Neoadjuvant Therapy,” will address these questions, clarifying which interventions garner the best outcomes in the adjuvant and neoadjuvant setting.
Neoadjuvant Nivolumab Plus Chemotherapy Results in Significantly Longer Event-Free Survival in Patients with Resectable NSCLC
Findings from a phase III study show that neoadjuvant nivolumab plus chemotherapy had a significant benefit over chemotherapy alone with respect to event-free survival and pathological complete response and had no adverse effect on surgical feasibility or surgical outcomes in patients with resectable stage IB to IIIA non-small cell lung cancer.
Triplet Therapy with ADT, Docetaxel and Abiraterone Plus Prednisone Improves Survival in De Novo Metastatic Castration-Sensitive Prostate Cancer
Combining androgen deprivation therapy, docetaxel, and abiraterone plus prednisone in patients with de novo metastatic castration-sensitive prostate cancer improved coprimary endpoints of radiographic progression-free survival and overall survival with a modest increase in side effects, mostly hypertension, according to findings from the PEACE-1 study.
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer
Sugemalimab after definitive concurrent or sequential chemoradiotherapy could be an effective consolidation therapy for patients with stage III NSCLC whose disease has not progressed after sequential or concurrent chemoradiotherapy. Longer follow-up is needed to confirm this conclusion.
Cabozantinib is indicated as monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma, refractory or not eligible to radioactive iodine who have progressed during or after prior systemic therapy.
This special article provides updated treatment recommendations on thyroid cancer. New targeted systemic therapies have now been approved for treating patients with advanced/metastatic thyroid cancers. This article summarises these new options and the order in which they should be used.
In the largest and most detailed population-based cohort study to date, the researchers from the Karolinska Institutet in Stockholm, Sweden found that individuals with autism spectrum disorders, when present with comorbid intellectual disability and/or birth defects, were at a higher risk of cancer in early life, compared with individuals without autism spectrum disorders.
A comprehensive multidisciplinary approach is crucial to accurately diagnosing and optimally managing immune-related adverse events (irAEs) in patients with metastatic non–small cell lung cancer.
ASCO Refines Guidance on Using Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer
A new ASCO guideline update provides further recommendations on the use of biomarkers to guide decision-making on adjuvant endocrine therapy and chemotherapy in patients with early-stage breast cancer.
Education Session to Highlight Immunotherapies As Emerging Targets of Prostate Cancer Treatment Development
With the advent of immunotherapies helping to drive improvements in cancer survival and disease recurrence, a growing number of phase 3 clinical trials are underway or in development to investigate these groundbreaking treatments in prostate cancer.
Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies
Tucatinib with trastuzumab and capecitabine is recommended, within its marketing authorisation, as an option for treating HER2‑positive locally advanced or metastatic breast cancer in adults after 2 or more anti‑HER2 treatment therapies.
Ivosidenib and Azacitidine Combination Shows Significant Clinical Benefit in Patients with Newly Diagnosed IDH1-Mutated AML
In a phase III, AGILE study, ivosidenib and azacitidine significantly improved event-free survival (EFS), response, and overall survival (OS) as compared with placebo and azacitidine in patients with newly diagnosed IDH1-mutated acute myeloid leukaemia (AML) who were ineligible for induction chemotherapy.
Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy
Patients with non-small-cell lung cancer that are resistant to PD-1 and PD-L1 targeted therapy have poor outcomes. Studies suggest that radiotherapy could enhance antitumour immunity. Therefore, we investigated the potential benefit of PD-L1 (durvalumab) and CTLA-4 (tremelimumab) inhibition alone or combined with radiotherapy.
Enzalutamide Plus ADT Significantly Prolongs Survival in Patients with Metastatic Hormone-Sensitive Prostate Cancer
Enzalutamide in combination with androgen deprivation therapy (ADT) showed clinical benefits in the phase III ARCHES study for the treatment of men with metastatic hormone-sensitive prostate cancer (mHSPC).
PTChO serdecznie zaprasza do udziału w drugim spotkaniu z hybrydowego cyklu Akademia Czerniaka 2022. Wydarzenie odbędzie się 20 maja. Udział online lub osobisty w Hotel Tarnovia w Tarnowie. Przewodniczący Komitetu Naukowego: prof. dr hab. n. med. Piotr Rutkowski.
Do czego służy badanie śródoperacyjne? Czy może stanowić ostateczne rozpoznanie? Jak prawidłowo pobrać materiał do badania histopatologicznego? Na czym polega ocena badania cytologicznego szyjki macicy? Te i wiele więcej zagadnień poruszymy spotkaniu z prof. Andrzejem Marszałkiem – wybitnym patomorfologiem.
It is intended for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies.
ViaMedica zaprasza do udziału w konferencji Od genetyki do kliniki, która odbędzie się w formule hybrydowej. Wydarzenie odbędzie się 13-14 maja. Udział online lub osobisty w Hotel Best Western Plus Olsztyn. dr hab. n. med. Tomasz Kubiatowski, prof. CMKP.
Clinical Practice Guideline – The Role of Patient-Reported Outcome Measures in the Continuum of Cancer Clinical Care
This ESMO Guideline provides key recommendations on the role of PROMs during the care of patients with cancer. It covers the use of PROMs in patients with cancer from the start of active treatment during follow-up and at the end of life. Recommendations are based on available scientific evidence and the authors’ collective expert consensus.
Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer
Niraparib is recommended as an option for treating relapsed, platinum-sensitive high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to the most recent course of platinum-based chemotherapy in adults.
The VISION study recently demonstrated that LuPSMA prolongs survival for men with metastatic castration-resistant prostate cancer and has a favorable safety profile.
ASCO Guideline Rapid Update Addresses the Use of Neoadjuvant Pembrolizumab in High-Risk Early-Stage TNBC
A rapid update to the ASCO guideline on neoadjuvant therapy for breast cancer adds a recommendation on the use of pembrolizumab in patients with high-risk early-stage triple-negative breast cancer. The update follows a recent analysis from the randomized phase 3 KEYNOTE-522 trial that showed a significant event-free survival benefit.
Evidence-based recommendations were developed to address evaluation and staging workup of patients with suspected stage III NSCLC, surgical management, neoadjuvant and adjuvant approaches, and management of patients with unresectable stage III NSCLC.
The addition of trastuzumab to neoadjuvant chemoradiotherapy for HER2-overexpressing oesophageal cancer was not effective. Trastuzumab did not lead to increased toxicities, suggesting that future studies combining it with or using other agents targeting HER2 in oesophageal cancer are warranted.
In patients included in MyPathway, a multi-basket study assessing approved therapies in non-indicated advanced solid tumours with relevant alterations, alectinib showed activity in patients with ALK-rearranged advanced solid tumours other than non-small cell lung cancer.
FDA Approves Lutetium Lu 177 Vipivotide Tetraxetan for Metastatic Castration-Resistant Prostate Cancer
FDA approved lutetium Lu 177 vipivotide tetraxetan for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy.
Polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) is indicated for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL).
Nutrition affects morbidity and mortality in patients with cancer, yet oncologists do not adequately address this issue. When it comes to patients with cancer—whether newly diagnosed, in active treatment, or in survivorship — an important point to consider in dietary guidance is avoidance of overly rigid rules for eating.
For metastatic melanoma, which should be used in the first-line setting: PD-1 plus LAG-3 inhibitor therapy or PD-1 plus CTLA-4 inhibitor therapy? What is the role of BRAF/MEK in patients with BRAF-mutant disease?
NIL wspólnie z Towarzystwem Chirurgów Polskich zaprasza chirurgów i lekarzy dyscyplin zabiegowych na szkolenie. W programie: Jak wykorzystać czas przed operacją by przygotować pacjenta do zabiegu, Prehablitacja w pigułce – to prostsze niż nazwa wskazuje, Kierunek zdrowie – prehabilitacja w praktyce. Prowadzący: Prof. Tomasz Banasiewicz.
Daratumumab monotherapy is recommended as an option for treating relapsed and refractory multiple myeloma in adults who have had a proteasome inhibitor and an immunomodulator, and whose disease progressed on the last treatment.
FDA Approves a Fixed-Dose Combination of Nivolumab and Relatlimab for Unresectable or Metastatic Melanoma
FDA approved nivolumab and relatlimab-rmbw (Opdualag) for adult and paediatric patients 12 years of age or older with unresectable or metastatic melanoma. Opdualag is a fixed-dose combination of the LAG-3-blocking antibody relatlimab and the PD1-blocking antibody nivolumab.
Leukemia Patients With Certain Gene Regulation Patterns May Be Less Likely to Respond to CAR T Therapy
Acute lymphoblastic leukemia (ALL) cells from patients whose cancers did not respond to CD19-targeted CAR T therapy had gene regulation signatures that could potentially facilitate treatment resistance, according to results presented at the AACR Annual Meeting 2022.
Accounting for Genetic Factors that Cause Normal Variations in PSA Levels May Improve the Accuracy of Prostate Cancer Detection
The accuracy of prostate-specific antigen (PSA) screening for prostate cancer could be improved by accounting for genetic factors that cause changes in PSA levels that are not associated with cancer, according to data presented during the AACR Annual Meeting 2022.
Increased Efficacy of Pembrolizumab or Pembrolizumab-Chemotherapy with Increasing PD-L1 Expression in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
The phase III KEYNOTE-048 study investigated pembrolizumab monotherapy or pembrolizumab plus chemotherapy compared with cetuximab plus chemotherapy in patients with previously untreated recurrent or metastatic HNSCC.
Lekarz od wieków pozostaje zawodem o bardzo wysokim poziomie zaufania społecznego. Jednak nawet lekarze pozostają tylko ludźmi, a co za tym idzie, nie są nieomylni. Dlatego też, zaczynając pracę w tej profesji, warto zapoznać się z tematem lekarskiej odpowiedzialności cywilnej, a także ubezpieczeń od tejże odpowiedzialności.
The approval of abemaciclib in adjuvant EBC was limited to patients with high risk of recurrence and Ki-67 ≥ 20%, given their favorable benefit:risk with a statistically significant IDFS advantage and no observed detriment on survival.
Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion
Patients with metastatic or advanced cancer should undergo genomic sequencing in a certified laboratory if the presence of one or more specific genomic alterations has regulatory approval as biomarkers to guide the use of or exclusion from certain treatments for their disease.
A new chimeric antigen receptor (CAR) T-cell product had an acceptable safety profile and showed early signs of efficacy as a monotherapy and in combination with an mRNA vaccine in patients with solid tumors, according to preliminary data from a phase I/II clinical trial.
KRAS G12C Inhibitor Sotorasib May Offer Long-term Clinical Benefit in Patients with Non-small Cell Lung Cancer
Patients with non-small cell lung cancer (NSCLC) treated with the KRAS G12C inhibitor sotorasib (Lumakras) had a two-year overall survival rate of 32.5 percent, according to data from the CodeBreaK 100 clinical trial.
Treatment with Nivolumab and Low-Dose Ipilimumab is Effective and Tolerable in Patients with Previously Treated Progressive Classical Kaposi Sarcoma
In a prospective, phase II study that assessed the efficacy of nivolumab in combination with low-dose ipilimumab in patients with previously treated classical Kaposi sarcoma, the study team observed high response rates and prolonged duration of response with tolerable toxicity.
Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer
Our findings provide the strongest level of evidence so far to the magnitude of the benefit of ADT treatment intensification with radiotherapy for men with localised prostate cancer. Adding ADT and prolonging the portion of ADT that follows radiotherapy is associated with improved metastasis-free survival in men.
EMA Recommends Extension of Indications for Pembrolizumab to MSI-H or dMMR Cancers and to Metastatic Cervical Cancer with PD-L1 CPS ≥1
New indications concern the treatment of patients with MSI-H or dMMR advanced colorectal, endometrial, gastric, small intestine, or biliary cancers, and PD-L1-positive metastatic cervical cancer.
In recent years, circulating tumor DNA has been evaluated in many cancer types and settings, including screening, diagnosing, detecting residual disease, guiding adjuvant therapy, detecting recurrence, monitoring response to therapy, defining mutational profile, and identifying resistance mechanisms.
Benefit of Adjuvant Capecitabine After Curative Resection of Biliary Tract Cancer Maintained with a Long-Term Analysis
The long-term (5-year) survival data from the BILCAP study confirm the benefit of capecitabine as adjuvant therapy after surgical resection of biliary tract cancer and it should be considered as the standard of care.
Europejska Agencja Leków (EMA) wydała pozytywną rekomendację dla stosowania pembrolizumabu do leczenia chorych z guzami MSI-H lub dMMR w zaawansowanym lub nawrotowym raku endometrium z progresją w trakcie lub po leczeniu chemioterapią opartą na związkach platyny.
FDA approved pembrolizumab as a single agent, for patients with advanced endometrial carcinoma that is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and who are not candidates for curative surgery or radiation.
Konferencja w całości poświęcona jest omówieniu wyników badań patomorfologicznych, genetycznych i molekularnych. Gwałtowny rozwój nowych metod leczenia raka piersi, jaki nastąpił w ciągu ostatnich lat, sprawił że pacjentkom może być trudno poruszać się w gąszczu obco brzmiących terminów. Dlatego chcemy przedstawić nowe czynniki, decydujące o odpowiednim doborze leczenia, jak również nieco uporządkować wiedzę o tych znanych już wcześniej.
Both first-line treatment with nivolumab plus chemotherapy and first-line treatment with nivolumab plus ipilimumab resulted in significantly longer overall survival than chemotherapy alone in patients with advanced oesophageal squamous-cell carcinoma.
BRCA1/2 Pathogenic Variant Carriers with Serous Tubal Intraepithelial Carcinoma at Risk-Reducing Salpingo-Oophorectomy are at Increased Risk of Peritoneal Carcinomatosis
The authors concluded that BRCA1/2 pathogenic variant carriers with serous tubal intraepithelial carcinoma at risk-reducing salpingo-oophorectomy are at increased risk of peritoneal carcinomatosis.
ctDNA Detection After Initial Treatment of Early-Stage NSCLC Has Potential to Identify Patients Who May Benefit from Further Therapeutic Intervention
The authors concluded that analysis of ctDNA before and after treatment with curative intent of patients with early-stage NSCLC demonstrated that detection of ctDNA using sensitive personalised assays can inform patient prognosis and help guide patient treatment.
Joining forces to optimise cancer treatments in clinical practice: EMA & EORTC launch Cancer Medicines Forum with academia
A significant step at the European level and in terms of regulatory science, the European Medicines Agency together with the European Organisation for Research and Treatment of Cancer has launched the Cancer Medicines Forum. The forum aims at advancing research into optimising cancer treatments and will contribute to foster high standards in cancer care in the European Union.
Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases
To our knowledge, this is the first prospective study showing the activity and safety of pyrotinib plus capecitabine in patients with HER2-positive breast cancer and brain metastases, especially in radiotherapy-naive population.
NCCN Annual Conference Focuses on Cancer Patient Journey; with Cutting-Edge Research and Latest Evidence-Based Care Recommendations
The NCCN 2022 Annual Conference brings together more than a thousand oncology professionals from around the world to learn about the latest evidence-based treatment recommendations and evaluate new research.
EMA adopted a positive opinion for the medicinal product tebentafusp indicated as monotherapy for the treatment of human leukocyte antigen (HLA) A*02:01 positive adult patients with unresectable or metastatic uveal melanoma.
ASCO Guideline Rapid Recommendation Update: Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I-IIIA Completely Resected Non–Small-Cell Lung Cancer
ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an evidence review.
In this course participants will obtain a thorough knowledge of the fundamentals and state-of-the-art applications of fluorescence imaging of tumors (primary, metastases, lymph nodes), sentinel lymph nodes and lymphatics, vital structures (bile ducts, ureters, nerves) and perfusion assessment of organs and tissues.
Tumour Budding Demonstrates Independent Prognostic Value for Disease-Free and Overall Survival in Patients with Stage III Colon Cancer
Tumour budding is an emerging prognostic biomarker in colon cancer and currently influences decision-making in patients with pT1 and stage II colon cancer. In stage III colon cancer, its prognostic impact has been limited to small and retrospective cohorts.
Sotorasib is recommended for use as an option for treating KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer in adults whose disease has progressed on, or who cannot tolerate, platinum-based chemotherapy or anti-PD-1/PD-L1 immunotherapy.
The US National COVID Cohort Collaborative Consortium Provides Real-World Evidence on Breakthrough COVID-19 Infections in Vaccinated Patients With Cancer
Patients with cancer, especially haematologic malignancies, are at higher risk for developing breakthrough infections and severe outcomes. The findings were published in the Journal of Clinical Oncology.
New mechanisms of genomic escape from established covalent and novel non-covalent Bruton’s tyrosine kinase inhibitors described. The findings were published in the New England Journal of Medicine.
Czy komórki endometriozy ulegają nowotworzeniu? Jakie są czynniki ryzyka sprzyjające transformacji endometriozy w raka jajnika? Co to są nowotwory jajnika typu low-grade? Na te i inne pytania odpowie ekspert w dziedzinie ginekologii onkologicznej, Pani Prof. Anita Chudecka-Głaz.
FDA approved ciltacabtagene autoleucel for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
Nivolumab with ipilimumab is recommended, within its marketing authorisation, as an option for untreated advanced renal cell carcinoma in adults whose disease is intermediate or poor risk as defined in the International Metastatic Renal Cell Carcinoma Database Consortium criteria
EMA adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product relugolix, intended for the treatment of adult patients with advanced hormone-sensitive prostate cancer.
Precision Immunotherapy Developments in Microsatellite Stable (MSS) Gastroesophageal Cancer: Can We Use a Key Instead of a Hammer?
CheckMate-649 and KEYNOTE-590 trials validated the advantage of adding PD-1 inhibitors nivolumab and pembrolizumab, respectively, to 5-FU–based chemotherapy regimens in patients with advanced, chemotherapy-naive gastroesophageal cancer.
A Follow-Up Not Inferior to Radioiodine Ablation in Patients with Low-Risk Differentiated Thyroid Cancer Undergoing Thyroidectomy
In a prospective, randomised phase III study that involved patients with low-risk differentiated thyroid cancer, follow-up without the use of radioiodine after thyroidectomy was not inferior to the administration of 1.1 GBq of radioiodine after the administration of recombinant human thyrotropin.
First-Line Treatment with Ribociclib plus Letrozole Shows a Significant Overall Survival Benefit in HR-positive, HER2-negative Advanced Breast Cancer
First-line treatment with ribociclib plus letrozole showed a significant overall survival (OS) benefit as compared with placebo plus letrozole in postmenopausal patients with HR-positive, HER2-negative advanced breast cancer.
Organizator cyklu konferencji Akademia Czerniaka 2022 zaprasza na pierwszą w tym roku konferencję, która odbędzie się w Gdańsku, 1 kwietnia, o godz. 14:00. W konferencji można uczestniczyć online lub stacjonarnie* w Gdańsku w Hotelu Scandic. Zostaną omówione: leczenie uzupełniające, leczenie przerzutów in-transit i wznowy miejscowej, inne nowotwory skóry (DFPS, zaawansowany BCC, SCC, rak z komórek Merkla), sytuacje specjalne - leczenie przerzutów do mózgu, czerniaki błon śluzowych, czerniak z nieznanego ogniska pierwotnego.
Short-Term Radiotherapy with Preoperative Chemotherapy Followed by Surgery is Efficacious with Acceptable Toxicity in Locally Advanced Rectal Cancer
A randomised, phase III STELLAR study evaluated whether a total neoadjuvant therapy approach comprising hypofractionated radiation (5 Gy × 5) followed by chemotherapy is non-inferior to standard chemoradiotherapy (CRT) in patients with locally advanced rectal cancer.
FDA approved olaparib for the adjuvant treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated human epidermal growth factor receptor 2 (HER2)-negative high-risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy.
Pembrolizumab Significantly Improved Disease-Free Survival Versus Placebo as Adjuvant Therapy in Patients With Stage IB-IIIA Non-Small Cell Lung Cancer Regardless of PD-L1 Expression
EORTC announced results from the pivotal Phase 3 KEYNOTE-091 trial. The study found that adjuvant treatment with KEYTRUDA significantly improved disease-free survival, one of the dual primary endpoints, reducing the risk of disease recurrence or death by 24% compared to placebo.
EMA Adopts a Revised Opinion for Enfortumab Vedotin After Further Safety Information Emerged During the Decision-Making Process
EMA adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product enfortumab vedotin, intended for the treatment of adult patients with urothelial cancer.
ASCO Guidelines Emphasize Crucial Role Biomarkers Play in Treatment Selection for HER2-Negative Breast Cancer
In this article, we provide a brief summary of the guideline updates and clinical practice considerations for the treatment of hormone receptor (HR)–positive and HR-negative/HER2-negative metastatic breast cancer.
A population-based cohort study of all patients with inflammatory bowel disease diagnosed in Norway and Sweden from 1987 through 2016 was conducted to quantify the risk of small bowel adenocarcinoma and neuroendocrine tumours in patients with ulcerative colitis and Crohn’s disease.
Genomic Profiling of Pediatric Cancer May Expand Treatment Options for Patients Experiencing a Relapse
Genomic sequencing of tumors from pediatric cancer patients experiencing a relapse enabled 107 patients to receive an appropriate matched therapy that is not the standard of care, according to data from the international clinical trial MAPPYACTS, published in Cancer Discovery, journal of the AACR.
Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency
Dostarlimab is recommended for use within the Cancer Drugs Fund as an option for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency in adults who have had platinum-based chemotherapy.
Updated CHOICE-01 Data: Toripalimab Improves OS and PFS in NSCLC When Added to First-Line Chemotherapy
Growing evidence supports the use of toripalimab, a humanized monoclonal antibody directed against PD-1, in combination with standard chemotherapy as first-line treatment of advanced non–small cell lung cancer.
More Mature RELATIVITY-047 Data Bolster Potential Use of Combination Relatlimab/Nivolumab in Melanoma
Dual targeting of the LAG-3 and PD-1 immune checkpoint pathways with relatlimab and nivolumab shows additional advantages in patients with previously untreated advanced melanoma.
Randomised Phase III Trial Evaluating Radiation Following Surgical Excision for Good-Risk Ductal Carcinoma In Situ
RT significantly reduced all and invasive IBR for good-risk DCIS with durable results at 15 years. These results are not an absolute indication for RT but rather should inform shared patient-physician treatment decisions about ipsilateral breast risk reduction in the long term following lumpectomy.
FDA approved nivolumab with platinum-doublet chemotherapy for adult patients with resectable non-small cell lung cancer (NSCLC) in the neoadjuvant setting. Efficacy was evaluated in CHECKMATE-816 study.
Classifications is proposed according sensitivity of atypical EGFR mutations to tyrosine kinase inhibitors. A multicentre, retrospective analysis performed by the national Network Genomic Medicine in Germany represents the largest available real-world dataset of atypical EGFR mutations.
One-fourth of BRAFV600E metastatic colorectal cancer are microsatellite instability–high (MSI-H), and one-fifth of MSI-H mCRC display the BRAFV600E mutation (MSI-H)—both of which are associated with poor survival and limited response to chemotherapy, with or without targeted therapy.
ASCO, Ontario Health Recommendations Address Clinical Management and De-escalation Treatment of the Axilla in Early-Stage Breast Cancer
The guideline recommends that patients with early-stage breast cancer who are younger than age 70 without significant competing comorbidities should undergo sentinel lymph node biopsy for axillary staging.
EMA adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product abemaciclib. New indication concerns the use in patients with early breast cancer at high risk of recurrence
Recommendations for adjuvant therapy for patients with resected stage II colon cancer. ASCO convened an Expert Panel to conduct a systematic review of relevant studies and develop recommendations for clinical practice. Twenty-one observational studies and six randomized controlled trials met the systematic review inclusion criteria.
Addition of a Live Bacterial Product Enhances the Clinical Outcome in Patients with mRCC Treated with Nivolumab-Ipilimumab Combination
In a randomised, open-label, single-centre study, a bifidogenic live bacterial product CBM588 augmented response to immune checkpoint inhibitors through modulation of the gut microbiome. CBM588 enhanced the clinical outcome in patients with treatment-naïve metastatic renal cell carcinoma (mRCC) treated with nivolumab–ipilimumab combination.
The National Comprehensive Cancer Network publishes two new NCCN Guidelines for Malignant Peritoneal Mesothelioma and for Ampullary Adenocarcinoma, to standardize treatment and improve outcomes for these rare tumor types; also reaches milestone expanding library of NCCN Chemotherapy Order Templates.
PTChO zaprasza na cykl webinariów „Advances in diagnostics and therapy of melanoma and other skin cancers”. Cykl składa się z trzech spotkań online w następujących terminach: 24.03.2022, 28.04.2022, 09.06.2022. Więcej informacji o webinarium znajduje się na stronie https://melanoma.viamedica.pl.
No Impact on Survival from Dose Reduction and Interruption for the Management of Olaparib Associated Adverse Events
In the SOLO2 study of olaparib, dose reductions and interruptions were used to manage adverse events. However, patients who underwent protocol recommended dose alterations related to adverse events did not have inferior survival outcomes compared to those who received at or very close to the recommended dose.
NICE draft guidance does not recommend pembrolizumab plus chemotherapy for triple negative breast cancer
The evidence showed that pembrolizumab plus chemotherapy is more effective than paclitaxel or nab-paclitaxel, although the long-term benefit is uncertain. In addition, there was no trial data directly comparing pembrolizumab plus chemotherapy with atezolizumab plus chemotherapy, another targeted treatment which NICE already recommends.
The incidence of late pulmonary side effects was statistically significantly higher after IM-MS lymph node irradiation, as were some of the cardiac events, without a difference between left- and right-sided treatments. Absolute rates and differences were very low, without increased non-breast cancer-related mortality, even before introducing heart-sparing techniques.
New indications concern the treatment of unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma and the adjuvant treatment of muscle invasive urothelial carcinoma.
Humoral Response to the Third Dose of the mRNA-based COVID-19 Vaccine in a Large Cohort of Patients with Cancer
In a letter to editor published on 21 February 2022 in the Annals of Oncology, Dr. Vincenzo Di Noia and colleagues described the serological response to the third dose of the BNT162b2 mRNA COVID-19 vaccine in a large cohort of patients with cancer. Most patients were on active anticancer treatment during the 28 days before the administration.
People can access a new life extending lung cancer treatment after NICE recommends its use within the Cancer Drugs Fund
An innovative life-extending drug - sotorasib - for treating mutation-positive locally advanced or metastatic non-small-cell lung cancer (NSCLC) in adults is being recommended by NICE as an option for use within the Cancer Drugs Fund.
With Increasingly Effective HER2-Targeted Agents, Does Carboplatin Have Utility in HER2-Positive Breast Cancer?
Several trials have evaluated strategies for sparing chemotherapy in patients with nonmetastatic HER2-positive breast cancer, including the use of trastuzumab, pertuzumab, and ado-trastuzumab emtansine. For patients with more advanced tumors, neoadjuvant regimens may be used to achieve a pathologic complete response.
Hematologic toxicity associated with chimeric antigen receptor (CAR) T-cell therapy remains a major challenge for safe administration of CAR T-cell products for relapsed/refractory malignancies.
Lung Metastases, Cytoreductive Nephrectomy and Favourable Risk Group Associated with a Higher Probability of Response to First-Line Combination Therapy in mRCC
In an analysis of 1,084 patients with metastatic renal cell carcinoma performed by the international metastatic renal cell database consortium, the presence of lung metastases, cytoreductive nephrectomy performed after diagnosis of metastatic disease and before first-line therapy and better IMDC risk group were associated with a higher probability of response to first-line immunotherapy combination regimens.
PTChO serdecznie zaprasza na praktyczny kurs kadawerowy „Plastyka piersi – prepektoralne rekonstrukcje wyniosłości piersiowej". 25 marca 2022 r. (piątek): Centrum Edukacji Medycznej, Warszawa. Kierownik naukowy: prof. dr hab. n. med. Agnieszka Kołacińska – Wow, Instruktor: prof. dr hab. n. med. Dawid Murawa.
PSMA PET imaging may prove useful in the diagnosis and treatment of metastatic castration-resistant prostate cancer by assessing a patient's response to therapy and by defining the phenotype of disease.
Advances in Adjuvant Therapy for Renal Cell Carcinoma in the Era of Immune Checkpoint Inhibitors: Pembrolizumab Shows Promise
Adjuvant therapy in renal cell carcinoma (RCC) is an area of investigation motivated by the alarming statistic that 30% of patients with localized disease will experience metastatic recurrence after nephrectomy.
EMA adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product pegfilgrastim (Stimufend), intended to reduce the duration of neutropenia and the incidence of febrile neutropenia after cytotoxic chemotherapy.
Adding Darolutamide to ADT and Docetaxel Prolongs Overall Survival in Patients with Metastatic, Hormone-Sensitive Prostate Cancer
In phase III ARASENS study that involved patients with metastatic, hormone-sensitive prostate cancer, overall survival (OS) was significantly longer among patients who received darolutamide plus androgen-deprivation therapy (ADT) and docetaxel than among those who received placebo plus ADT and docetaxel.
ASCO-OH (CCO) Guideline Update: Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer
Adjuvant bisphosphonate therapy should be discussed with all postmenopausal patients (natural or therapy-induced) with primary breast cancer, irrespective of hormone receptor status and human epidermal growth factor receptor 2 status, who are candidates to receive adjuvant systemic therapy.
Cancer Mortality Predictions for the 10 Major Causes of Cancer Mortality and Total Cancer in 2022 in the European Union
A report published in March 2022 issue of the Annals of Oncology confirms predicted declining mortality rates for most major cancers and total cancers in both sexes in European Union (EU) estimated at 6% for men and 4% for women over the past 5 years.
Taken as two 150 mg tablets twice daily together with anti-cancer medicines trastuzumab and capecitabine, tucatinib works by blocking a specific area of the HER2 gene in cancer cells, which stops the cells from growing and spreading.
Wytyczne postępowania z wynikami testów skriningowych w HPV-zależnej strategii prewencji wtórnej raka szyjki macicy. Konsensus PTGiP, PTGO, PTMR, PTP oraz PTKiPSM 2022 to podjęte przez wskazane towarzystwa naukowe wyzwanie wypracowania optymalnego dla polskich warunków opartego o EBM konsensusu skriningu rsm na wszystkich jego etapach w strategii HPV-zależnej.
In NeoTRIP, Atezolizumab with Neoadjuvant Carboplatin/Nab-Paclitaxel was Feasible in TNBC, but Led to Non-Significant pCR Increase
The study primary endpoint is event-free survival, and lack of improvement in pathologic complete response may be misleading as to the impact of atezolizumab on long-term efficacy in high-risk triple-negative breast cancer.
Once-a-day capsule for people with some forms of ovarian, fallopian tube and peritoneal cancer recommended for routine use in the NHS
Taken as a once-a-day capsule, niraparib is recommended for people whose cancer has relapsed and have a specific mutation in their cancer known as a BRCA mutation and who have had two courses of platinum-based chemotherapy.
Late Toxicity After Adjuvant Conventional Radiation Versus Image-Guided Intensity-Modulated Radiotherapy for Cervical Cancer
Postoperative Adjuvant Radiation in Cervical Cancer (PARCER), a phase III randomised trial, compared late toxicity after image-guided intensity-modulated radiotherapy (IG-IMRT) with three-dimensional conformal radiation therapy (3D-CRT) in women with cervical cancer undergoing postoperative radiation.
Tucatinib was studied in combination with trastuzumab and capecitabine in patients with metastatic HER2-positive breast cancer in a phase 3 randomized clinical trial (HER2CLIMB); the tucatinib combination showed efficacy over the control population, who were treated with trastuzumab, capecitabine, and placebo.
Non–small cell lung cancer (NSCLC) constitutes 80% to 85% of all lung cancers. Surgical resection offers the best opportunity for survival in the early stages, yet a high risk of developing recurrent disease remains.
Immune checkpoint inhibitors (ICIs) have substantially impacted treatment outcomes for patients with triple-negative breast cancer (TNBC) and have led to a paradigm shift of testing triple-negative tumors for PD-L1 when considering chemoimmunotherapy for metastatic disease.
Mid-treatment imaging can be used to de-escalate therapy for oropharynx cancer, leading to fewer side effects
A new phase II trial finds that PET scans obtained before and midway through treatment for p16-positive oropharynx cancer (OPC) can help determine whether a patient can receive a lower dose of radiation therapy in the second half of their treatment course without compromising cancer control.
Tumor tissue modified viral (TTMV)-HPV DNA biomarker test predicts recurrence of HPV-driven oropharynx cancer after treatment
A large, multi-institutional study demonstrates that a blood test to detect circulating tumor DNA can accurately predict recurrence of HPV-driven oropharyngeal cancer following treatment. Results also indicate that the biomarker test may detect recurrent disease earlier than imaging or other standard methods of post-treatment surveillance.
Late Breast Cancer Recurrence Less Aggressive and Associated with Better Prognosis Compared to Early Recurrence
In a first large population-based cohort study to investigate the impact of late breast cancer recurrence on mortality, to evaluate prognostic factors, and to compare survival after late recurrence with survival after early recurrence, women who developed late recurrence had better prognosis compared with those with early recurrence.
Pemigatinib, a Selective FGFR 1–3 Inhibitor Is Safe, Tolerable and Demonstrates Pharmacologic, Clinical Activity
Pemigatinib, a potent and selective FGFR 1–3 inhibitor, was safe and tolerable and demonstrated pharmacologic/clinical activity in cholangiocarcinoma, urothelial carcinoma, recurrent pilocytic astrocytoma, head and neck, pancreatic, gallbladder, uterine, and non-small cell lung cancers.
Older Patients with Cancer and High-Risk Geriatric Profiles at Greater Risk for Death and Other Adverse Sequelae of COVID-19
In a large study of 5671 older adults with COVID-19 and cancer, performed by the COVID-19 and Cancer Consortium (CCC19), the CCC19 geriatric risk index was associated with poorer outcomes, including clinical complications, hospitalisation, and mortality.
Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer
This secondary analysis of a randomised clinical trial showed that CRT followed by chemotherapy resulted in higher pathological complete response without compromising disease-free survival, toxicity, QoL and is thus proposed as the preferred total neoadjuvant therapy sequence if organ preservation is a priority.
Frontline Treatment with Brentuximab Vedotin Plus CHP Provides Clinically Meaningful Improvement in Survival Compared to CHOP in Patients with PTCL
In 5-year update of ECHELON-2 study, frontline treatment of patients with peripheral T-cell lymphoma (PTCL) with brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone continues to provide clinically meaningful improvement in progression-free survival and overall survival.
ASCO Provisional Clinical Opinion Offers Guidance for Using and Interpreting Genomic Testing in Patients With Advanced Cancer
Somatic genomic testing should be a routine part of clinical care for many patients with metastatic or advanced solid tumors, according to a new ASCO provisional clinical opinion. As reported in the Journal of Clinical Oncology, the Expert Panel found that genomic testing in oncology practice has evolved to the point where a wide spectrum of patients with cancer may benefit.
T-cell Responses May Help Predict Protection Against SARS-CoV-2 Infection in Individuals With and Without Cancer
T-cell responses directed against the receptor-binding domain of the SARS-CoV-2 spike protein were associated with protection from SARS-CoV-2 infection in vaccinated individuals with or without cancer, with lower T-cell responses observed in patients with blood cancers, according to results from a study published in Cancer Discovery.
Ukazała się nowa publikacja Krajowego Rejestru Nowotworów oraz Narodowego Instytutu Onkologii – Nowotwory złośliwe w Polsce w 2019 roku.
PTGO po raz drugi zaprasza na spotkanie z cyklu „Spotkania z Ekspertem AKADEMII GINEKOLOGA ONKOLOGA”. Tym razem naszym gościem będzie prezes Polskiego Towarzystwa Ginekologii Onkologicznej, ekspert w dziedzinie diagnostyki ultrasonograficznej, profesor Włodzimierz Sawicki.
Long-term survival after SABR is non-inferior to VATS L-MLND for operable stage IA NSCLC. SABR remains promising for such cases but multidisciplinary management is strongly recommended.
Adjuvant Pembrolizumab After Nephrectomy in Renal Cell Carcinoma: Embracing the Promises and Acknowledging the Uncertainties
The positive interim analysis of the KEYNOTE-564 trial led to FDA approval of pembrolizumab in the adjuvant setting for patients with renal cell carcinoma whose risk of experiencing recurrence is intermediate-high or high after nephrectomy; the approval also includes patients with metastatic RCC following nephrectomy and resection of all metastatic lesions.
Cemiplimab Prolongs Overall Survival Among Patients with Recurrent Cervical Cancer After First-Line Platinum-Containing Chemotherapy
Treatment with cemiplimab in a phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 study led to significantly longer overall survival (OS) than chemotherapy among patients with recurrent cervical cancer who had had disease progression after first-line platinum-containing chemotherapy.
Novel targeted therapies, such as trastuzumab deruxtecan, can be associated with rare adverse events including interstitial lung disease. In cancer therapies with the potential for pulmonary toxicity, pulmonary function tests provide an objective measure for baseline and longitudinal assessment.
Neoadjuvant Pembrolizumab Combined with Chemotherapy Followed by Adjuvant Pembrolizumab Significantly Improves Event-Free Survival in High-Risk, Early TNBC
In a phase III study, neoadjuvant pembrolizumab combined with chemotherapy followed by adjuvant pembrolizumab resulted in a significant improvement, as compared with neoadjuvant chemotherapy alone, in event-free survival among patients with previously untreated stage II or III triple-negative breast cancer.
Association of Delayed Surgery With Oncologic Long-term Outcomes in Patients With Locally Advanced Rectal Cancer Not Responding to Preoperative Chemoradiation
In this cohort study, a longer interval before surgery after completing neoadjuvant CRT was associated with worse overall and disease-free survival in tumours with a poor pathological response to preoperative CRT. Based on these findings, patients who do not respond well to CRT should be identified early after the end of CRT and undergo surgery without delay.
Copanlisib Shows Promising Clinical Activity in Select Tumours with PIK3CA Mutation in Refractory Setting
The NCI-MATCH is a tumour-agnostic platform that enrols patients on the basis of matching genomic alterations. The NCI-MATCH ECOG-ACRIN study (EAY131) subprotocol Z1F evaluated copanlisib, specific phosphoinositide 3-kinase (PI3K) inhibitor, in patients with PIK3CA mutations.
This short guide is designed to be a quick reference that contains the important ideas about cancer screening. Readers should refer to other publications for comprehensive discussion and detailed guidance on cancer screening programmes.
Examination of adverse events by sex using combined data from 23,296 patients enrolled in 202 phase II and III clinical studies conducted by SWOG between 1989 and 2019 revealed greater severity of both symptomatic adverse events and haematologic adverse events in women across multiple treatment modalities, indicating that broad-based sex differences exist.
Surgery is a reasonable option for patients with brain metastases. Patients with large tumors with mass effect are more likely to benefit than those with multiple brain metastases and/or uncontrolled systemic disease. Patients with symptomatic brain metastases should receive local therapy regardless of the systemic therapy used.
Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer
Pembrolizumab with carboplatin and paclitaxel is recommended as an option for untreated metastatic squamous non-small-cell lung cancer (NSCLC) in adults, only if their tumours express PD‑L1 with a tumour proportion score of 0% to 49%, their tumours express PD‑L1 with a tumour proportion score of 50% or more and they need urgent clinical intervention, it is stopped at 2 years of uninterrupted treatment or earlier if their disease progresses.
Overcoming Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Is There a Role for VEGF Inhibitor Treatment?
Anti–PD-1 and VEGFi combinations appear to be encouraging strategies for overcoming primary and acquired resistance to immune checkpoint inhibitors. Leading the pack is the quadruple combination of atezolizumab / bevacizumab / carboplatin / paclitaxel (ABCP), approved for first-line treatment of metastatic non–small lung cancer.
With 3 Years Minimum Follow-Up, Nivolumab Plus Ipilimumab Continues to Provide Long-Term Survival Benefit Over Chemotherapy in Unresectable Malignant Pleural Mesothelioma
With a follow-up of at least 3 years, the results from the CheckMate 743 represent the first long-term survival data in a phase III study evaluating first-line immune checkpoint inhibitor (ICI) in patients with unresectable malignant pleural mesothelioma.
Robust and Sustained Survival Benefit with Consolidation Durvalumab After Concurrent Chemoradiotherapy for Unresectable, Stage III NSCLC
Updated survival analyses from the PACIFIC study demonstrate robust and sustained survival benefit with durvalumab in patients with unresectable, stage III non–small-cell lung cancer (NSCLC) and no disease progression after concurrent chemoradiotherapy.
Innovative new drug for treating endometrial cancer in adults recommended by NICE as an option for use within the Cancer Drugs Fund
NICE has published its final appraisal document on dostarlimab, an immunotherapy treatment which could benefit 124 people a year in England as a second-line treatment for endometrial cancer with high microsatellite instability or mismatch repair deficiency.
Researchers at Fox Chase Cancer Center conducted the largest published, peer-reviewed, study to-date examining the short-term adverse effects of mRNA COVID-19 vaccination in patients with cancer—finding they experienced no more, and no different, side effects compared to non-cancer patients.
FDA approved tebentafusp-tebn, a bispecific gp100 peptide-HLA-directed CD3 T cell engager, for HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma. Efficacy was evaluated in IMCgp100-202 (NCT03070392), a randomised, open-label, multicentre study of 378 patients with metastatic uveal melanoma.
Nomogram for Predicting the Prognoses of Patients With Pancreatic Head Cancer After Pancreaticoduodenectomy
There are many factors affecting the prognosis in pancreatic head cancer after pancreaticoduodenectomy. Postoperative radiotherapy and chemotherapy can improve patient survival. These still need to be further validated in the future.
EMA adopted a positive opinion for the medicinal product lisocabtagene maraleucel, intended for the treatment of adults with relapsed or refractory diffuse large B cell lymphoma, primary mediastinal large B cell lymphoma and follicular lymphoma grade 3B, after at least two previous lines of treatments.
Triple Therapy with Pertuzumab, Trastuzumab and Docetaxel is Feasible and Tolerable for HER2-Mutated, Pretreated Advanced NSCLC
For the first time in patients with HER2-mutated advanced non-small cell lung cancer, the results of treatment with the combination of pertuzumab, trastuzumab and docetaxel, which is widely used for the management of HER2-positive breast cancer have been extrapolated in the IFCT-1703 R2D2 study.
Besides female breast and ovarian cancers, BRCA1/2 pathogenic variants are associated with increased risks of breast cancer in men, and pancreatic and stomach cancers in both sexes, and BRCA2 carriers are at elevated prostate cancer risk. No associations were found with risks of other cancers.
Pembrolizumab is recommended, within its marketing authorisation, as an option for the adjuvant treatment of completely resected stage 3 melanoma with lymph node involvement in adults.
Checkpoint Inhibitors for All or Only for High PD-L1 Expression: Exploring First-Line Therapy for Patients With Metastatic Gastroesophageal Malignancies
Recent clinical trials of immune checkpoint inhibitor (ICI) therapy suggest the practice-changing potential of these agents for patients with advanced gastroesophageal malignancies.
The Role of Adjuvant Therapy in Muscle-Invasive Bladder Cancer: Implications Across the Disease Spectrum
Postoperative administration of immune checkpoint inhibitors is being studied as a less toxic treatment approach for muscle-invasive urinary bladder cancer. CheckMate-274 found a statistically significant difference in median disease-free survival for nivolumab vs placebo.
Exploring Nonsurgical Salvage Options for Bacillus Calmette-Guérin–Unresponsive Carcinoma In Situ of the Bladder: An Evolving Algorithm
Many trials—accruing and soon to open—are likely to change the management algorithm over the coming decade to incorporate organ-sparing alternatives for patients with bacillus Calmette-Guérin (BCG)–unresponsive carcinoma in situ (CIS) of the bladder.
ASCO and the Society for Neuro-Oncology convened an Expert Panel and conducted a systematic review of the literature to provide guidance to clinicians regarding therapy for diffuse astrocytic and oligodendroglial tumors in adults. Fifty-nine randomized trials focusing on therapeutic management were identified.
Progression-free and overall survival were significantly longer with pembrolizumab than with placebo among patients with persistent, recurrent, or metastatic cervical cancer who were also receiving chemotherapy with or without bevacizumab.
Updated ROAR Analysis Confirms the Benefit of Dabrafenib Plus Trametinib in BRAF V600E–Mutated Anaplastic Thyroid Cancer
Updated analysis of the anaplastic thyroid cancer cohort from an open-label, non- randomised phase II Rare Oncology Agnostic Research study confirms earlier observations that the combination of dabrafenib plus trametinib has meaningful clinical activity in patients with BRAF V600E–mutated advanced or metastatic anaplastic thyroid cancer.
Trastuzumab Deruxtecan Shows Durable Anticancer Activity in Patients with Previously Treated HER2-Mutated Metastatic NSCLC
In a phase II DESTINY-Lung01 study, treatment with trastuzumab deruxtecan showed durable anticancer activity in 91 patients with HER2-mutated non-small cell lung cancer.
The MINDACT (EORTC 10041/BIG3-04) study, a multicentre, randomised phase 3 clinical trial, aims to identify those women with early-stage breast cancer who can be spared chemotherapy after surgery through the use of a genomic and clinical risk assessment.
Benefit of First-Line Pembrolizumab Plus Chemotherapy in Esophageal Cancer Bolstered by Longer-Term Efficacy, Safety, and QOL
Updated KEYNOTE-590 data continue to show overall and progression-free survival benefits in all key subgroups of interest, along with manageable safety and stable quality of life. These findings reinforce the status of pembrolizumab plus chemotherapy as a first-line standard of care for advanced esophageal cancer.
Although surgical resection is the traditional treatment for localized renal cell carcinoma, sunitinib and pembrolizumab have each demonstrated disease-free survival benefit in the adjuvant setting, in the S-TRAC and KEYNOTE-564 trials, respectively.
Optimizing Immunotherapy Combinations in Mismatch Repair–Proficient/Microsatellite-Stable Metastatic Colorectal Cancer
The greatest breakthrough in the treatment of metastatic colorectal cancer recently has been the use of ICIs for deficient mismatch repair – status tumors; ICIs, such as pembrolizumab or combination nivolumab/ipilimumab, can provide prolonged disease control in some patients.
Dual-Immunotherapy STRIDE Regimen Likely to Become a New First-Line Option for Patients With Advanced Hepatocellular Carcinoma
The HIMALAYA trial demonstrated that a single priming dose of tremelimumab plus once-monthly durvalumab significantly improved overall survival compared with sorafenib for patients with advanced unresectable hepatocellular carcinoma, meeting the primary endpoint.
First-Line Lenvatinib Plus TACE Improves Efficacy Outcomes Compared With Lenvatinib Monotherapy in Advanced Hepatocellular Carcinoma
Phase 3 LAUNCH trial shows that adding TACE to lenvatinib improves efficacy outcomes in previously untreated patients with Barcelona Clinic Liver Cancer stage C Hepatocellular Carcinoma.
Presence of ctDNA Following CRC Resection Heralds Increased Relapse Risk and Characterizes Adjuvant Chemotherapy Benefits
GALAXY, the largest study evaluating molecular residual disease in colorectal cancer (CRC), demonstrates that tracking circulating tumor DNA after surgery serves as a strong prognostic marker and may provide the opportunity to optimize clinical outcomes for patients with CRC
Circulating T Cell Characteristics Associated with Immune Checkpoint Inhibitors-Induced irAdverseEvents
In patients with melanoma who are treated with immune checkpoint inhibitors, clonally diverse and activated memory CD4-positive T cells at baseline are associated with the development of severe immune-related adverse events (irAEs), irrespective of the affected organ system.
Progression-Free Survival and Overall Survival Significantly Longer with Lenvatinib Plus Pembrolizumab Than with Chemotherapy in Advanced Endometrial Cancer
Findings from the Study 309–KEYNOTE-775 among patients who had disease progression after the receipt of previous systemic platinum-based therapy.
On 2 February, Stella Kyriakides, European Commissioner for Health and Food Safety, will host a hybrid event entitled “Ensuring equal access to all: Cancer in Women - Europe’s Beating Cancer Plan” to raise awareness of cancer in women and to announce the latest actions under the EU’s Cancer Plan.
A Combination of Atezolizumab and Enzalutamide Does Not Improve Overall Survival in Unselected Patients with mCRPC Whose Disease Progressed on Abiraterone
In the phase III IMbassador 250 study, a combination of an immune checkpoint inhibitor atezolizumab with a second-generation oral androgen receptor antagonist enzalutamide did not improve survival over enzalutamide alone in patients with metastatic castration-resistant prostate cancer whose disease progressed on abiraterone.
AI algorithms have shown promise for grading prostate cancer, specifically in prostatectomy samples and biopsies, and by assisting pathologists in the microscopic reviews, but they are susceptible to various biases in their development and validation.
Selected patients with brain metastases (BM) are candidates for radiotherapy. A lactatogenic metabolism, common in BM, has been associated with radioresistance. We demonstrated that BM express nitric oxide (NO) synthase 2 and that administration of its substrate L-arginine decreases tumour lactate in BM patients.
TOPAZ-1: Durvalumab Plus Gemcitabine and Cisplatin Could Become New First-Line Standard of Care for Advanced Biliary Tract Cancer
TOPAZ-1, the first global phase 3 study to evaluate use of immunotherapy in the first-line setting in advanced biliary tract cancers, demonstrated that adding the PD-L1 inhibitor durvalumab to gemcitabine and cisplatin—the current first-line standard of care—significantly improves overall survival and other efficacy outcomes without exacerbating toxicity.
Incidence of regional and distant metastasis is higher in paediatric patients compared with adults with differentiated thyroid cancer. Study shows that RET and NTRK fusions are the most prevalent genetic alterations in paediatric differentiated thyroid cancer.
This textbook provides a practically applicable resource for understanding the surgical oncology management of pancreatic cancer. It discusses relevant aspects of anatomy and pathophysiology along with the latest diagnostic techniques. Insightful descriptions are then provided detailing how to perform critical surgical procedures when treating these patients.
Combination Therapies May Improve Outcomes Due to Independent, Rather Than Synergistic or Additive, Drug Action
Independent drug action, not synergy nor additivity, accounted for the clinical efficacy of nearly all examined combination therapies involving immune checkpoint inhibitors in clinical trials, according to results from a retrospective analysis published in Clinical Cancer Research.
Expanded CheckMate-649 Data Confirm the Benefit of First-Line Nivolumab Plus Chemotherapy in Metastatic Esophagogastric Cancer
Long-term efficacy and safety data for first-line nivolumab plus chemotherapy bolster its use as standard treatment in patients with advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma.
Although the established treatments for stage II testicular seminoma have an excellent cure rate, the long-term toxicities and increased risk for second primary cancers associated with these approaches are a concern.
Patients with uterine carcinosarcoma and ovarian carcinosarcoma have very poor outcomes and more efficacious treatments are needed. The objective of the phase 3 randomized noninferiority GOG-0261 trial was to determine if the survival of patients with UCS or OCS receiving paclitaxel/carboplatin was inferior to patients who were treated with paclitaxel/ifosfamide.
A Phase III Study of Spartalizumab in Combination with Dabrafenib and Trametinib Did Not Meet Primary Endpoint in BRAF V600–Mutated Metastatic Melanoma
COMBI-i did not show a statistically significant difference in investigator-assessed progression-free survival in the broad population of patients with BRAF V600–mutated metastatic melanoma treated in this phase III study of spartalizumab in combination with dabrafenib and trametinib versus placebo in combination with dabrafenib and trametinib.
ASCO Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Rapid Recommendation Update: Abemaciclib With Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer
ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an evidence review and follow the guideline development processes outlined in the ASCO Guideline Methodology Manual.
Z radością informujemy, że od 1 stycznia 2022 dostęp do zasobów polskojęzycznej wersji pisma Nowotwory. Journal of Oncology, które dotychczas ukazywało się drukiem pod tytułem Nowotwory – Biuletyn Polskiego Towarzystwa Onkologicznego, zostanie otwarty dla wszystkich.
Testicular seminoma and non-seminoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up
This ESMO Clinical Practice Guideline provides key recommendations on the management of testicular seminoma and non-seminoma. Authorship includes a multidisciplinary group of experts from different institutions and countries in Europe. Key treatment recommendations are provided.
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection
Osimertinib is recommended for use as adjuvant treatment after complete tumour resection in adults with stage 1b to 3a non‑small‑cell lung cancer whose tumours have epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations. It is recommended only if osimertinib is stopped at 3 years, or earlier if there is disease recurrence or unacceptable toxicity.
Tucatinib Added to Trastuzumab and Capecitabine Continues to Demonstrate a Significant OS Improvement in Patients with HER2-positive Metastatic Breast Cancer
Continued overall survival benefit and tolerability of tucatinib in combination with trastuzumab and capecitabine, demonstrated in a final analysis of the HER2CLIMB study, augments data from the primary analysis and further supports the use of this combination in patients with previously treated HER2-positive metastatic breast cancer after progression on two HER2-targeted therapies.
Targeted therapies have dramatically improved treatment outcomes for patients with molecularly defined subsets of NSCLC, and the FDA continues to rapidly approve new therapies for NSCLC mutations/fusions in the metastatic setting.
ASCO and Ontario Health Provide Updated Recommendations on Using Adjuvant Bone-Modifying Treatments in Nonmetastatic Breast Cancer
An update to a joint guideline from Cancer Care Ontario and ASCO provides revised recommendations for the use of adjuvant bone-modifying agents for patients with nonmetastatic breast cancer with the overarching goal of improving relapse and survival rates.
Adjuvant Capecitabine-Containing Regimen Improves Modestly Overall Survival in Patients with Early Breast Cancer
The Finland Capecitabine Trial (FinXX) researchers found that addition of capecitabine to a taxane-anthracycline chemotherapy backbone improved overall survival in patients with early breast cancer during a median follow-up for 15 years after the date of random assignment.
Neoadjuvant Nivolumab Plus Ipilimumab Shows Promising Activity in Early-Stage MSI/dMMR Esophagogastric Junction and Gastric Adenocarcinoma
Neoadjuvant treatment with nivolumab and ipilimumab in patients with MSI/dMMR esophagogastric junction and gastric adenocarcinoma yielded a pathologic complete response rate of 59%—far higher than the 10% pCR rate expected with cytotoxic chemotherapy.
Adagrasib monotherapy demonstrates encouraging activity in patients with a variety of advanced KRAS G12C-mutated gastrointestinal malignancies. Notably, in patients with pancreatic ductal adenocarcinoma, single-agent adagrasib confers a 50% partial response rate and a 100% disease control rate.
Patients with metastatic CRC who had sarcopenia at baseline were more likely to experience severe neutropenia during first-line FOLFOX or FOLFIRI. The findings also suggest that lean body mass may be an important factor in determining 5-FU dosing.
Large Analysis Illustrates Advantages of Using Liquid Biopsy to Identify, Manage Disease in Patients With Advanced MSI-H GI Cancers
A large-scale analysis suggests that liquid biopsy performs about as well as tissue biopsy for identifying MSI-H in patients with advanced GI cancers and can be used successfully to guide treatment with immune checkpoint inhibitors.
Z okazji Europejskiego Tygodnia Profilaktyki Raka Szyjki Macicy PTGO chce przypomnieć Państwu obecne możliwości i wytyczne dotyczące pierwotnej i wtórnej profilaktyki w raku szyjki macicy. Zapraszamy na spotkanie 27 stycznia z Ekspertami w tej dziedzinie, Profesorem Janem Kotarskim i Profesorem Robertem Jachem.
Zarząd Sekcji Urologii Onkologicznej (SUO) Polskiego Towarzystwa Urologicznego zaprasza do wzięcia udziału w 9. Sympozjum Sekcji Urologii Onkologicznej, które odbędzie się w Warszawie w dniach 4-5 marca 2022 r. Celem spotkania jest przedstawienie wyników najnowszych badań i osiągnięć w zakresie urologii, omawianych podczas zbliżającego się spotkania European Section of Oncological Urology – ESOU.
The role of radiotherapy in metastatic renal cell carcinoma is controversial. We prospectively tested the feasibility and efficacy of radiotherapy to defer systemic therapy for patients with oligometastatic renal cell carcinoma.
Impressive Responses to PD-1 Blockade in a Large Cohort of Children and Young Adults with Recurrent/Progressive Germline DNA Replication Repair-Deficient Cancers
Study reveals impressive responses to PD-1 blockade and an associated improved survival for relapsed/refractory hypermutated cancers in children and young adults with germline DNA replication repair deficiency.
Paclitaxel and Carboplatin Not Inferior When Compared with Paclitaxel and Ifosfamide for the Treatment of Patients with Uterine Carcinosarcoma
With regard to overall survival (OS), paclitaxel and carboplatin was not inferior and demonstrated improved progression-free survival (PFS) when compared with paclitaxel and ifosfamide in patients with uterine carcinosarcoma.
Metastatic colorectal cancer (mCRC) remains a leading cause of cancer-related mortality, and amplification of the HER2 gene is the latest molecular subset to be therapeutically targetable in this disease.
Pembrolizumab Demonstrates Robust and Durable Antitumour Activity in Patients with Previously Treated Advanced MSI-H/dMMR Endometrial Cancer
Findings from the KEYNOTE-158 study support the use of pembrolizumab as a treatment option for patients with advanced MSI-H/dMMR endometrial cancer with treatment failure on prior therapy.
A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides guidance on the use of radiation therapy to treat adult patients with primary liver cancers using external beam radiation therapy (EBRT).
Selpercatinib is recommended for use as an option for treating RET fusion-positive advanced non-small-cell lung cancer (NSCLC) in adults who need systemic therapy after immunotherapy, platinum-based chemotherapy or both.
Study led by MD Anderson Cancer Center found more than two-thirds of patients with blood cancer who experienced septic shock died within 28 days.
Patients with cancer who develop breakthrough COVID-19 remain at risk of severe outcomes despite full vaccination.
Higher Rates of Metastasis-Free Survival in Men with High-Risk Non-Metastatic Prostate Cancer with Combination Treatment Than with ADT Alone
Findings from a meta-analysis of two randomised controlled phase III studies of the STAMPEDE platform protocol.
Pembrolizumab Showed Statistically Significant Improvement in Disease-Free Survival Versus Placebo as Adjuvant Treatment for Patients With Stage IB-IIIA Non-Small Cell Lung Cancer Regardless of PD-L1 Expression
Merck known as MSD outside the US and Canada, EORTC and ETOP announced that the Phase 3 KEYNOTE-091 trial, also known as EORTC-1416-LCG/ETOP-8-15 – PEARLS, investigating pembrolizumab anti-PD-1 therapy, met one of its dual primary endpoints of disease-free survival for the adjuvant treatment of patients with stage IB-IIIA non-small cell lung cancer following surgical resection regardless of PD-L1 expression.
Among premenopausal women with one to three positive lymph nodes and a recurrence score of 25 or lower, those who received chemoendocrine therapy had longer invasive disease–free survival and distant relapse–free survival than those who received endocrine-only therapy.
Dual Inhibition of LAG-3 and PD-1 in Patients with Previously Untreated Metastatic or Unresectable Melanoma
A phase II/III, RELATIVITY-047 study evaluated dual inhibition of LAG-3 and PD-1 using a new combination of LAG-3–blocking antibody relatlimab and PD-1–blocking antibody nivolumab, as compared with nivolumab alone.
Zapraszamy na kolejną edycję konferencji poświęconej chorobom jelita grubego. Konferencja odbędzie się w dniach 21-22 kwietnia 2022 roku w Krakowie. W trakcie wydarzenia poruszone zostaną aktualne tematy dotyczące nowotworów jelita grubego i technik endoskopowych.
New Treatment Options for Hepatocellular Carcinoma Raises Questions for Optimal Sequencing of Therapies
Treatment options have greatly expanded for patients with advanced hepatocellular carcinoma, with benefits seen with tyrosine kinase inhibitors, checkpoint inhibitors, and antiangiogenic antibodies.
W ramach webinaru zostaną przedstawione najnowsze doniesienia, dotyczące postępowania u chorych na nowotwory piersi, ze szczególnym uwzględnieniem tych z konferencji „San Antonio Breast Cancer Symposium 2021”. Webinar odbędzie się 14 stycznia 2022 roku.
Total neoadjuvant therapy (TNT), which is full chemotherapy and chemoradiation in the preoperative period, is increasingly viewed by clinicians as the treatment of first resort, perhaps even the standard of care. No single protocol for TNT exists, making treatment selection challenging.
Combining Immunotherapy With Neoadjuvant Chemoradiation in the Treatment of Locally Advanced, Resectable Esophago-Gastric Cancers
The role of immunotherapy in the treatment of locally advanced, resectable esophago-gastric cancers is expanding, with recent ASCO guidelines advocating the selective utilization of immune checkpoint inhibition in the adjuvant setting after trimodality therapy.
The therapeutic landscape for patients with relapsed/refractory multiple myeloma (MM) continues to evolve with the introduction of new targets and advances in cellular therapy and immunology.
Protecting People with Cancer from COVID-19: New Recommendations from Cancer Guidelines Organization
National Comprehensive Cancer Network published significant updates to the expert consensus recommendations on vaccination and pre-exposure prophylaxis of COVID-19 in people with cancer.
Radioligand therapy with 177Lu-PSMA-617 prolonged imaging-based progression-free survival and overall survival when added to standard care in patients with advanced PSMA-positive metastatic castration-resistant prostate cancer.
New indication concerns the treatment of patients with metastatic colorectal cancer for whom due to toxicity is not possible to continue treatment with another fluoropyrimidine.
EMA adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product tepotinib, intended for the treatment of patients with advanced non-small cell lung cancer harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping.
Guideline Update Highlights the Importance of Shared Decision - Regarding the Use of Adjuvant Therapy in Stage II Colon Cancer
ASCO has published updated guidance on the use of adjuvant therapy in the management of stage II colon cancer, providing clinicians with a newer evidence-based framework that can be used in shared decision-making with patients.
Use of Consolidation Durvalumab and Adjuvant Osimertinib Among Key Recommendations in New ASCO Guideline on Stage III NSCLC Treatment
A new ASCO guideline provides key recommendations for the evaluation and management of stage III non–small cell lung cancer (NSCLC). Recommendations made by the ASCO Expert Panel cover evaluation and staging of NSCLC, neoadjuvant and adjuvant therapy, and the management of unresectable disease.
Nivolumab Does Not Prolong Overall Survival Compared with Sorafenib In First-Line Treatment for Advanced Hepatocellular Carcinoma
In CheckMate 459 study nivolumab monotherapy did not significantly prolong overall survival (OS) compared with sorafenib as first-line treatment for patients with advanced hepatocellular carcinoma. However, nivolumab showed durable clinical activity in terms of response frequency and durability.
2021 was an exciting year for advancements in prostate cancer with novel diagnostic imaging, particularly prostate-specific membrane antigen (PSMA) and now the first theranostic targeted therapy.
The benefits of timely cystectomy must be weighed against the risks—most important, the increased morbidity and potentially decreased quality of life associated with radical surgery when compared with less invasive treatments.
Association of Antineoplastic Therapy With Decreased SARS-CoV-2 Infection Rates in Patients With Cancer
Patients who received ACE2-lowering antineoplastic compounds, including mTOR/PI3K inhibitors and antimetabolites exhibited statistically significantly lower rates of SARS-CoV-2 infection compared with patients given other antineoplastics.
Pancreatic cancer is the fifth leading cause of cancer death in Europe. As cases are almost always diagnosed at an advanced stage, and with few treatment options available, the resulting 5-year survival rates are among the lowest (<5%) of any cancer.
Tisagenlecleucel Is Safe and Effective in Pretreated Patients with Relapsed/Refractory Follicular Lymphoma
The ELARA investigators are now reporting the findings from the primary, prespecified interim analysis of their study of tisagenlecleucel in adults with relapsed/refractory follicular lymphoma after two or more treatment lines or who relapsed after autologous stem cell transplant.
EMA adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product lorlatinib.bNew indication concerns the treatment of adult patients with ALK positive advanced NSCLC previously not treated with an ALK inhibitor.
EMA Recommends Granting a Marketing Authorisation for Enfortumab Vedotin for the Treatment of Urothelial
EMA adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product enfortumab vedotin, intended for the treatment of adult patients with urothelial cancer. An antibody drug conjugate induces cytotoxicity in cancer cells by binding to the nectin-4.
The Inaugural WHO Classification of Childhood Tumors Will Provide a Unified, Updated Resource for the Diagnosis of Pediatric Cancers
The first classification of pediatric cancers soon to be published by the International Agency for Research on Cancer (IARC) as part of the new World Health Organization (WHO) Classification of Tumors series was summarized in a review article published in Cancer Discovery, a journal of the American Association for Cancer Research.
W ramach międzynarodowej współpracy pomiędzy National Comprehensive Cancer Network a Narodowym Instytutem Onkologii opublikowano pierwszą polską edycję wytycznych NCCN dotyczących leczenia nowotworów. Opracowane w wyniku współpracy ekspertów wytyczne zostały oparte na dowodach naukowych i konsensusie ekspertów. Zawierają najnowsze zalecenia dotyczące leczenia nowotworów raka szyjki macicy.
2021 has exposed the weaknesses and lack of resilience of European healthcare systems with major consequences for cancer care and cancer patients, regrettably not too different from 2020. More than ever, this past year has stressed the need for crucial attention not only to restore cancer services but to build back better and be prepared to face upcoming challenges.
Over the past 5 years, clinical trials have demonstrated a clear benefit in overall survival with the intensification of upfront systemic therapy in the first-line treatment of metastatic and high-risk localized or node-positive prostate cancer.
ASCO Guideline Update: Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy
Purpose: to increase awareness, outline strategies, and offer guidance on the recommended management of immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitor (ICPi) therapy.
FDA approved pafolacianine, an optical imaging agent, for adult patients with ovarian cancer as an adjunct for interoperative identification of malignant lesions. Pafolacianine is a fluorescent drug that targets folate receptor which may be overexpressed in ovarian cancer.
A Remarkable Group of Patients with Haematological Disorders with No or Low Immune Response After Second COVID-19 Vaccine Dose
A remarkable group of patients were measured with no or low immune response after second COVID-19 vaccine dose, especially those with lymphoid neoplasms. Of those who tested negative for vaccine-related antibodies, most were on active therapy. The study team underlined that further explorations are needed with focus on potential risk of COVID-19 infections despite full vaccination.
The European Cancer Organisation has published a Report: “Making Hope Reality: Action on Treatment and Care for Metastatic Cancer Patients”. The report provides a detailed account of the presentations and contributions shared during a special Community 365 Roundtable Meeting on Metastatic Cancer held in October 2021.
Several ongoing studies are researching the best combination strategies to improve response rates in neuroendocrine tumors with 177Lu-dotatate. Other promising treatment avenues for NETs include novel α-particle–emitting radiopharmaceuticals, as well as multireceptor tyrosine kinase inhibitors, both single agent and in combination with immune checkpoint inhibitors.
Reflecting recent significant classification changes and new data on the use of biomarkers to inform treatment for central nervous system tumors, a new guideline offers oncologists up-to-date recommendations for managing gliomas in adult neuro-oncology patients.
The European Cancer Organisation, in strong alliance with a collaboration of 22 healthcare professional and patient organisations, is today marking the publication the "Essential Requirements for Quality Cancer Care: Pancreatic Cancer”. This new consensus charter for improved care and standards for a too-long neglected tumour type.
Six Months Immunogenicity of COVID-19 mRNA-based Vaccine in Patients with Actively Treated Solid Malignancies
Results of the Vax-On study of mRNA-BNT162b2 immunogenicity in patients with actively treated solid malignancies suggest that proximity to cancer treatment does not affect seroconversion response, which remains adequate even 5 months after the second COVID-19 vaccine dose. Updated results of the Vax-On study favour the third vaccine dose for actively treated patients with cancer.
Accelerated Hypofractionated Image-Guided vs Conventional Radiotherapy for Patients With Stage II/III Non-Small Cell Lung Cancer and Poor Performance Status
This phase III randomised clinical trial found that hypofractionated IGRT (60 Gy in 15 fractions) was not superior to CFRT (60 Gy in 30 fractions) for patients with stage II/III NSCLC ineligible for concurrent chemoradiotherapy.
Limited Effect of Endocrine Therapy on Distant Metastasis-Free Interval in Patients with Stage I Low-Risk Breast Cancer, but Fewer Breast Cancer Events
With 8 years median follow-up, a subgroup of patients included in the MINDACT study with stage I oestrogen receptor (ER)-positive, HER2-negative, low-risk breast cancer who received no adjuvant systemic therapy had a good 8-year distant metastasis-free interval rate, although a slightly better outcome and lower rates of locoregional recurrence and contralateral breast cancer were observed in patients who received endocrine therapy.
FDA approved rituximab in combination with chemotherapy for paediatric patients (≥6 months to <18 years) with previously untreated, advanced stage, CD20-positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL), or mature B-cell acute leukaemia (B-AL).
Decyzją Zarządu Polskiego Towarzystwa Chirurgii Onkologicznej kolejny, XXVIII Zjazd PTChO w formie konferencji naukowo-szkoleniowej odbędzie się w dniach od 26 do 28 maja 2022 roku w Gdańsku. Jako przewodniczący Komitetu Organizacyjnego powołani zostali przez Zarząd profesorowie: Tomasz Jastrzębski i Zoran Stojcev.
ASCO Guideline Update: Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor–Negative
This guideline updates recommendations of the ASCO guideline on chemotherapy and targeted therapy for patients with human epidermal growth factor receptor 2–negative metastatic breast cancer (MBC) that is either endocrine-pretreated or hormone receptor (HR)–negative.
ASCO Guideline Update: Endocrine Treatment and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
Purpose to update recommendations of the ASCO systemic therapy for hormone receptor (HR)-positive metastatic breast cancer (MBC) guideline. An Expert Panel conducted a systematic review to identify new, potentially practice-changing data.
ASCO Guideline: Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy
The multidisciplinary team issued recommendations to aid in the recognition, workup, evaluation, and management of the most common CAR T-cell–related toxicities, including cytokine release syndrome, immune effector cell–associated neurotoxicity syndrome, B-cell aplasia, cytopenias, and infections.
ASCO Updates Guidance on Use of Abemaciclib and Endocrine Therapy in Patients With High-Risk Early Breast Cancer
A rapid update to the ASCO guideline on optimal adjuvant chemotherapy and targeted therapy for early breast cancer provides guidance on the use of the oral CDK4/6 inhibitor abemaciclib with endocrine therapy (ET) in patients with high-risk early breast cancer.
Two Years of Adjuvant Palbociclib Added to Endocrine Therapy Does Not Improve Outcomes in Early Breast Cancer
The results of the final protocol-defined analysis of the PALLAS study conducted in patients with early hormone receptor-positive, HER2-negative breast cancer.
Addition of adjuvant palbociclib to standard endocrine therapy does not improve outcomes in patients with early HR-positive breast cancer.
CAR T-Cell Treatment for Adults With Relapsed/Refractory B-Cell ALL: Understanding ZUMA-3 Data and Next Steps
Based on the ZUMA-3 data, the FDA recently approved brexucabtagene autoleucel for adult patients with R/R B-ALL. CAR T cells should be incorporated in earlier lines of therapy and, importantly, in MRD-positive/low-tumor-burden disease states.
FDA approved pembrolizumab for the adjuvant treatment of adult and paediatric patients with stage IIB or IIC melanoma following complete resection. Efficacy was evaluated in KEYNOTE-716.
Lack of Benefit of Adding Immune Checkpoint Inhibitors to Chemotherapy in Low PD-L1–Expressing Gastric, Gastro-oesophageal Junction, or Oesophageal Adenocarcinoma
Although current recommendations suggest that immune checkpoint inhibitors may be used for all patients with advanced gastric, gastro-oesophageal junction, or oesophageal adenocarcinoma in the first-line setting, the analyses of previously unpublished data from pivotal phase III randomised studies fail to demonstrate a survival advantage when adding ICIs to conventional chemotherapy in patients with low PD-L1–expressing tumours.
Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II)
In this randomised clinical trial, neither arm demonstrated evidence of superior safety, efficacy, or symptom burden; however, single-fraction SABR is more efficient to deliver. Therefore, single-fraction SABR, as assessed by the most acceptable outcome profile from all end points, could be chosen to escalate to future studies.
When classified into gain-of-function and non–gain-of-function, p53 mutations could stratify the prognosis of right-sided versus left-sided metastatic colorectal cancer.
Nivolumab Demonstrates Clinical Benefits in a Statistically Evaluable Number of Patients with carcinoma of unknown primary
An investigator-initiated phase II study is the first to show that nivolumab has clinical activity with manageable toxicity in a statistically evaluable number of patients with carcinoma of unknown primary.
Sequencing of Bone Marrow DNA May Predict Leukemia Relapse After CAR-T Therapy With Sufficient Time to Intervene
Next-generation sequencing for minimal residual disease was highly sensitive and more accurate than flow cytometry and monitoring of B-cell aplasia. according to a study published in Blood Cancer Discovery, a journal of the American Association for Cancer Research.
This ESMO Clinical Practice Guideline provides key recommendations for diagnosis, staging and management of bladder cancer. Recommendations for personalised medicine are also included.
Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
This ESMO Clinical Practice Guideline provides key recommendations for managing malignant pleural mesothelioma. The optimal diagnostic methods, pathological evaluation and staging are described.
Stanowisko Polskiego Towarzystwa Onkologicznego w sprawie projektu Ustawy o Krajowej Sieci Onkologicznej
Jak wskazuje NIK, skuteczność leczenia onkologicznego w Polsce jest gorsza niż w większości pozostałych krajów Unii Europejskiej, a według dostępnych prognoz istnieje ryzyko, że stan ten będzie się pogarszał. Tym samym potrzebne są istotne zmiany o charakterze systemowym, które przekładać się będą na poprawę wyników osiąganych w diagnozowaniu i leczeniu nowotworów.
Osimertinib is recommended for people with early-stage (1b to 3a) non-small-cell lung cancer (NSCLC) who have had surgery to remove their tumour and who have epidermal growth factor receptor (EGFR) gene mutations.
The results from a head-to-head comparison of two different neurokinin-1 receptor antagonists for the prevention of chemotherapy induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.
The 6.5-year data in the pivotal CheckMate 067 study show durable, improved clinical outcomes with nivolumab plus ipilimumab or nivolumab versus ipilimumab in patients with advanced melanoma and, in descriptive analyses, with the combination over nivolumab monotherapy.
The biological effect of radiotherapy, as quantified by GARD, is significantly associated with time to first recurrence and overall survival for patients with cancer treated with radiation. It is predictive of radiotherapy benefit, and physical dose of radiation is not.
Support for the role of neoadjuvant therapy in the management of nonmetastatic pancreatic adenocarcinoma is growing. With the high risk of rapid dissemination of disease, neoadjuvant therapy allows for the immediate delivery of systemic therapy to address micrometastatic disease present in most patients with localized pancreatic cancer at the time of diagnosis.
Narodowy Instytut Onkologii zaprasza do udziału w konferencji „Warsaw Summit of European Cancer Strategies”, która odbędzie się 9 grudnia 2021r. w formie hybrydowej (w NIO w Warszawie oraz na platformie Zoom). Szczyt poświęcony będzie różnorodnym tematom związanym z walką z rakiem, europejskim sieciom onkologicznym i wdrażaniu strategii onkologicznych w Europie Środkowo-Wschodniej.
Efficacy was evaluated in AMPECT study in patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumour.
Będzie to czwarty w tym roku webinar organizowany przez sekcję młodych chirurgów onkologicznych. Tematyką webinaru będzie chirurgia małoinwazyjna. Czy można się nauczyć chirurgii małoinwazyjnej nie mając od kogo na oddziale? Czy trzeba być dobrym laparoskopistą aby dobrze operować robotem?
Perioperative Chemotherapy for Resectable Liver Metastases in Colorectal Cancer: Do We Have a Blind Spot?
In 2004, the MOSAIC trial demonstrated that fluoropyrimidine-oxaliplatin doublets further improved OS for stage III disease6; this led to widespread use of perioperative or adjuvant infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX) for resectable colorectal cancer liver metastases.
In a phase III, randomised DAWNA-1 study, the combination of dalpiciclib, a new cyclin-dependent kinase (CDK) 4 and 6 inhibitor, with fulvestrant improved progression-free survival with manageable safety in patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancer who progressed or relapsed on endocrine therapy.
Results from the first prospective study showing that patients with HER2-amplified metastatic colorectal cancer identified by ctDNA genotyping benefit from dual-HER2 blockade similarly to patients identified by conventional tissue analysis,
Results from monotherapy group in UPSTREAM demonstrate trial’s feasibility in head and neck squamous cell carcinoma
The EORTC UPSTREAM trial set out to investigate the effect of targeting treatment to the specific gene alteration (biomarker) found in an individual patient’s tumour. Patients for whom no pre-specified biomarkers are identified in their tumour are treated by immunotherapy.
The implementation roadmap for the Europe's Beating Cancer Plan has now been published by the European Commission. It highlights the necessary steps to be taken in concrete actions towards a strong European Health Union.
It is intended for the treatment of patients with advanced NSCLC with KRAS G12C mutation who have progressed after at least one prior line of systemic therapy.
Randomised Study on Dose Escalation in Definitive Chemoradiation for Patients With Locally Advanced Esophageal Cancer
In definitive chemoradiation for esophageal cancer, radiation dose escalation up to 61.6 Gy to the primary tumour did not result in a significant increase in local control over 50.4 Gy. The absence of a dose effect was observed in both adenocarcinoma and squamous cell carcinoma.
This guideline provides evidence-based recommendations for the indications and technique-dose of external beam radiation therapy (EBRT) in hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (IHC).
FDA approved pembrolizumab for the adjuvant treatment of patients with renal cell carcinoma (RCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.
CAR T-cell therapy has recently entered standard-of-care practice for multiple myeloma with the U.S. Food and Drug Administration's approval of idecabtagene vicleucel and imminent review of ciltacabtagene autoleucel.
Study Identifies Determinants of Response to SARS-CoV-2 Vaccines Among Patients With Solid-Organ and Hematologic Malignancies
A recent study from Journal of Clinical Oncology found all 3 SARS-CoV-2 vaccines authorized for use in the United States to be well-tolerated in a large cohort of patients with solid-organ and hematologic malignancies.
Nivolumab is recommended for adjuvant treatment of completely resected oesophageal or gastro‑oesophageal junction cancer in adults who have residual disease after previous neoadjuvant chemoradiotherapy.
Fasting-mimicking Diet Is Safe, May Modulate Metabolism and Boost Antitumor Immunity in Cancer Patients
A diet involving short-term, severe calorie restriction was safe, feasible, and resulted in a decrease of blood glucose and growth factor concentration, reduction in peripheral blood immunosuppressive cells, and enhanced intratumor T-cell infiltration in cancer patients receiving standard-of-care therapy.
Results from two phase III studies, KEYNOTE-361 and IMvigor131, using combination chemotherapy and CPI therapy versus chemotherapy alone or CPI monotherapy showed no clear benefit with combination treatment.
Early Onset Is a Negative Prognostic Factor in High-Risk Stage III CRC, Hinting to Aggressive Nature of the Disease
A post hoc analysis of the database of the IDEA collaboration published in Journal of Clinical Oncology found young age to be negatively prognostic and associated with significantly higher relapse rate in patients with stage III early-onset colorectal cancer (EO-CRC), irrespective of greater treatment intensity and adherence.
DREAMseq: Upfront Dual Immunotherapy More Efficacious Than Dual Targeted Therapy for BRAFV600-Mutant Metastatic Melanoma
The randomized phase III ECOG-ACRIN EA6134 trial, also known as DREAMseq, demonstrates that for the 45% of patients with BRAFV600-mutant metastatic melanoma, starting with anti–PD-1/CTLA-4 immunotherapy confers better overall survival (OS) than starting with BRAF/MEK targeted therapy.
Six months of concomitant and adjuvant androgen suppression statistically significantly improves EFS and clinical disease-free survival in intermediate-risk prostatic carcinoma, treated by irradiation at 74 or 78 Gy. The effects on OS and DMFS did not reach statistical significance.
In ‘Earlier is Better: Advancing Cancer Screening and Early Detection’ the European Cancer Organisation, working with its dedicated Network on Prevention, Early Detection and Screening, has set out a number of pressing needs to be encapsulated in the new formal advice on cancer screening.
Immunotherapy May Yield Longer Treatment-free Survival Than Targeted Therapy in Advanced Renal Cell Carcinoma
Patients with advanced renal cell carcinoma who received the checkpoint inhibitor combination nivolumab plus ipilimumab experienced longer treatment-free survival (TFS) over a 42-month period than patients who received the targeted therapy sunitinib, regardless of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk group.
Chemo-immunotherapy improves overall survival compared with chemotherapy alone and represents a new standard of care for all patients with untreated advanced esophageal squamous cell carcinoma and most patients with untreated advanced gastroesophageal adenocarcinomas.
Bispecific antibodies are molecules designed to target malignant cells and immune effector cells simultaneously, they act as a bridge between these two antigens and result in cell-mediated cytotoxicity.
Disease-free survival (DFS) is one of the most complicated endpoints in oncology. Unlike progression-free survival in the advanced cancer setting, which refers to time from treatment to disease progression (or death) in patients who already have measurable cancer in their bodies.
High-quality surgery remains the best chance to cure solid cancer when diagnosed early and is fundamental in preventing, diagnosing and staging cancer, treating metastatic disease, preserving quality of life and alleviating symptoms. However, many challenges remain to fully unlock its potential.
Randomised Phase III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small-Cell Lung Cancer
Sparing the hippocampus during prophylactic cranial irradiation (PCI) better preserves cognitive function in patients with SCLC. No differences were observed with regard to brain failure, OS, and QoL compared with standard PCI.
EMA Publishes Guidance to Provide Key Methods and Good Regulatory Practices on the Planning and Conduct of Registry-Based Studies
EMA published the guideline on registry-based studies. This guideline addresses the methodological, regulatory and operational aspects involved in using registry-based studies to support regulatory decision-making.
Metastatic TNBC (mTNBC) is associated with poor prognosis. A recent analysis of France's Epidemiological Strategy and Medical Economics database showed that outcomes for mTNBC have not improved much over the last decade.
In an effort to design a more effective, time-limited regimen, BTK inhibitors have now been combined with venetoclax, with or without obinutuzumab; these combination regimens capitalize on the potentially synergistic effects of BTK and BCL-2 inhibitors.
ASCO Releases New Guidelines on the Management of Adverse Events in Patients Treated With Immune Checkpoint Inhibitors and CAR T-Cell Therapy
ASCO has released new recommendations for the management of adverse events related to two immunotherapy modalities with increasing application in cancer care—immune checkpoint inhibitors (ICIs) and CAR T-cell therapy.
FDA granted accelerated approval to asciminib for patients with Philadelphia chromosome-positive chronic myeloid leukaemia (Ph+ CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors (TKIs), and approved asciminib for adult patients with Ph+ CML in CP with the T315I mutation.
Risk of Age-related Diseases May Be Higher in Younger B-cell Non-Hodgkin Lymphoma Survivors Than in Their Older Counterparts
Younger B-cell non-Hodgkin lymphoma (B-NHL) survivors had a higher relative risk of developing age-related diseases than older B-NHL survivors five years or more after cancer diagnosis, according to results published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.
Selpercatinib is recommended for use within the Cancer Drugs Fund, as an option for treating: advanced RET fusion-positive thyroid cancer in adults who need systemic therapy after sorafenib or lenvatinib, advanced RET-mutant medullary thyroid cancer in people 12 years and older who need systemic therapy after cabozantinib or vandetanib.
Predicted excess cardiovascular risk is small for most patients, so radiotherapy may provide net benefit. However, for a minority of patients receiving high doses of radiation to cardiovascular structures, it may be preferable to consider advanced radiotherapy techniques to reduce doses or to omit radiotherapy and accept the increased relapse risk.
This study suggests that all women diagnosed with triple-negative breast cancer or ER-negative breast cancer should receive genetic testing and that women over age 65 years with BRCA1 and BRCA2 PVs and perhaps with PALB2 and CHEK2 PVs should be considered for magnetic resonance imaging screening.
EMA adopted a positive opinion, recommending the granting of a conditional marketing authorisation for the medicinal product amivantamab intended for the treatment of advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) exon 20 insertion mutations.
Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer
Apalutamide plus androgen deprivation therapy (ADT) is recommended, within its marketing authorisation, as an option for treating hormone‑relapsed non‑metastatic prostate cancer that is at high risk of metastasising in adults. High risk is defined as a blood prostate-specific antigen (PSA) level that has doubled in 10 months or less on continuous ADT.
Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer
Apalutamide plus androgen deprivation therapy (ADT) is recommended as an option for treating hormone-sensitive metastatic prostate cancer in adults, only if docetaxel is not suitable.
Patients With Early-Stage Breast Cancer Who Are Unrepresented in Clinical Trials Face Increased Mortality
New data on women with early breast cancer, presented during the 2021 ASCO Quality Care Symposium, suggest patients who are not well-represented in clinical trials may face reduced odds of survival, calling into question the generalizability of clinical trial results to real-world patients.
Long-Term Outcomes in Patients with Metastatic Melanoma Treated with Anti-PD1 Therapy Based on PET Response
FDG-PET has a predominant role in predicting long-term benefit over CT, especially in patients with no complete response. In those without CMR at 1-year, almost half will experience subsequent disease progression, such that a change in therapy could be implemented, whereas in CMR patients, FDG-PET may have a role in defining shorter treatment duration.
nab-Sirolimus Induces Rapid and Durable Responses in Patients With Malignant Perivascular Epithelioid Cell Tumors
A new study from Journal of Clinical Oncology reporting on the outcomes from the phase II AMPECT trial found that rapamycin inhibitor nab-sirolimus induces rapid and durable responses in patients with malignant perivascular epithelioid cell tumors (PEComas).
Patient Selection, Risk Management, Critical to Treating Asymptomatic Brain Metastasis in Patients With Non–Small Cell Lung Cancer
Up to a quarter of patients with advanced non–small cell lung cancer (NSCLC) that doesn't harbor a driver mutation can develop brain metastases (mets), and they contribute to neurocognitive symptoms and diminished quality of life.
Germline Pathogenic Variants in CDH1, BRCA2, CHEK2, ATM, and PALB2 Associated with Increased Risk of Invasive Lobular Carcinoma
The largest study involving multigene panel testing of women with invasive lobular carcinoma describes the frequency of germline pathogenic variants in invasive lobular carcinoma and the differences in gene-specific frequencies between invasive lobular carcinoma and infiltrating ductal carcinoma.
Patients with Non-Small-Cell Lung Cancer with Brain Metastases: New Data on the Significant Challenges for which Physicians Feel Unequipped
40 per cent of healthcare providers surveyed across the five countries in Europe and the United States feel less than well equipped to care for non-small-cell lung cancer (NSCLC) patients with brain metastases, according to a new survey carried out by Ipsos MORI in collaboration with the European Cancer Organisation.
Atezolizumab is recommended, within its marketing authorisation, as an option for untreated locally advanced or metastatic urothelial cancer in adults whose tumours express PD-L1 at a level of 5% or more and when cisplatin-containing chemotherapy is unsuitable.
NICE has published draft guidance for public consultation which does not recommend tucatinib (also called TUKYSA and made by Seagen Inc), in combination with trastuzumab and capecitabine, for some types of breast cancer that has spread.
Shortened course of radiation therapy offers similar long-term side effects following prostate removal surgery
Using fewer - but higher - doses of radiation to treat men with prostate cancer who had their prostates removed does not increase long-term side effects or lower their quality of life compared to conventional radiation treatment, a new, multi-institutional clinical trial shows.
Cure Probability Models for Evaluation of Patients with a Previous Cancer Diagnosis for Solid Organ Transplantation
Findings from a first study that applied a formal statistical framework to inform the evaluation of transplant candidates with a previous cancer diagnosis were published on 22 October 2021 in the Journal of Clinical Oncology.
Wytyczne NCCN w zakresie praktyki klinicznej w onkologii - Rak jajnika w tym rak jajowodu i pierwotny rak otrzewnej
Opublikowana została polska wersja językowa wytycznych National Comprehensive Cancer Network (NCCN) w zakresie praktyki klinicznej w onkologi dotycząca raka jajnika wraz z rakiem jajowodu i pierwotnym rakiem otrzewnej. Polska edycja powstała w ramach współpracy pomiędzy NCCN, USA a Narodowym Instytutem Onkologii im. Marii Skłodowskiej-Curie (NIO-PIB).
Genetic biomarker test predicts recurrence and survival outcomes for men with high-risk prostate cancer
A new meta-analysis finds that a genetic biomarker test accurately predicts how men with high-risk prostate cancer will respond to treatment with radiation and hormone therapy. The study indicates that physicians potentially can use genetic test scores to personalize treatment for men with the most aggressive form of prostate cancer.
Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node
Inguinofemoral radiotherapy is a safe alternative for IFL in patients with SN micrometastases, with minimal morbidity. For patients with SN macrometastasis, radiotherapy with a total dose of 50 Gy resulted in more isolated groin recurrences compared with IFL.
EMA adopted a positive opinion, recommending the granting of a marketing authorisation for the first-in-class medicinal product sacituzumab govitecan, intended for the treatment of unresectable or metastatic triple negative breast cancer (TNBC).
High-dose radiation therapy can be used to lengthen progression-free survival for people with advanced lung cancer when systemic therapy has not fully halted the growth or spread of metastases, according to a new study.
FDA approved atezolizumab for adjuvant treatment following resection and platinum-based chemotherapy in patients with stage II to IIIA non-small cell lung cancer (NSCLC) whose tumours have PD-L1 expression on ≥1% of tumour cells, as determined by an FDA-approved test.
Clinical trial reported at the 2021 ASCO Annual Meeting confirmed that the use of interim PET/CT scans is highly valuable as a biomarker of disease and can successfully be used to improve patient outcomes.
Nivolumab Plus Low-Dose Ipilimumab Demonstrates Clinical Benefit in First-Line Treatment for MSI-H/dMMR mCRC
Durable and deep tumour responses were observed in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer (mCRC) treated with first-line nivolumab plus low-dose ipilimumab, regardless of baseline demographic and tumour characteristics, including BRAF or KRAS mutation status.
Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy
Nivolumab is recommended as an option for treating recurrent or metastatic squamous cell carcinoma of the head and neck in adults whose disease has progressed on platinum based chemotherapy, only if the disease has progressed within 6 months of having chemotherapy
Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer
Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy is recommended, within its marketing authorisation, as an option for untreated locally advanced unresectable or metastatic carcinoma of the oesophagus or HER2‑negative gastro-oesophageal junction adenocarcinoma in adults whose tumours express PD‑L1 with a combined positive score (CPS) of 10 or more.
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Provides key recommendations and algorithms for managing metastatic breast cancer. Covers diagnosis, staging, risk assessment, treatment, disease monitoring, palliative care and the patient perspective.
Adjuvant Abemaciclib Combined with Endocrine Therapy Improves IDFS in HR-Positive, HER2−Negative, Node-Positive, High-Risk, Early Breast Cancer
Invasive disease-free survival benefit deepened and distant relapse-free survival benefit was maintained in patients with hormone receptors (HR)-positive, HER2-negative, node-positive, high risk early breast cancer treated with adjuvant CDK4/6 inhibitor, abemaciclib and endocrine therapy.
MRI with targeted and standard biopsy in men with MRI results suggestive of prostate cancer was noninferior to standard biopsy for detecting clinically significant prostate cancer in a population-based screening-by-invitation trial and resulted in less detection of clinically insignificant cancer.
Zilovertamab Vedotin Is Safe and Demonstrates Activity In Heavily Pretreated Patients With Lymphoid Malignancies
In heavily pretreated patients with lymphoid malignancies, zilovertamab vedotin demonstrated no unexpected side effects and showed evidence of antitumour activity in a phase I, first-in-human, dose-escalation study.
Webinar „Prevention and Treatment of Peritoneal Metastases: Combining Complete Cytoreductive Surgery with HIPEC”
7 listopada 2021 w niedzielę o godzinie 20.00 czasu indyjskiego (16:30 czasu polskiego) odbędzie się webinar "Prevention and Treatment of Peritoneal Metastases: Combining Complete Cytoreductive Surgery with HIPEC". Będzie to niesamowita okazja by posłuchać profesora Paula Sugarbakera z USA, ojca chirurgii HIPEC.
FDA approved pembrolizumab in combination with chemotherapy, with or without bevacizumab, for patients with persistent, recurrent or metastatic cervical cancer whose tumours express PD-L1 combined positive score (CPS) ≥1
PTCHO objęło patronatem merytorycznym warsztaty dotyczące diagnostyki biopsyjnej i leczenia chirurgicznego z rekonstrukcją gruczołu piersiowego, które odbędą się na utrwalonych preparatach anatomicznych. Warsztaty są skierowano głównie do osób w trakcie specjalizacji.
The European Cancer Organisation Publishes a Position Paper on Self-Sampling and HPV Screening in Europe
The Europe’s Beating Cancer Plan sets out recommendations for cervical cancer elimination across the EU, including an ambitious goal to offer screening to 90% of the eligible population by 2025. The ECO today publishes a new Position Paper “Self-Sampling and HPV Screening in Europe” with recommendations that will help member states achieve this.
EMA adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product pembrolizumab. New indication concerns the treatment of PD-L1 positive locally recurrent unresectable or metastatic TNBC.
American Association for Cancer Research (AACR) released the 11th edition of its annual Cancer Progress Report, which underscores how cancer research, largely supported by federal investments in the National Institutes of Health (NIH) and the National Cancer Institute (NCI), continues to drive progress for patients with cancer.
A Third Dose of BNT162b2 is Safe and Improves Humoural Immunity Against SARS-CoV-2 in Patients with Solid Tumours
Researchers reported the serological and cellular immune responses after two-dose BNT162b2 vaccination of patients with solid tumours on active cytotoxic chemotherapy compared to healthy controls and the outcomes of a phase I study of a third vaccine dose subsequently initiated in the cancer cohort.
Merging the Histologic and Molecular Data Into an Integrated Score Significantly Improves Precision in Stratification of Meningiomas
Retrospectively and prospectively validated data from a multicentre retrospective analysis allowed to the German Consortium on Aggressive Meningiomas researchers to devise and validate an integrated score that leverages the advantages of WHO grading, specific copy-number variations (CNVs), and methylation-based classifications.
Amerykańskie Towarzystwo Radioterapii Onkologicznej (ASTRO) przedstawiło zestawienie najważniejszych badań, których wyniki zostaną omówione podczas dorocznego Kongresu ASTRO, który odbędzie się 24 -27 października w Chicago w formie tradycyjnej oraz online.
Prof. Iwona Ługowska, Ruth Plummer i Paulo A. Ascierto napisali „Melanoma and other skin cancers” – dwuczęściowy informator – przewodnik poświęcony czerniakowi i innym rodzajom raka skóry. Powodem tej publikacji są nowe możliwości leczenia pacjentów. Autorzy zebrali dostępną sobie wiedzę i dzielą się nią ze środowiskiem medycznym w nowej publikacji.
FDA granted recognition to a partial listing of the Memorial Sloan Kettering Cancer Center’s Oncology Knowledge Base (OncoKB) as the first tumour mutation database to be included in the Public Human Genetic Variant Database.
A Peptide-drug Conjugate that Targets the Acidic Environment of Cancer Cells May Improve the Efficacy of Immunotherapy
A peptide-drug conjugate that targets the acidic environment of cancer cells enhanced the efficacy of immune checkpoint inhibitors in preclinical cancer models, according to results presented at the AACR-NCI-EORTC Virtual International Conference.
Inhibition of the Aurora Kinase A Protein May Help Overcome Lung Cancer Resistance to KRAS Inhibition
In preclinical models, combining an investigational Aurora Kinase A (AURKA) inhibitor with a KRAS inhibitor or a WEE1 inhibitor showed efficacy against lung cancer cells with intrinsic or acquired resistance to KRAS inhibition.
Adding ErbB Tyrosine Kinase Inhibitor to KRAS Inhibitor May Help Circumvent Lung Cancer Resistance to Prior Therapies
Combination of the KRAS inhibitor sotorasib (Lumakras) with afatinib, a pan-ErbB tyrosine kinaseinhibitor, was feasible in treating non-small cell lung cancer (NSCLC) patients with mutated KRAS whose disease had progressed on prior therapies, including KRAS inhibitors alone.
DNA Alkylation Drug May Improve Outcomes for Adolescents and Young Adults With Central Nervous System Tumors
In a phase II clinical trial, the drug 4-demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) improved survival for some adolescent and young adult (AYA) patients with cancers involving the central nervous system, according to results presented at the AACR-NCI-EORTC Virtual International Conference.
FDA Approves Brexucabtagene Autoleucel for Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukaemia
FDA approved brexucabtagene autoleucel for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL). Efficacy was evaluated in ZUMA-3 study that evaluated brexucabtagene autoleucel, a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, in adults with relapsed or refractory B-cell precursor ALL.
Elevated allostatic load was associated with a lower likelihood of completing chemotherapy and a lower overall survival rate in patients with lymph node-positive or high-risk lymph node-negative HER2-negative breast cancer.
Adjuvant Chemotherapy Customisation Based on ERCC1 and TS mRNA Levels Does Not Improve Efficacy in Resected NSCLC
ITACA study was open-label, randomised, investigator-initiated study to evaluate the predictive utility of ERCC1 and TS mRNA expression levels in completely resected stage II-IIIA non-small cell lung cancer. The results indicate that adjuvant chemotherapy customisation based on ERCC1 and TS mRNA levels did not improve efficacy.
Promising FOCUS4-C Findings Warrant Further Study of WEE1 Blockade in TP53- and RAS-Mutant Metastatic Colorectal Cancer
Adavosertib, an investigational small-molecule inhibitor of WEE1, demonstrated encouraging efficacy and favorable safety in the phase II FOCUS4-C trial conducted in 69 patients with metastatic colorectal cancer (CRC) featuring TP53 and RAS mutations.
W ramach konkursu Agencja Badań Medycznych dofinansuje projekty przewidujące utworzenie i rozwój Onkologicznych Centrów Wsparcia Badań Klinicznych (OnkoCWBK). Inicjatywa ma na celu zwiększenie liczby zarówno badań klinicznych w obszarze onkologii, zwiększenie liczby uczestników w Polsce, a także wykorzystanie potencjału sektora badań klinicznych komercyjnych i niekomercyjnych.
EMA adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product ripretinib, intended for the treatment of advanced gastrointestinal stromal tumour (GIST) in patients who have received prior treatment with three or more kinase inhibitors.
Abiraterone Acetate Plus Prednisone and LHRH Analogue is Active and Safe in AR-Expressing, Castration-Resistant Salivary Gland Carcinoma
The primary aim of the phase II study was reached, demonstrating for the first time that abiraterone acetate combined with prednisone and luteinizing hormone-releasing hormone (LHRH) analogue is active in castration-resistant, androgen receptor (AR)-positive salivary gland carcinoma.
New indication concerns the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, GEJ or oesophageal adenocarcinoma.
Patients Treated With Chemotherapy and B Cell–Targeting Agents Show Impaired Serological Response to COVID-19 Vaccination
Findings from the largest study to measure anti-SARS-CoV-2 antibody levels after vaccination in patients with haematological and solid malignant tumours.
Immunotherapy in Patients With Locally Advanced Esophageal Carcinoma: ASCO Treatment of Locally Advanced Esophageal Carcinoma Guideline Rapid Recommendation Update
FOCUS4-N Supports a Treatment Break as a Sound Alternative to Maintenance Therapy in Metastatic Colorectal Cancer
The meta-analysis, like FOCUS4-N, showed that “although maintenance therapies can extend the time to progression, they have no impact on OS. This includes the standard range of therapies, capecitabine and bevacizumab being the cardinal ones.
FDA approved cabozantinib for adult and paediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior vascular endothelial growth factor receptor (VEGFR)-targeted therapy and who are ineligible or refractory to radioactive iodine.
Atezolizumab has been recommended by NICE for people whose tumour expresses PD-L1 at a level of 5% of more and when platinum-containing chemotherapy is unsuitable. The recommendation comes after additional clinical evidence which showed that people who have atezolizumab are likely to live up to 8 months longer than those who have platinum-containing chemotherapy.
Changes in patient-reported outcomes (PROs) seen after just 1 month predicted for treatment response and survival outcomes in patients with advanced gastrointestinal cancers, according to data presented during the 2021 ASCO Quality Care Symposium.
In a phase II study conducted by the MD Anderson Cancer Center researchers, poziotinib resulted in a 27% confirmed partial response (PR) rate and a median progression-free survival (PFS) of 5 months in patients with advanced HER2 exon 20 mutated non-small cell lung cancer (NSCLC).
This article focuses on the recent immunotherapy updates to the treatment of renal cell carcinoma (RCC) as given in the RCC: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
EMA adopted a positive opinion, recommending the granting of a conditional marketing authorisation for the medicinal product pralsetinib, intended for the treatment of patients with rearranged during transfection (RET) fusion positive non-small cell lung cancer (NSCLC).
Rybocyklib z najdłuższą medianą przeżycia całkowitego kiedykolwiek zaobserwowaną w zaawansowanym HR+/HER2-ujemnym raku piersi
Rybocyklib w skojarzeniu z letrozolem, u kobiet w wieku pomenopauzalnym z zaawansowanym rakiem piersi typu HR+/HER2-, pozwolił osiągnąć medianę przeżycia całkowitego wynoszącą ponad 5 lat (63,9 miesiąca), korzyść w zakresie przeżycia wyniosła ponad 12 miesiący.
Patients with advanced oesophageal cancer having SEMS insertion for the primary management of their dysphagia did not gain additional benefit from concurrent palliative radiotherapy and it should not be routinely offered.
Treatment with Tebentafusp Results in Longer Overall Survival Among Previously Untreated Patients with Metastatic Uveal Melanoma
In the randomised, phase III study, treatment with tebentafusp, a soluble T-cell receptor and CD3-directed bispecific fusion protein, was associated with longer overall survival (OS) than the investigator’s choice of therapy in HLA-A*02:01– positive patients with metastatic uveal melanoma.
Vax-On Points to Maintenance of Active Anticancer Treatment Throughout the Whole COVID-19 Vaccination Schedule
In a large population of patients with solid tumours undergoing active anticancer treatment, the researchers confirmed a favourable safety profile of mRNA-BNT162b2 vaccine, which may reassure on maintaining active anticancer treatment throughout the whole vaccination schedule.
New research in JNCCN finds four out of five cancer therapies tested in Phase III trials do not achieve clinically-meaningful benefit in prolonging survival, and is the first study to quantify the number of false-positive, false-negative, and true-negative trial results.
FDA Grants Accelerated Approval to Tisotumab Vedotin-tftv for Recurrent or Metastatic Cervical Cancer
FDA granted accelerated approval to tisotumab vedotin-tftv, a tissue factor-directed antibody and microtubule inhibitor conjugate, for adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.
The findings from the first randomised study that evaluated the addition of an epidermal growth factor receptor (EGFR) antibody to fluorouracil/folinic acid maintenance therapy in patients with RAS wild-type metastatic colorectal cancer show that panitumumab adds efficacy to fluorouracil/folinic acid as maintenance therapy in terms of progression-free survival.
Radioembolization Delays Disease Progression in Patients With Unresectable Colorectal Liver Metastases
Long-awaited findings from the EPOCH trial demonstrate that a locoregional therapy can confer a clinically meaningful benefit in patients with systemic disease. This randomized phase III trial conducted over 8 years in individuals with unresectable colorectal liver metastases.
In soft tissue sarcomas (STS), several aspects about multifocal disease (MFD) —the presence of two or more discontiguous tumors within one body location —are still unclear. Liposarcoma is the most common histologic subtype to have MFD, but it can also occur in angiosarcoma.
A Novel Combination of Cabozantinib Plus Atezolizumab Demonstrates Encouraging Activity and Acceptable Tolerability in Advanced RCC
In the COSMIC-021 study, cabozantinib plus atezolizumab demonstrated encouraging clinical activity in patients with advanced renal cell carcinoma (RCC). Robust clinical activity was observed across dose levels and histologic subtypes.
People with intellectual disability are at an increased risk of any cancer, as well as several specific cancer types. The findings from a population-based cohort study of Swedish children born to mothers from the Nordic countries suggest a need for extended surveillance and early intervention in cancer among people with intellectual disability.
Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guideline for diagnosis, treatment and follow-up. This Clinical Practice Guideline provides key recommendations on the management of gastrointestinal stromal tumours. Recommendations have been agreed following a consensus meeting of representatives from ESMO, EURACAN and GENTURIS.
Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer
Intensification of chemotherapy using FOLFIRINOX before preoperative chemoradiotherapy significantly improved outcomes compared with preoperative chemoradiotherapy in patients with cT3 or cT4 M0 rectal cancer. The significantly improved disease-free survival in the neoadjuvant chemotherapy group and the decreased neurotoxicity indicates that the perioperative approach is more efficient and better tolerated than adjuvant chemotherapy.
Pembrolizumab Does Not Prolong Overall Survival Compared to Chemotherapy in Platinum-Pretreated Recurrent or Metastatic Nasopharyngeal Carcinoma
According to results of the KEYNOTE-122, multicentre, open-label, randomised phase III study that evaluated the efficacy and safety of pembrolizumab versus chemotherapy in patients with platinum-pretreated, recurrent or metastatic nasopharyngeal carcinoma, pembrolizumab did not prolong overall survival (OS) over chemotherapy in that population.
Automated Detection of Microsatellite Status in Early Colon Cancer by Infrared Imaging Combined with Artificial Intelligence
The researchers of PRODI used tissue sections from the prospective multicentre AIO ColoPredictPlus 2.0 registry study to verify the novel label-free infrared (IR) imaging combined with artificial intelligence (AI) for tumour detection and classification of microsatellite status. They reported that AI integrated IR imaging can automatically classify unstained tumour sections precisely in less than 30 min.
Copanlisib Combined with Rituximab Shows Superior Efficacy over Placebo and Rituximab in Relapsed Marginal Zone Lymphoma
A subset analysis of the randomised, double-blind, placebo-controlled phase III CHRONOS-3 study that focused on patients with relapsed marginal zone lymphoma, showed superior efficacy of treatment with a PI3K inhibitor, copanlisib plus rituximab compared to placebo plus rituximab.
FDA granted accelerated approval to zanubrutinib (Brukinsa, BeiGene) for adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen.
New results from immunotherapy trials from the EORTC gynaecological and lung cancer groups presented at ESMO 2021
Late-breaking results from two Phase 2 EORTC trials of immunotherapy were presented at the 2021 ESMO congress on Friday 17 September. Immunotherapy drugs are relatively new additions to cancer treatment, and work by stimulating the immune system so that it can find and attack cancer cells.
Organ-Sparing Potentials from the Neoadjuvant Pembrolizumab Treatment in Patients with dMMR/MSI-H Solid Tumours
In a phase II open-label study performed among patients with localised, unresectable or high risk resectable, microsatellite instability high (MSI-H)/deficient mismatch repair (dMMR) solid tumours, treatment with neoadjuvant pembrolizumab was safe and resulted in high rates of radiographic and endoscopic responses.
Deep Learning Model Applied to Digital Pathology Slides Could Predict the Risk of Relapse in Invasive Breast Cancer
To better identify patients with early breast cancer who are at risk of relapse, the researchers from the startup Owkin and Gustave Roussy conceived a diagnostic tool that applies deep learning to digital pathology slides and clinical data. They showed that their model could predict the risk of relapse in patients with oestrogen receptor (ER)-positive, HER2-negative early breast cancer.
Tolerability, pharmacokinetics and efficacy of samuraciclib were assessed in a first-in-human, modular study. Treatment with this first-in-class, oral, selective inhibitor of CDK7 demonstrated an acceptable safety profile and evidence of antitumour activity in patients with advanced solid tumours.
Trastuzumab Deruxtecan Demonstrates Robust and Durable Activity in Previously Treated Metastatic NSCLC with HER2 mutations
The DESTINY-Lung01 study assessed the efficacy and safety of HER2 antibody-drug conjugate trastuzumab deruxtecan in patients with metastatic non-small cell lung cancer (NSCLC) with HER2 mutations. Trastuzumab deruxtecan demonstrated robust and durable activity in this population, with a manageable safety profile.
Ruszył kolejny cykl bezpłatnych szkoleń szkoleń online dla pielęgniarek/pielęgniarzy i personelu medycznego. Do końca roku zaplanowano 10 spotkań w następujących modułach tematycznych: leczenie przeciwnowotworowe, wybrane problemy współczesnej onkologii, powikłania w leczeniu onkologicznym, leczenie wspomagające w onkologii, praktyczne aspekty opieki pielęgniarskiej.
Extended Adjuvant Treatment with Letrozole Results in Longer Survival in Postmenopausal Patients with Breast Cancer
According to results from a prospective, open-label, phase III study conducted among the postmenopausal patients with stage I to III breast cancer who were treated with 2 to 3 years of tamoxifen, extended treatment with 5 years of letrozole resulted in longer disease-free survival (DFS) and overall survival (OS) compared to the treatment with 2 to 3 years of letrozole.
For the first time since 20 years in the bladder peri-operative setting, the authors have design a randomised phase III controlled study comparing the efficacy of GC or dd-MVAC in patients for whom chemotherapy has been decided before or after surgery.
Intermittent Relacorilant Combined with Nab-paclitaxel Improves PFS in Recurrent Platinum-Resistant Ovarian Cancer
In the first randomised, controlled study to explore the efficacy and safety of relacorilant, a selective glucocorticoid receptor modulator, in combination with nab-paclitaxel compared to nab-paclitaxel alone, combined treatment improved progression-free survival (PFS) and showed a favourable safety profile among the women with recurrent platinum-resistant and/or platinum-refractory ovarian cancer.
Epcoritamab Shows a Manageable Safety and Robust Antitumour Activity in Heavily Pretreated B-Cell Non-Hodgkin Lymphoma
Epcoritamab is a highly selective and potent bispecific antibody for CD3 and CD20 that induces T-cell-mediated cytotoxic activity against CD20-positive malignant B-cells. In a first-in-human phase I/II study subcutaneous epcoritamab was safely administered in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
How diabetes mellitus affects the efficacy of immune checkpoint inhibitors (ICIs) is yet to be defined. It prompted the investigators from 21 Italian and 1 UK institutions to evaluate the impact of diabetes mellitus in a retrospective cohort of patients with advanced cancer treated with a single-agent ICI.
Considering Cost and Toxicity Choosing Between CDK4/6 and mTOR Inhibitors for the Treatment of Breast Cancer
The CDK4/6 pathway and PI3K/AKT/mTOR pathway are implicated in the development of resistance to endocrine therapy. In vivo studies show that PI3K and mTOR inhibition can restore sensitivity to endocrine therapy.
Determining How to Treat Chemosensitive Sarcomas: Evaluating Patient Risk of Recurrence and Death Plays an Important Role
The question of using adjuvant chemotherapy in adult patients with soft tissue sarcoma is an important one. Although most patients who present with localized disease can be cured with wide local excision alone, previous data showed that about half of these patients will die of subsequent metastatic disease.
An interim analysis of the clinical study suggested that the risk of sudden or cardiac death in patients on an ACE inhibitor when entering the study was increased in patients randomised to ibrutinib and rituximab, compared to those randomised to fludarabine, cyclophosphamide and rituximab.
Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy
Abemaciclib plus fulvestrant is recommended as an option for treating hormone receptor‑positive, human epidermal growth factor receptor 2 (HER2)‑negative, locally advanced or metastatic breast cancer in adults who have had endocrine therapy only if exemestane plus everolimus is the most appropriate alternative to a cyclin‑dependent kinase 4 and 6 (CDK 4/6) inhibitor.
In the TROG 13.01 phase II randomised clinical study that compared single-fraction versus multifraction stereotactic ablative radiation therapy (SABR) in patients with pulmonary metastases, the researchers demonstrated that neither arm was superior in terms of safety, efficacy, or symptom burden; however, single-fraction SABR is of shorter duration and more efficient to deliver.
Lack of Evidence for the Use of Telemedicine in the Prevention and Surveillance for Recurrences and New Cancers
There is a lack of evidence on the use of telemedicine in the prevention and surveillance for recurrences and new cancers, as well as in the management of chronic medical conditions, and health promotion. The findings were published on 9 September 2021 in the Annals of Oncology.
Adjuvant temozolomide chemotherapy, but not concurrent temozolomide chemotherapy, was associated with a survival benefit in patients with 1p/19q non-co-deleted anaplastic glioma. Clinical benefit was dependent on IDH1 and IDH2 mutational status.
Pivotal Role of the Institutional Molecular Tumour Board in Evaluating the Results of a Customised Next-Generation Sequencing Panel
Results of a molecular-based approach using a customised next-generation sequencing (NGS) panel at a single academic institution were published in the British Journal of Cancer. The molecular screening aimed to select the best potential therapeutic strategy for patients with advanced cancer to receive the treatment within the early clinical study programme.
Adjuvant PARP Inhibitors in Patients With High-Risk Early-Stage HER2-Negative Breast Cancer and Germline BRCA Mutations: ASCO Hereditary Breast Cancer Guideline Rapid Recommendation Update
A significant improvement in invasive and distant disease-free survival constituted a strong signal for an update of the 2020 ASCO-ASTRO-SSO guideline recommendation focused specifically on the role of PARP inhibitors in patients with early-stage, HER2-negative breast cancer and germline BRCA mutations.
No Benefit of Additional Tumour Testing in HER2-negative Metastatic Breast Cancer with Already Confirmed Germline BRCA Mutations
According to findings from a prespecified exploratory analysis of the OlympiAD study, in patients with HER2-negative metastatic breast cancer and already confirmed germline BRCA mutations, there is no clear benefit of additional tumour testing for the homologous recombination deficiency (HRD) score or detection of gene-specific loss of heterozygosity (LOH) to determine if they are likely to respond to the treatment with PARP inhibitor.
The policy paper „Comprehensive Cancer Care Across the EU: Advancing the Vision” provides essential points of advance on implementing the commitment of the European Commission to develop a new EU Network of Comprehensive Cancer Centres and meet an objective of 90% of eligible cancer patients achieving access to such Centres by 2030.
The draft guidance looks at treating prostate cancer in adults which no longer responds to hormone therapy and who are at high risk of the cancer spreading to other parts of their body, or is still sensitive to hormone therapy but has already spread.
Nivolumab plus ipilimumab and 2 cycles of platinum-doublet chemotherapy is not recommended, within its marketing authorisation, for untreated metastatic non-small-cell lung cancer (NSCLC) in adults whose tumours have no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutations.
More Than 25 Additional Years Needed to Slow an Increasing Incidence of Oropharyngeal Cancer by Current HPV Vaccination Rate
According to the projections of the population-based age-period-cohort study performed by a group of the authors from the Johns Hopkins University in Baltimore, who published their findings on 2 September 2021 in the JAMA Oncology, current human papillomavirus (HPV) vaccination rate will have a limited association with overall incidence of oropharyngeal cancer until 2045 because older individuals who are not vaccinated remain at high risk.
Considering specificities of non-small cell lung cancer (NSCLC) biology and corresponding treatment strategies for advanced disease, a group of experts from Memorial Sloan Kettering Cancer Centre in New York, proposed a practical, clinical definition of acquired resistance to PD-(L)1 blockade for use in clinical reports and prospective clinical studies.
Phase III Randomised Trial of Prophylactic Cranial Irradiation With or Without Hippocampus Avoidance in SCLC
This randomised phase III trial did not find a lower probability of cognitive decline in patients with SCLC receiving HA-PCI compared with conventional PCI. No increase in brain metastases at two years was observed in the HA-PCI arm.
In a study published in the Nature Cancer, the research team from National Cancer Centre Research Institute in Tokyo, Japan took advantage of cancer cells purified from malignant ascites and established corresponding cell lines as the resources for genomic analyses to overcome the technical limitations associated with analyses of primary tumours.
W dniach 2-4 września 2021 odbywa się w Poznaniu XXVII Zjazd Polskiego Towarzystwa Chirurgii Onkologicznej, pierwszy zjazd tego Towarzystwa po pandemii z osobistym udziałem jego członków. Przewodniczącym Zjazdu jest prof. Dawid Murawa, obecny Prezes PTChO. Zjazd odbywa się pod patronatem m.in. Marszałka Senatu prof. Tomasz Grodzkiego, który sam jest chirurgiem zajmującym się leczeniem chorych onkologicznych.
A Personalised Prediction Model Based on Clinical and Genomic Data Outperforms Established Prognostic Models in MDS
New prediction model can provide probability of survival and leukaemia transformation at diagnosis of myelodysplastic syndrome and throughout a patient's disease course.
Recent reports (USA) suggest 20% to 40% of all patients with cancer use cannabis in some form during or after treatment. Among those patients who use cannabis, two-thirds report using it to help manage pain, anxiety, or insomnia. However, the science and clinical knowledge of cannabis fall significantly behind state laws.
Assuring high-quality, equitable care for every patient with cancer is a key part of ASCO's mission. According to Devika Das, MD, MSHQS, a member of ASCO's International Quality Task Force, the field of quality studies is in the beginning stages of a metamorphosis that will likely only accelerate over the next few years.
The discovery of molecular alterations has led to a significant improvement in the outcomes of patients with advanced lung cancer. Recently, the results of the ADAURA study established osimertinib as the standard-of-care adjuvant therapy in resectable NSCLC with sensitizing mutations in the EGFR gene, marking the entry of targeted therapy in the treatment landscape of early-stage disease.
Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging and systemic and local therapy
Surveillance and Early Cancer Detection are Associated with Improved Survival in Constitutional Mismatch Repair Deficiency Syndrome
Constitutional mismatch repair deficiency syndrome is a cancer predisposition syndrome associated with inheritance of biallelic pathogenic variants in mismatch repair (MMR) genes leading to deficient MMR during DNA replication. It is characterised by early-onset synchronous and metachronous multiorgan tumours.
Inguinofemoral Radiotherapy Could Spare Patients with Vulvar Cancer and Sentinel Node Micrometastases the Morbidity of Lymphadenectomy
Inguinofemoral radiotherapy for patients with vulvar cancer and micrometastases in the sentinel node is safe alternative for inguinofemoral lymphadenectomy according to the GROINSS-V-II study investigators. The radiotherapy side effects were acceptable with less frequent treatment-related morbidity compared with inguinofemoral lymphadenectomy.
NCCN announced significant updates to the NCCN: Cancer and COVID-19 Vaccination guidance. This is the fourth version of NCCN’s COVID-19 vaccination guide and incorporates the latest data plus recent approvals from the FDA and CDC regarding a third mRNA vaccine dose for immunocompromised people.
FDA approved ivosidenib for adult patients with previously treated, locally advanced or metastatic cholangiocarcinoma with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.
Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer
Neoadjuvant durvalumab combined with stereotactic body radiotherapy is well tolerated, safe, and associated with a high major pathological response rate. This neoadjuvant strategy should be validated in a larger trial.
Impact of Multigene Germline Genetic Testing on Selection of Germline-Directed Therapy in Patients with Metastatic or Recurrent Cancer
27.08 Among 11,947 patients with metastatic or recurrent cancer that spanned across more than 50 different tumour types, 8% of patients had a tumour with germline alteration considered therapeutically actionable and 3.2% of these patients received germline genotype–directed treatment.
W dniach od 10 do 15 grudnia odbędą się 9. warsztaty interdyscyplinarne „Perioperative Management in CRS and HIPEC of Peritoneal Malignancy”. Organizatorem warsztatów jest Charité - University Medicine Berlin. Warsztaty odbywają się pod patronatem towarzystw medycznych: DGAV, BDC, BDA, DGAI oraz ESSO.
Ability of Deep Learning to Accurately Diagnose Frequent STS Subtypes from Conventional Histopathological Slides
Findings from one of the first studies to investigate the use of artificial intelligence in the pathological management of soft tissue sarcoma (STS) show that a deep learning model was able to classify five of the most common STS subtypes from histology alone. When aided by the deep learning model, pathologists were more accurate, faster, and more certain in their diagnosis.
Among all patients with neuroendocrine tumors (NETs), the risk of dying of cancer was higher than that of dying of other causes, but mortality varies by primary tumor site, according to a new study published in the August 2021 issue of JNCCN—Journal of the National Comprehensive Cancer Network.
Novel Trial Finds Benefit of Combination Chemotherapy for Patients With Relapsed/Progressive Rhabdomyosarcoma
Findings from the first randomized controlled trial of temozolomide plus vincristine-irinotecan (VI) among pediatric and adult patients with relapsed/progressive rhabdomyosarcoma (RMS; VIT-0910 trial) suggest the combination chemotherapy improves efficacy over VI alone.
The role of immunotherapy as first-line treatment for advanced urothelial cancer in patients not eligible for cisplatin therapy is uncertain. Carboplatin-containing regimens were previously the standard of care, but outcomes were poor.2 Accelerated approvals were given to atezolizumab and pembrolizumab based on phase II data.
The phase III KEYNOTE-775 study compared combination lenvatinib/pembrolizumab with standard single-agent chemotherapy in 827 patients with advanced, metastatic, or recurrent EC progressing after prior platinum-based chemotherapy. Immunotherapy led to a significant improvement of ORR, PFS, and OS when compared to chemotherapy.
Polskie Towarzystwo Chirurgii Onkologicznej zaprasza na kurs „Diagnostyka inwazyjna gruczołu piersiowego”, który odbędzie się 1 września 2021 w Szpitalu Uniwersyteckim w Zielonej Górze. Ilość miejsc ograniczona do 10 osób – decyduje kolejność zgłoszeń.
Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement
Pemigatinib is recommended, within its marketing authorisation, as an option for treating locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that has progressed after systemic therapy in adults.
In KEYNOTE-061 randomised study, PD-1 blockade with immune checkpoint inhibitor (ICI) pembrolizumab did not significantly improve overall survival (OS) over paclitaxel in second-line treatment for advanced gastric/gastro-oesophageal junction (GEJ) adenocarcinoma with PD-L1 combined positive score (CPS) ≥1.
FDA approved nivolumab for the adjuvant treatment of patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection. Evidence for efficacy in the adjuvant treatment of patients with high-risk urothelial carcinoma is based on the results of CHECKMATE-274 study.
Badanie prowadzone przez naukowców z University of Texas MD Anderson Cancer Center wykazało znaczący związek między przyjmowaniem leków obniżających poziom cholesterolu, powszechnie znanych jako statyny, a wskaźnikami przeżycia pacjentek z potrójnie negatywnym rakiem piersi (TNBC).
A cell therapy with autologous tumour-infiltrating lymphocytes (TILs), followed by maintenance nivolumab, was safe and clinically active upon initial progression on nivolumab monotherapy in patients with metastatic non-small cell lung cancer (NSCLC).
The HILUS-Trial-a Prospective Nordic Multicenter Phase II Study of Ultracentral Lung Tumours Treated With Stereotactic Body Radiotherapy
On the basis of the presented data, 7.0 Gy × 8.0, prescribed to the planning target volume-encompassing isodose, should not be used for tumours located within 1 cm from the main bronchi and trachea. Group B-type tumours may be considered for the treatment on the basis of an individual risk-benefit assessment.
FDA granted accelerated approval to dostarlimab-gxly for adult patients with mismatch repair deficient (dMMR) recurrent or advanced solid tumours, as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options.
Guideline Rapid Update Provides New Direction on the Care of Patients With Residual Disease in Locally Advanced Esophageal Cancer
An ASCO guideline rapid update is revising recommendations for the management of locally advanced esophageal carcinoma to include provision of nivolumab following adjuvant chemoradiotherapy (CRT) and surgery.
Adoptive Transfer of Tumor-infiltrating Lymphocytes May Be Less Effective in Patients With Pretreated Metastatic Melanoma
Patients with metastatic melanoma that had relapsed on anti-PD-1 therapies or BRAF/MEK inhibitors did not respond as well to an investigational therapy that involves the adoptive cell transfer of tumor-infiltrating lymphocytes as patients naive to these treatments, according to results of a study published in Clinical Cancer Research Journal.
The results from a phase III clinical study provide the first clinical evidence that sparing the hippocampus during prophylactic cranial irradiation (PCI) better preserves cognitive function in patients with small-cell lung cancer (SCLC).
Seminoma is a relatively rare and highly curable disease that occurs mainly in young men. Treatment usually affects the patient's quality of life with long-term toxicities. The treatment of clinical stage I seminoma is still debatable. Clinical management is variable and guidelines do not recommend one therapy over another.
Przed XXVII Zjazdem PTChO, odbędzie się dwudniowy kurs „Wprowadzenie do specjalizacji z chirurgii onkologicznej”. Kurs odbędzie się w dniach 1 i 2 września w Poznaniu, w Hotelu Novotel Poznań Centrum.
Abiraterone with prednisone or prednisolone plus androgen deprivation therapy (ADT) is not recommended, within its marketing authorisation, for treating newly diagnosed high-risk hormone sensitive metastatic prostate cancer in adults.
Study findings point to potential to integrate prior antibiotic exposure in decision-making process for first-line treatment of advanced non-small cell lung cancer.
Patients Want Complementary and Alternative Treatments; Here's How to Implement Integrative Oncology Into Practice
Treatment of cancer, as it turns out, requires much more than establishing and executing a drug therapy plan. To address some of these questions, an oncologist might refer the patient to a nutritionist and to a physical therapist.
Immunoterapia stała się ważnym narzędziem w leczeniu raka płuc, zwłaszcza terapie z wykorzystaniem inhibitorów punktów kontrolnych, które blokują wybrane mechanizmy kontrolne systemu immunologicznego, pozwalając komórkom odpornościowym na efektywniejsze rozpoznawanie i zabijanie komórek nowotworowych.
This ESMO Clinical Practice Guideline provides key recommendations for managing the last weeks and days of life for the adult cancer patient with advanced cancer.
FDA approved belzutifan a hypoxia-inducible factor inhibitor for adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumours (pNET), not requiring immediate surgery.
Total neoadjuvant therapy (TNT) is often used to downstage locally advanced rectal cancer (LARC) and decrease locoregional relapse; however, more than one-third of patients develop recurrent metastatic disease. As such, novel combinations are needed.
A Blood-Based, Multigenomic Signature is an Effective Diagnostic and Has Clinical Utility in NETs Management
The 51-gene expression-based liquid biopsy accurately diagnoses neuroendocrine tumours and is an effective surrogate marker compared to chromogranin A.
Abemaciclib plus fulvestrant is recommended as an option for treating hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in adults who have had endocrine therapy.
Elucidating a Risk of Developing Second Primary Malignancy During and After Treatment with PARP Inhibitors
Although PARP inhibitors interfere with DNA repair processes leading to warnings in terms of risk for developing second primary malignancies, findings from a systematic review and safety meta-analysis of placebo-controlled randomised controlled studies are reassuring for patients starting PARP inhibitors in the first-line setting that there is no increased risk of developing second primary malignancies.
FDA approved the combination of lenvatinib plus pembrolizumab for first-line treatment of adult patients with advanced renal cell carcinoma. Evidence for efficacy of combination treatment is based the results of the CLEAR study.
Through the years, doxorubicin has been considered the gold standard as first-line cytotoxic chemotherapy in most patients with advanced soft-tissue sarcomas. This was based on the landmark EORTC 62012 study.
Pathogenic Variant Probability in High-Risk Genes Supports Genetic Testing in Older Women With Breast Cancer
here is mounting evidence that all women diagnosed with breast cancer, including those age 65 and older at diagnosis, should receive genetic testing. This is supported by results from a recent study.
A major gap remains between guidelines advocating for information and counseling on fertility preservation for all patients at risk of cancer-related infertility and the reality of practice in oncology settings.
Similar Disease-Free Survival with Extended Intermittent or Continuous Treatment with Letrozole in Breast Cancer
Final results of the Study of Letrozole Extension (SOLE) indicate that treatment with intermittent letrozole did not show superiority in terms of disease-free survival compared with continuous treatment in the extended adjuvant setting for postmenopausal women with hormone receptor-positive breast cancers.
PZWL razem z kierownikiem naukowym prof. dr hab. n. med. Jadwigą Dwilewicz-Trojaczek, zaprosił wybitnych specjalistów hematologów i onkologów do przedstawienia aktualnej wiedzy na temat diagnostyki oraz leczenia nowotworów układu krwiotwórczego i chłonnego.
Prof. Jean-Yves Blay of the Université Claude Bérard in Lyon, France and colleagues reported on 2 August 2021 in the Annals of Oncology findings from an analysis of the clinical efficacy of COVID-19 vaccination in a series of 1503 patients with cancer under active treatment for cancer.
Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases
Stereotactic body radiotherapy at a dose of 24 Gy in two daily fractions was superior to conventional external beam radiotherapy at a dose of 20 Gy in five daily fractions in improving the complete response rate for pain. These results suggest that use of conformal, image-guided, stereotactically dose-escalated radiotherapy is appropriate in the palliative setting for symptom control for selected patients with painful spinal metastases.
First-in-class Histone Deacetylase Inhibitor Gel Shows Promise for the Treatment of Patients with Basal Cell Carcinoma
Remetinostat, a topical cream and first-in-class inhibitor of histone deacetylation, showed signs of clinical efficacy in patients with basal cell carcinoma, according to results from a phase II clinical trial published in Clinical Cancer Research, a journal of the American Association for Cancer Research.
ER-Low Positive Breast Cancer Shows Similar Clinical Behaviour and Response to Neoadjuvant Chemotherapy to TNBC
In a monoinstitutional study, the investigators evaluated clinical outcomes in patients with oestrogen receptor (ER)-low positive, HER2-negative, stage I-III breast cancer as compared to patients with triple-negative breast cancer (TNBC) undergoing (neo)adjuvant chemotherapy.
A new era in cancer treatment dawned with the first FDA approval for CD19 antigen–directed chimeric antigen receptor (CAR) T-cell therapy in 2017 for acute lymphoblastic leukemia. Since then, new constructs have been approved for high-grade B-cell lymphomas, mantle cell lymphoma, follicular lymphoma, and multiple myeloma.
PZWL zaprasza na kolejną edycję wirtualnej akademii. Wybitni specjaliści omówią najbardziej palące tematy leczenia wspomagającego w onkologii. Wydarzenie jest bezpłatne i przeznaczone dla lekarzy wszystkich specjalizacji uczestniczących w procesie leczenia chorych na nowotwory.
Avapritinib Not Superior to Regorafenib in Terms of Median PFS in Third-Line or Later Treatment of Patients with Unresectable or Metastatic GIST
Findings from phase III VOYAGER study indicate that avapritinib is not superior to regorafenib in terms of median progression-free survival (PFS) in third-line or later treatment of patients with molecularly unselected unresectable or metastatic gastrointestinal stromal tumour.
Amivantamab demonstrated robust and durable responses in patients with epidermal growth factor receptor Exon 20 insertion (EGFR Exon20ins)-mutated non-small cell lung cancer (NSCLC) after progression on standard-of-care platinum-based chemotherapy.
Recently, interest has risen regarding HER2-directed therapies in central nervous system (CNS) metastases for patients with HER2-positive metastatic breast cancer; new data have shown promising activity among newer HER2-targeted agents.
Ixazomib Shows Clinically Meaningful, But Not Statistically Significant, Survival Benefit in Patients With Relapsed/Refractory Multiple Myeloma
Final overall survival (OS) analysis of the phase III TOURMALINE-MM1 trial found that ixazomib produces clinically meaningful, albeit statistically insignificant, improvement in OS in patients with relapsed/refractory multiple myeloma.
Despite adjustment for previously unmeasured confounders, breast-conserving surgery with radiotherapy yielded better survival than mastectomy irrespective of radiotherapy. If both interventions are valid options, mastectomy should not be regarded as equal to breast conservation.
Phase III study results point to noninferiority of acalabrutinib, while it provides improved safety in patients with previously treated chronic lymphocytic leukaemia.
FDA approved pembrolizumab for high-risk, early-stage, triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. KEYNOTE-522 study was the basis for approval in the neoadjuvant and adjuvant setting.
Rak wątroby – nowa terapia pozwala na leczenie chirurgiczne pacjentów, którzy według obecnych kryteriów zostali uznani za nieuleczalnie chorych
Połączenie kabozantynibu, leku będącego inhibitorem kinazy, oraz stosowanego w immunoterapii niwolumabu, może umożliwić leczenie chirurgiczne u niektórych pacjentów z rakiem wątroby, którzy ze względu na stopień zaawansowania nowotworu normalnie zostaliby uznani za przypadki nieoperacyjne.
Combined hormone/radiotherapy treatment improves event-free and disease-free survival in patients with localised intermediate risk prostate cancer
Adding ADT to EBRT to patients with localised intermediate risk prostate cancer significantly increases their event-free survival (EFS)1 and disease-free survival (DFS)2, and these effects are still evident after 12 years of median follow-up, say the investigators in the latest results from an EORTC trial published in The Journal of Clinical Oncology this week.
In light of findings from multiple recent clinical trials in HER2-negative metastatic breast cancer, ASCO has revised its treatment recommendations to inform more evidence-based care for metastatic breast cancer. This guideline update provides important clinical guidance about the new use of immune checkpoint inhibitors, antibody-drug conjugates, and PARP inhibitors.
A recently updated ASCO guideline offers both new and revised guidance on the treatment of hormone receptor (HR)–positive, HER2-negative metastatic breast cancer. Update encourages use of CDK4/6 inhibitors, alpelisib.
EMA adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Imatinib Koanaa, intended for the treatment of leukaemia and gastrointestinal stromal tumours.
During the last year, a flurry of clinical trial data have provided greater insight into mechanisms of novel therapies for breast cancer management. Some of these data, including abstracts presented during the 2021 ASCO Annual Meeting, have wide practice-changing implications in triple-negative breast cancer (TNBC) or patients with high-risk, HER2-negative, early-stage disease.
Advances in Targeted Therapies, Immunotherapy Improve Treatment Options for Patients With Lung Cancer
Major advances in lung cancer announced during the 2021 ASCO Annual Meeting follow a year of stunning progress in targeted therapies and immunotherapy that has energized the field. We have seen more progress in the development of targeted therapies and improvement in the lives of our patients in the last 5 years than over the past 25 years in the lung cancer space.
Recent analysis of large case-control data sets allows for the assessment of many additional genes associated with breast cancer, including ATM, BARD1, CDH1, CHEK2, NF1, PALB2, PTEN, RAD51C, and RAD51D, and offers compelling insights on hereditary breast cancer genetics.
Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency
Clinical trial evidence suggests that nivolumab plus ipilimumab may extend how long people live. The most relevant trial did not directly compare nivolumab plus ipilimumab with usual treatments, but indirect comparisons suggest that it substantially increases how long it takes for the cancer to get worse and how long people live.
Healthy lifestyle factors such as abstinence from smoking and drinking, low body mass index, and exercise correlated with decreased cancer incidence, even in individuals with a high genetic risk, according to results of a study published in Cancer Research, a journal of the American Association for Cancer Research.
Updated worldwide estimates of cancers associated with alcohol consumption stratified by gender, tumour localisation and country indicate causal relation of alcohol with a substantial number of cancer cases that could potentially be avoided. Among all new cancers in 2020, 4.1% were related to alcohol consumption.
W dniu 3.09.2021 rozpocznie się dwudniowa konferencja „Rak piersi – aktualne zalecenia w zakresie leczenia miejscowego i programów lekowych”. Sesja pierwsza będzie poświęcona problemom radioterapii po rekonstrukcji piersi. Organizatorzy zachęcają polskie ośrodki chirurgiczne i radioterapeutyczne do podzielenia się swoimi doświadczeniami w tym zakresie.
High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer
The higher radiotherapy dose of 60 Gy resulted in a substantial survival improvement compared with 45 Gy, without increased toxicity, suggesting that twice-daily thoracic radiotherapy of 60 Gy is an alternative to existing schedules.
A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides guidance on the use of radiation therapy to treat adult patients with soft tissue sarcoma (STS).
Women Over Age 65 Years with Pathogenic Variants in Cancer Predisposition Genes Continue to Be at Increased Risk of Breast Cancer
Women over age 65 years with pathogenic variants in cancer predisposition genes rarely benefit from hereditary cancer genetic testing. A population-based study examined whether women in this age category may qualify for clinical genetic testing and magnetic resonance imaging (MRI) screening.
Withdrawal concerns the application to extend the use of atezolizumab to include the treatment of early or locally advanced triple-negative breast cancer.
FDA approved pembrolizumab in combination with lenvatinib for patients with advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.
Some people who have a rare form of bile duct cancer are set to benefit from life-extending treatment pemigatinib after NICE published final draft guidance today (22nd July 2021).
Prefrail and Frail Young Adult Survivors of Childhood Cancers Experience Significant Neurocognitive Decline
Over a 5-year follow-up interval, frail young adult survivors of childhood cancers experienced significantly larger declines than nonfrail survivors in memory, attention, processing speed, and executive function domains.
Pembrolizumab Demonstrates Robust, Durable Antitumour Activity and Promising Survival in Advanced Cutaneous Squamous Cell Carcinoma
The results of the second interim analysis of the KEYNOTE-629 study that include initial data for the locally advanced cohort and updated data for the recurrent/metastatic cohort of patients with cutaneous squamous cell carcinoma confirm durable pembrolizumab antitumour activity and promising survival in both settings.
How the CROWN Study Affects Treatment of Patients With ALK-Positive Metastatic Non–Small Cell Lung Cancer
Based on data from the CROWN study, lorlatinib is now approved by the U.S. Food and Drug Administration for use in patients with newly diagnosed advanced ALK-positive non–small cell lung cancer (NSCLC), joining ceritinib, alectinib, brigatinib, and ensartinib.
Prognostic Significance of Lynch-like versus Sporadic MSI-H Endometrial Cancer Treated With Pembrolizumab
In a single-arm, open-label phase II study, the investigators evaluated pembrolizumab in patients with recurrent mismatch repair deficient (dMMR) and/or microsatellite instability-high (MSI-H) endometrial cancer.
Chemoradiotherapy and MRI-based IGABT result in effective and stable long-term local control across all stages of locally advanced cervical cancer, with a limited severe morbidity per organ. These results represent a positive breakthrough in the treatment of locally advanced cervical cancer, which might be used as a benchmark for clinical practice and all future studies.
FDA approved belumosudil, a kinase inhibitor, for adult and paediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy.
Hypogammaglobulinemia and Sars-CoV-2 Viraemia Determine COVID-19 Severity in Patients with Haematological Malignancies
Team of scientists investigated clinical factors associated with higher risk for severe COVID-19 in patients with haematological malignancies. They wrote in the Annals of Oncology that the coronavirus infection itself, rather than cytokine storm, lead to severe and lethal COVID-19 in these patients.
Ficlatuzumab Plus Chemotherapy Shows Promise for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia
The investigational therapeutic ficlatuzumab in combination with chemotherapy showed signs of clinical efficacy in patients with relapsed/refractory acute myeloid leukemia, according to results published in Blood Cancer Discovery, a journal of the American Association for Cancer Research.
40% of cancers are preventable. For this reason, both the European Union and World Health Organization actively support countries in policy propositions that can assist in addressing modifiable cancer risks. But are there opportunities to move faster and go further? A new report by the European Cancer Organisation suggests so.
Combined MRI-directed and Standard Biopsy in Men With Elevated PSA and Positive Results on MRI Non-inferior to Standard Biopsy
In a study of population-based screening by invitation, the results showed that among men with elevated PSA levels, combined biopsy performed only in men who had positive results on magnetic resonance imaging (MRI) was non-inferior to standard biopsy for detecting clinically significant prostate cancer.
The National Cancer Institute definition of survivorship stipulates that a cancer survivor as an individual is considered to be a survivor from the time of diagnosis to the end of life. It acknowledges that cancer treatment and its consequences do not end when a specific cancer-directed therapy ends, while also implying that the road to recovery and adaptation can begin as soon as a patient is diagnosed.
Approximately 50% of patients with muscle-invasive urothelial carcinoma develop metastatic disease within 2 years of radical cystectomy alone, which commonly leads to death.1 Clinicians and researchers have strived for decades to improve this metastasis rate by integrating systemic therapy.
Incremental Progress, Reassuring Results Featured Among Gynecologic Malignancies Research at 2021 ASCO Annual Meeting
Although several studies in gynecologic malignancies have potential to change practice down the road, the OUTBACK trial on adjuvant chemotherapy in cervical cancer was the most impactful work presented at this year's Annual Meeting.
Cabazitaxel has proven benefit as a second-line therapy for patients with mCRPC who have progressed rapidly (< 12 months) through prior ASTI treatment. Immunotherapy for prostate cancer remains under clinical investigation, with pembrolizumab indicated only for prostate cancers with MSI-high or TMB-high molecular phenotypes.
Adjuvant Platinum Chemotherapy Does Not Improve Outcomes in Patients With Triple-Negative Breast Cancer With Residual Disease
Recently published findings from the phase III EA1131 trial show that, compared to capecitabine, adjuvant platinum chemotherapy does not improve outcomes in patients with triple-negative breast cancer (TNBC) with residual disease.
FDA Approves Daratumumab and Hyaluronidase-fihj With Pomalidomide and Dexamethasone for Multiple Myeloma
FDA approved daratumumab and hyaluronidase-fihj in combination with pomalidomide and dexamethasone for adult patients with multiple myeloma who have received at least one prior line of therapy including lenalidomide and a proteasome inhibitor.
FDA Approves Asparaginase Erwinia Chrysanthemi (Recombinant)-rywn for Acute Lymphoblastic Leukaemia and Lymphoblastic Lymphoma
FDA approved asparaginase erwinia chrysanthemi (recombinant)-rywn as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (LBL) in adult and paediatric patients 1 month or older who have developed hypersensitivity to E. coli-derived asparaginase.
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck
The primary objective of prolonging progression-free survival with avelumab plus chemoradiotherapy followed by avelumab maintenance in patients with locally advanced squamous cell carcinoma of the head and neck was not met. These findings may help inform the design of future trials investigating the combination of immune checkpoint inhibitors plus CRT.
FDA Grants Regular Approval to Enfortumab Vedotin-ejfv for Locally Advanced or Metastatic Urothelial Cancer
FDA approved enfortumab vedotin-ejfv, a Nectin-4-directed antibody and microtubule inhibitor conjugate, for adult patients with locally advanced or metastatic urothelial cancer who have previously received a PD1 or PD-L1 inhibitor and platinum-containing chemotherapy, or are ineligible for cisplatin-containing chemotherapy and have previously received one or more prior lines of therapy.
Analysis of the Gut Microbiome Provides Clues to Survival Following Nivolumab Therapy for Advanced Gastric Cancer
A team of investigators from Japan detected several genomic pathways and bacterial genera in the pre-treatment gut microbiome of patients with advanced gastric cancer that were significantly associated with survival times following treatment with nivolumab. These findings were presented at the ESMO World Congress on Gastrointestinal Cancer 2021.
Longer-Term Follow-Up of Breast Cancer Trials Add Further Insight Into Efficacy of Promising Combination Regimens
Several pivotal trials in recent years have contributed to greater understanding of the durability and efficacy of certain novel combination regimens for breast cancer. Long-term follow-up data from three trials HER2CLIMB, PALOMA-3, and MONALEESA-3—further established these therapeutic regimens as potentially important components of clinical care.
Research has repeatedly shown that geriatric assessment, toxicity risk tools, comanagement strategies, and multidisciplinary care models are more accurate than traditional performance status metrics to evaluate older patients with cancer.
Adding Avelumab to Preoperative Chemoradiotherapy Provides Promising Anti-Tumour Activity in Locally Advanced Rectal Cancer
Many patients with locally advanced rectal cancer receiving a preoperative regimen of standard chemoradiotherapy plus avelumab achieved pathological complete response and the majority of patients showed a major pathological response, according to findings from a phase II AVANA study presented at the ESMO World Congress on Gastrointestinal Cancer 2021.
It is intended for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem-cell transplant (ASCT).
Enzalutamide plus androgen deprivation therapy (ADT) is recommended, within its marketing authorisation, as an option for treating hormone-sensitive metastatic prostate cancer in adults.
Nivolumab is recommended as an option for treating locally advanced or metastatic non-squamous non-small-cell lung cancer (NSCLC) in adults after chemotherapy, only if: their tumours are PD-L1 positive, and it is stopped at 2 years of uninterrupted treatment, or earlier if their disease progresses, and they have not had a PD-1 or PD-L1 inhibitor before.
Expression of AR-regulated Genes in CTCs Is Prognostic for Survival and Radiographic Progression in Metastatic Prostate Cancer
07.07 Novel liquid biopsy technology to collect mRNA from circulating tumour cells (CTCs) may be used to measure expression of androgen receptor (AR) splice variants, AR targets, and neuroendocrine prostate cancer markers.
The management of acquired resistance to EGFR-mutated non–small cell lung cancer (NSCLC) has undergone significant change since osimertinib was approved by FDA for first-line treatment of the most common EGFR-activating mutations, EGFR E19del and L858R, in December 2020.
At least 42% of newly diagnosed cancers in the United States are potentially avoidable because they are attributable to lifestyle factors such as smoking, alcohol consumption, poor nutrition, and lack of physical activity.
Age is perhaps the most significant risk factor for cancer incidence. With increased longevity of the population, early detection, and more effective therapies, the number of older patients with cancer and survivors of cancer will continue to rise.
20 listopada 2021 roku, w sobotę, odbędzie się konferencja „UroScrabble”. Wydarzenie kierowane jest do urologów, onkologów, nefrologów, lekarzy rodzinnych oraz wszystkich specjalistów zainteresowanych tematyką wyszczególnioną w programie.
Trastuzumab deruxtecan demonstrated clinically meaningful benefit across specific subgroups of patients with HER2-positive and HER2-low advanced gastric cancer according to findings from a post-hoc exploratory biomarker analysis presented at the ESMO World Congress on Gastrointestinal Cancer 2021.
Radiotherapy plays an important role in breast cancer management. After breast-conserving surgery, radiotherapy reduces the probability of recurrence and improves overall survival. Adjuvant whole-breast irradiation (WBI) was previously delivered in daily treatments, given over five–six weeks. These treatments, coupled with other multidisciplinary advances such as increasing the use of systemic therapy, yielded outstanding outcomes.
First-Line Encorafenib, Binimetinib, and Cetuximab Combination Provides Clinical Benefit and Manageable Safety in BRAF V600E–Mutated mCRC
Almost half of patients with previously untreated BRAF V600E–mutated metastatic colorectal cancer (mCRC), who generally have a poorer prognosis, demonstrated response and 88% showed disease control following combination treatment with encorafenib, binimetinib, and cetuximab.
Preoperative ctDNA Levels Are Detectable in the Majority of Patients with Resectable Colorectal Cancer
A team of investigators in Japan used a personalised assay for circulating tumour DNA (ctDNA) levels in plasma to monitor minimal residual disease following surgery in patients with resectable colorectal cancer. Their subgroup analysis found statistically significant associations between ctDNA levels and the pathological disease stage.
ctDNA Analysis is Feasible for Detection of Minimal Residual Disease After Treatment Across a Variety of MMRd Tumour Types
Circulating tumour DNA analysis is a feasible tumour agnostic approach for evaluation of the efficacy of checkpoint blockade in patients at high risk of recurrence.
Characterisation of KRAS, Including KRAS G12C, Mutations in Gastrointestinal and Metastatic Colorectal Cancer
Three studies delineating the prevalence of KRAS mutations in gastrointestinal and colorectal cancer, with specific focus on the KRAS G12C mutation, and an evaluation of patient outcomes according to the mutation status were presented at the ESMO World Congress on Gastrointestinal Cancer 2021.
Over the past decade, immunotherapies have transformed the treatment of patients with certain aggressive cancers, including lung and melanoma. However, less progress has been made in difficult-to-treat brain tumors. But data presented during the 2021 ASCO Annual Meeting offered promising findings for patients with unique subtypes of brain tumors.
New Research Exploring the Role of Pembrolizumab in Locally Advanced Oral Cancers Warrants Further Investigation
The incidence of oral cancer is increasing in young adults and in adults who have never smoked, representing a high unmet need. New research on neoadjuvant pembrolizumab suggests that immunotherapy may play a promising role in locally advanced oral cancers.
Obese patients with colorectal cancer receive lower cumulative doses of adjuvant chemotherapy, relative to their body surface area (BSA), than non-obese patients, show results from a large meta-analysis reported at the ESMO World Congress on Gastrointestinal Cancer 2021.
Doctors and patients are being advised to reduce unnecessary antibiotic use following new data suggesting that these medicines may increase the risk of cancer of the large intestine (colon), especially in people under 50 years.
The Investigational PD1 Antibody, Tislelizumab, Shows Promise in Patients With Unresectable Hepatocellular Carcinoma
A novel anti-PD1 agent, tislelizumab, is under development for the treatment of patients with solid tumours and has demonstrated clinical benefit in unresectable hepatocellular carcinoma (HCC), according to findings from a phase II study presented at the ESMO World Congress on Gastrointestinal Cancer 2021.
New indication concerns adjuvant treatment of oesophageal or gastro-oesophageal junction cancer with residual disease following prior neoadjuvant chemoradiotherapy.
Sexual health problems, including genital symptoms, changes in sexual response, and psychosocial issues, are prevalent in women with cancer, yet these patients are rarely asked about their sexual concerns. Oncology teams must commit to assessing and addressing sexual health, and multiple resources are available for the busy professional.
The ASCO Annual Meeting Plenary Session consistently features some of the most important treatment advances that have occurred over the past year across the broad spectrum of cancers. We asked experts to share their thoughts on the five randomized phase III clinical trials presented during the 2021 Session and how the results of these trials are likely to influence clinical practice.
Ovarian cancer carries a heavy morbidity and mortality burden, particularly in settings and regions of the globe that feature significant limitations in health care resources. Given that ovarian cancer is more lethal than breast cancer, clinicians in resource-limited areas require guidance on the appropriate assessment and treatment of patients with this disease.